Official Title:  A Randomized, Double- Blind, Placebo- Controlled, Multi -Center Study 
to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With 
ISN/RPS 2003 Class III or IV Lupus Nephritis 
Study ID: [REMOVED] 
Document  Date : Protocol Version 4 : 18-April- 2023 
CONFIDENTIAL  
This clinical study is being sponsored globally by F. Hoffmann -La Roche Ltd of Basel, 
Switzerland.   However, it may be implemented in individual countries by Roche’s local affiliates, 
including Genentech, Inc. in the United States.  The information contained in this document, especially 
any unpublished data, is the property of F.  Hoffmann -La Roche Ltd (o r under its control) and therefore 
is provided to you in confidence as an investigator, potential investigator, or consultant, for review by 
you, your staff, and an applicable Ethics Committee or Institutional Review Board.  It is understood that 
this info rmation will not be disclosed to others without written authorization from Roche except to the 
extent necessary to obtain informed consent from persons to whom the drug may be administered.  
Obinutuzumab —F. Hoffmann -La Roche Ltd  
Protocol WA29748, Version 4  PROTOCOL  
TITLE:  A RANDOMIZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, MULTI -CENTER STUDY 
TO EVALUATE THE SAFETY AND EFFICACY  OF 
OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 
2003 CLASS III OR IV LUPUS NEPHRITIS  
PROTOCOL NUMBER:  WA29748  
VERSION NUMBER:  4 
EUDRACT NUMBER:  2015 -002022 -39 
IND NUMBER:  125,054  
TEST PRODUCT:  Obinutuzumab (GA101; RO5072759)  
NCT NUMBER : [STUDY_ID_REMOVED]  
SPONSOR:  F. Hoffmann -La Roche Ltd
APPROVAL DATE:  See electronic signature and date stamp on the final 
page of this document .  
Obinutuzumab —F. Hoffmann -La Roche Ltd  
2/Protocol WA29748, Version 4 PROTOCOL HISTORY  
Protocol  
Version  Date Final  
4 See electronic date stamp on final page.  
3 2 February 2016  
2 24 July 2015  
1 6 May 2015  
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
3/Protocol WA29748, Version 4 PROTOCOL AMENDMENT, VERSION 4: 
RATIONALE  
Protocol WA 29748 has been amended primarily to update the details for the end of  the 
study.  Substantial changes to the protocol, along with a rationale for each change, are 
summarized below:  
 Personal identifiable information (i.e., name and telephone number) for the Medical 
Monitors has been removed f rom the protocol (front matter and Section  5.4.1 ).  
Medical Monitor contact information has been replaced with a sentence indicating 
that this information will be provided separately to sites.  
 The description of the end of study has been updated to emphasi ze that it is defined 
as the last patient’s last visit at Week 104 when B -cell follow -up (BCFU) visits for all 
patients will end. This represents a minimum of 78 weeks (~18 months) of safety 
follow -up after the last dose of study drug to assess the occurre nce of adverse 
events and to enable an assessment of peripheral blood CD19+ B cell return.   An 
analysis of the relationship between obinutuzumab exposure and B -cell count for 
patients with Lupus Nephritis (LN) in this study ( WA29748 ) who have already 
completed 18 -months of follow -up has been performed and shows  that the vast 
majority of patients recovered or replete d their B -cells by 18 months after their last 
obinutuzumab dose, while a small percentage of patients experienced prolonged B -
cell depletio n.  During the extended B -cell depeletion period , the safety profile of 
patients under follow -up was consistent  with the overall safety profile observed  up 
until Week 104. This finding is in -line with considerable experience with other anti -
CD20 antibodies  with the same mechanism of action in sutoimmune  diseases   
(Section 3.2) . 
 The reporting of the term “sudden death” has been updated to also require the 
presumed cause of death (Section  5.3.5.8).  
 Adverse event reporting for hospitalization has been clarified (Section  5.3.5.11).  
 The Sponsor record retention policy has been clarified  (Section 7.5) . 
 A description of the technical and organizational security measures taken to protect 
personal data has been added to align with CTR requirements (Section 8.4). 
 The process for reviewing and handling protocol deviations has been updated per 
internal standard operating procedures (Section 9.2).  
 Due to certain local requirements and an alignment of Sponsor process, it has been 
clarified that summaries of clinica l study results may be available in health authority 
databases for public access in addition to redacted Clinical Study Reports 
(Section  9.5). 
 
Additional minor changes have been made to improve clarity and consistency. 
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol.  
Obinutuzumab —F. Hoffmann -La Roche Ltd  
4/Protocol WA29748, Version 4  TABLE OF CONTENTS  
PROTOCOL AMENDMENT A CCEPTANCE FORM  ................................ ..........  11 
PROTOCOL SYNOPSIS  ................................ ................................ ....................  12 
1. BACKGROUND  ................................ ................................ ............  24 
1.1 Background on Lupus Nephritis  ................................ ...............  24 
1.2 Background on Obinutuzumab  ................................ ................  26 
1.3 Study Rationale and Benefit -Risk Assessment  ........................  27 
2. OBJECTIVES  ................................ ................................ ................  32 
2.1 Efficacy Objectives  ................................ ................................ .. 32 
2.2 Safety Objectives  ................................ ................................ ..... 32 
2.3 Pharmacodynamic Objective  ................................ ...................  32 
2.4 Pharmacokinetic Objectives ................................ .....................  32 
2.5 Patient -Reported Outcome Objective  ................................ ...... 32 
2.6 Exploratory Objectives  ................................ .............................  33 
3. STUDY DESIGN  ................................ ................................ ...........  33 
3.1 Description of Study  ................................ ................................ . 33 
3.2 End of Study  ................................ ................................ ............  35 
3.3 Rationale for Study Design  ................................ ......................  35 
3.3.1  Rationale for Obinutuzumab Dose and Schedule  ....................  35 
3.3.2  Rationale for Patient Population  ................................ ..............  36 
3.3.3  Rationale for Control Group  ................................ .....................  36 
3.3.4  Rationale for Biomarker Assessments  ................................ ..... 36 
3.4 Outcome Measures  ................................ ................................ . 37 
3.4.1  Efficacy Outcome Measures  ................................ ....................  37 
3.4.2  Safety Outcome Measures  ................................ ......................  38 
3.4.3  Pharmacodynamic Outcome Measure  ................................ ..... 39 
3.4.4  Pharmacokinetic Outcome Measures  ................................ ...... 39 
3.4.5  Patient -Reported Outcome Measure  ................................ ....... 39 
3.4.6  Exploratory Outcome Measures  ................................ ..............  39 
4. MATERIALS AND METHOD S ................................ ......................  41 
4.1 Patients  ................................ ................................ ....................  41 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
5/Protocol WA29748, Version 4 4.1.1  Inclusion Criteria  ................................ ................................ ...... 41 
4.1.2  Exclusion Criteria  ................................ ................................ ..... 42 
4.2 Method of Treatment Assignment and Blinding  .......................  44 
4.3 Study Treatment  ................................ ................................ ...... 45 
4.3.1  Formulation, Packaging, and Handling  ................................ .... 45 
4.3.1.1  Obinutuzumab and Placebo ................................ .....................  45 
4.3.1.2  Methylprednisolone and Placebo  ................................ .............  45 
4.3.1.3  Mycophenolate Mofetil/Mycophenolic Acid  ..............................  45 
4.3.2  Dosage, Administration, and Compliance  ................................  46 
4.3.2.1  Obinutuzumab and Placebo ................................ .....................  46 
4.3.2.2  Mycophenolate Mofetil/Mycophenolic Acid  ..............................  48 
4.3.2.3  Corticosteroid Administration  ................................ ...................  49 
4.3.3  Dosage Modification  ................................ ................................  51 
4.3.4  Investigational Medicinal Product Accountability  .....................  52 
4.3.5  Post-Study Access to Obinutuzumab  ................................ ...... 52 
4.4 Concomitant Therapy  ................................ ..............................  53 
4.4.1  Permitted Therapy  ................................ ................................ ... 53 
4.4.1.1  Other Concomitant Therapy ................................ .....................  53 
4.4.1.2  Withdrawal of Immunosuppression after Week 52  ...................  55 
4.4.2  Concomitant Therapy and Clinical Practice  .............................  55 
4.4.3  Immunization during Peripheral B -Cell Depletio n ....................  55 
4.4.4  Prohibited Therapy  ................................ ................................ .. 56 
4.5 Study Assessments  ................................ ................................ . 57 
4.5.1  Informed Consent Forms and Screening Log  ..........................  57 
4.5.2  Medical History and Demographic Data  ................................ .. 57 
4.5.3  Physical Examinations  ................................ .............................  57 
4.5.4  Vital Signs  ................................ ................................ ................  58 
4.5.5  Systemic Lupus Erythematosus Disease Activity Index 
(SELENA -SLEDAI) Assessment  ................................ ..............  58 
4.5.6  Systemic Lupus International Collaborating Clinics/ 
American College of Rheumatology Damage Index for 
Systemic Lupus Erythematosus  ................................ ...............  58 
4.5.7  Glucocorticoid Toxicity Change Index  ................................ ...... 58 
4.5.8  Laboratory, Biomarker, and Other Biological Samples  ............  58 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
6/Protocol WA29748, Version 4 4.5.9  Electrocardiograms  ................................ ................................ .. 60 
4.5.10  Patient - and Physician -Reported Outcomes  ............................  60 
4.5.11  Samples for Roche Clinical Repository  ................................ .... 61 
4.5.11.1  Overview of the Roche Clinical Repository  ..............................  61 
4.5.11.2  Approval by the Ins titutional Review Board or Ethics 
Committee  ................................ ................................ ...............  61 
4.5.11.3  Sample Collection  ................................ ................................ .... 61 
4.5.11.4  Confidentiality  ................................ ................................ ..........  62 
4.5.11.5  Consent to Participate in the Roche Clinical Repository  ..........  63 
4.5.11.6  Withdrawal from the Roche Clinical Repository  .......................  63 
4.5.11.7  Monitoring and Oversight  ................................ .........................  63 
4.6 Patient, Treatment, Study, and Site Discontinuation  ................  64 
4.6.1  Patient Discontinuation  ................................ ............................  64 
4.6.2  Study Treatment Discontinuation  ................................ .............  64 
4.6.3  Study and Site Discontinuation  ................................ ................  65 
5. ASSESSMENT OF SAFETY  ................................ .........................  65 
5.1 Safety Plan  ................................ ................................ ..............  65 
5.1.1  Infusi on-Related Reactions  ................................ ......................  65 
5.1.2  Infections  ................................ ................................ .................  66 
5.1.2.1  Hepatitis B Reactivation  ................................ ...........................  66 
5.1.2.2  Progressive Multifocal Leukoencephalopathy  ..........................  67 
5.1.3  Immunizations  ................................ ................................ ..........  67 
5.1.4  Neutropenia  ................................ ................................ .............  67 
5.1.5  Thrombocytopenia  ................................ ................................ ... 67 
5.1.6  B-Cell Depletion and Recovery  ................................ ................  67 
5.1.6.1  Obinutuzumab Monotherapy - NHL and CLL Patients  .............  68 
5.1.6.2  Obinutuzumab in Combination with Chemotherapy - CLL 
Patients  ................................ ................................ ....................  68 
5.1.7  Immunoglobulin Depletion and Recovery  ................................  68 
5.1.8  Gastrointestinal Perforations ................................ ....................  69 
5.1.9  Management of Specific Adverse Events  ................................  69 
5.2 Safety Parameters and Definitions  ................................ ..........  72 
5.2.1  Adverse Events  ................................ ................................ ........  72 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
7/Protocol WA29748, Version 4 5.2.2  Serious Adverse Events (Immediately Reportable to the 
Sponsor)  ................................ ................................ ..................  72 
5.2.3  Adverse Events of Special Interest (Immediately 
Reportable t o the Sponsor)  ................................ ......................  73 
5.3 Methods and Timing for Capturing and Assessing 
Safety  Parameters  ................................ ................................ ... 74 
5.3.1  Adverse Event Reporting Period  ................................ ..............  74 
5.3.2  Eliciting Adverse Event Information  ................................ .........  74 
5.3.3  Assessment of Severity of Adverse Events  .............................  74 
5.3.4  Assessment of Causality of Adverse Events ............................  75 
5.3.5  Procedures for Recording Adverse  Events  ..............................  76 
5.3.5.1  Infusion -Related Reactions  ................................ ......................  76 
5.3.5.2  Diagnosis versus Signs and Symptoms  ................................ ... 76 
5.3.5.3  Adverse Events That Are Secondary to Other Events  .............  77 
5.3.5.4  Persistent or Recurrent Adverse Events  ................................ .. 77 
5.3.5.5  Abnormal Laboratory Values  ................................ ...................  78 
5.3.5.6  Abnormal Vital Sign Values  ................................ .....................  78 
5.3.5.7  Abnormal Liver Function Tests  ................................ ................  79 
5.3.5.8  Deaths  ................................ ................................ .....................  79 
5.3.5.9  Preexisting Medical Conditions  ................................ ................  80 
5.3.5.10  Lack of Efficacy or Worsening of Systemic Lupus 
Erythematosus  ................................ ................................ .........  80 
5.3.5.11  Hospitalization or Prolonged Hospitalization  ............................  80 
5.3.5.12  Adverse Events Associ ated with an Overdose or Error in 
Drug Administration  ................................ ................................ . 81 
5.4 Immediate Reporting Requirements from Investigator to 
Sponsor  ................................ ................................ ...................  81 
5.4.1  Emergency Medical Contacts  ................................ ..................  82 
5.4.2  Reporting Requirements for Serious Adverse Events and 
Adverse Events of Special Interest  ................................ ..........  82 
5.4.2.1  Events That Occur prior to Study Drug Initiation  ......................  82 
5.4.2.2  Events That Occur after Study Drug Initiation  ..........................  82 
5.4.3  Reporting Requirements for Pregnancies  ................................  82 
5.4.3.1  Pregnancies in Female Patients  ................................ ..............  82 
5.4.3.2  Pregnancies in Female Partners of Male Patients  ...................  83 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
8/Protocol WA29748, Version 4 5.4.3.3  Abortions ................................ ................................ ..................  83 
5.4.3.4  Congenital Anomalies/Birth Defects  ................................ ........  83 
5.5 Follow -Up of Patients after Adverse  Events .............................  84 
5.5.1  Investigator Follow -Up ................................ .............................  84 
5.5.2  Sponsor Follow -Up ................................ ................................ .. 84 
5.6 Post-Study Adverse Events  ................................ .....................  84 
5.7 Expedited Reporting to Health Authorities, Investigators, 
Institutional Review Boards, and Ethic s Committees  ...............  84 
6. STATISTICAL CONSIDER ATIONS AND ANALYSIS PLAN  .........  85 
6.1 Determination of Sample Size  ................................ .................  85 
6.2 Summaries of Conduct of Study  ................................ ..............  86 
6.3 Summaries of Treatment Group Comparability  ........................  86 
6.4 Efficacy Analyses  ................................ ................................ ..... 86 
6.4.1  Primary Efficacy Endpoint  ................................ ........................  86 
6.4.2  Secondary Efficacy Endpoints  ................................ .................  87 
6.4.3  Exploratory Efficacy Endpoints  ................................ ................  88 
6.5 Safety Analyses  ................................ ................................ ....... 88 
6.5.1  Adverse Events  ................................ ................................ ........  88 
6.5.2  Deaths  ................................ ................................ .....................  88 
6.5.3  Laboratory  Tests  ................................ ................................ ...... 88 
6.5.4  Vital Signs  ................................ ................................ ................  89 
6.6 Pharmacodynamic Analyses  ................................ ....................  89 
6.7 Pharmacokinetic Analyses  ................................ .......................  89 
6.8 Patient - and Physician -Reported Outcome Analyses  ..............  90 
6.9 Exploratory Analyses  ................................ ...............................  90 
6.10  Interim Analyses  ................................ ................................ ...... 91 
6.10.1  Planned Interim Analyses  ................................ ........................  91 
6.10.1.1  Pharmacodynamic Futility Interim Analysis:  ............................  91 
6.10.1.2  Renal Response Interim Analysis:  ................................ ...........  91 
7. DATA COLLECTION AND MANAGEMENT  ................................ . 92 
7.1 Data Quality Assurance  ................................ ...........................  92 
7.2 Electronic Case Report Forms  ................................ .................  92 
7.3 Source Data Documentation  ................................ ....................  92 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
9/Protocol WA29748, Version 4 7.4 Use of Computerized Systems  ................................ ................  93 
7.5 Retention of Records  ................................ ...............................  93 
8. ETHICAL CONSIDERATIO NS ................................ ......................  94 
8.1 Compliance with Laws and Regulations  ................................ .. 94 
8.2 Informed Consent  ................................ ................................ .... 94 
8.3 Institutional Review Board or Ethics  Committee  ......................  95 
8.4 Confidentiality  ................................ ................................ ..........  96 
8.5 Financial Disclosure  ................................ ................................ . 96 
9. STUDY DOCUMENTATION,  MONITORING, AND 
ADMINISTRATION  ................................ ................................ ....... 96 
9.1 Study Documentation  ................................ ..............................  96 
9.2 Protocol Deviations  ................................ ................................ .. 97 
9.3 Site Inspections  ................................ ................................ ....... 97 
9.4 Admi nistrative Structure  ................................ ...........................  97 
9.5 Dissemination of Data and Protection of Trade Secrets  ..........  97 
9.6 Protocol Amendments  ................................ .............................  98 
10. REFERENCES ................................ ................................ ..............  99 
 
 LIST OF TABLES  
Table  1 International Society of Nephrology/Renal Pathology Society 
2003 Classification of  Lupus  Nephritis  ................................ ........  25 
Table  2 Administration of Obinutuzumab Infusions  ................................ .. 47 
Table  3 Management of Infusion -Related Reactions  ...............................  48 
Table  4 Antimalarial Medications  ................................ .............................  53 
Table  5 Suggested Dose Ranges for Angiotensin -Converting 
Enzyme Inhibitors and Angiotensin -Receptor Blockers  ..............  54 
Table  6 Guidel ines for Management of Specific Adverse Events  ............  70 
Table  7 Adverse Event Severity Grading Scale for Events Not 
Specifically Listed in NCI CTCAE  ................................ ...............  75 
Table  8 Causal Attribution Guidance  ................................ .......................  76 
 
 LIST OF FIGURES  
Figure  1 Study Schema  ................................ ................................ .............  34 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
10/Protocol WA29748, Version 4  
 LIST OF APPENDICES  
Appendix  1  Schedule of Assessments  ................................ ........................  104  
Appendix  2  Follow -Up and B -Cell Follow -Up Assessments  ........................  108  
Appendix  3 International Society of Nephrology/Renal Pathology Society 
(ISN/RPS)  2003 Classification of Lupus Nephritis  ...................  109  
Appendix  4  Guidelines for Mycophenolate Mofetil (or Equivalent) Dosing  .. 113  
Appendix  5  Initial Prednisone/Prednisolone Tapering Schedule  .................  115  
Appendix  6  Criteria  for Classification of Systemic Lupus Erythematosus  ... 118  
Appendix  7  Study Drug Administration  ................................ .......................  120  
Appendix  8  Corticosteroid Equivalence Chart  ................................ .............  123  
Appendix  9  Instructions for Collecting and Analyzing Urine Samples  .........  124  
Appendix  10  Systemic Lupus International Collaborating Clinics/ 
American College of Rheumatology (SLICC/ACR)  ...................  127  
Appendix  11  Subject’s Global Assessment  ................................ ...................  130  
Appendix  12  Physician’s Global Assessment  ................................ ...............  131  
Appendix  13  Systemic Lupus Erythematosus Disease Activity Index -2K ..... 132  
Appendix  14  Glucocorticoid Toxicity Change Index  ................................ ...... 133  

Obinutuzumab —F. Hoffmann -La Roche Ltd  
11/Protocol WA29748, Version 4 PROTOCOL AMENDMENT A CCEPTANCE FORM  
TITLE:  A RANDOMIZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, MULTI -CENTER STUDY 
TO EVALUATE THE SAFETY AND EFFICACY  OF 
OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 
2003 CLASS III OR IV LUPUS NEPHRITIS  
PROTOCOL NUMBER:  WA29748  
VERSION NUMBER:  4 
EUDRACT NUMBER:  2015 -002022 -39 
IND NUMBER:  125,054  
NCT NUMBER:  [STUDY_ID_REMOVED]  
TEST PRODUCT:  Obinutuzumab (GA101; RO5072759)  
SPONSOR:  F. Hoffmann -La Roche Ltd  
I agree to conduct the study in accordance with the current protocol.  
   
Principal Investigator’s Name  (print)    
   
Principal Investigator’s Signature   Date  
Please retain the signed original of this form for your study files.  Please return a copy as 
instructed by your  local study monitor . 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
12/Protocol WA29748, Version 4 PROTOCOL SYNOPSIS  
TITLE:  A RANDOMIZED, DOUBLE -BLIND, PLACEBO -CONTROLLED, 
MULTI -CENTER STUDY TO EVALUATE THE SAFETY AND 
EFFICACY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 
2003 CLASS III OR IV LUPUS NEPHRITIS  
PROTOCOL NUMBER:  WA29748  
VERSION NUMBER:  4 
EUDRACT NUMBER:  2015 -002022 -39 
IND NUMBER:  125,054  
NCT NUMBER:  NCT 02550652  
TEST PRODUCT:  Obinutuzumab (GA101; RO5072759)  
PHASE:  II 
INDICATION:  ISN/RPS Class III or IV Lupus Nephritis  
SPONSOR:  F. Hoffmann -La Roche Ltd  
 
OBJECTIVES  
EFFICACY OBJECTIVES  
The primary efficacy objective for this study is as follows:  
 To evaluate the efficacy of obinutuzumab compared with placebo in patients with 
International Society of Nephrology ( ISN)/Renal Pathology Society ( RPS) Class III or IV 
lupus nephritis ( LN) as measured by complete renal response ( CRR ) at 52 weeks  
 
The secondary efficacy objectives for this study are as follows:  
 To assess overall renal response (defined as CRR plus partial renal response [PRR] ) 
 To evaluate the ability of obinutuzumab to improve time -to-response (CRR plus PRR) over 
the course of 52 we eks 
 
SAFETY OBJECTIVES  
The safety objectives for this study are as follows:  
 To evaluate the safety of obinutuzumab compared with placebo in patients with Class III or 
IV LN, focusing on the nature, frequency, and severity of serious and non -serious adverse  
events, as well as effects on laboratory values, vital signs, or other safety biomarkers  
 To characterize the immunogenic potential of obinutuzumab by measuring  human anti -drug 
antibodies  and assessing their relationship with other outcome measures  
 To full y characterize adverse events of special interest, including infusion reactions, 
infections, thrombocytopenia, and neutropenia  
 
PHARMACODYNAMIC OBJE CTIVE  
The pharmacodynamic (PD) objective for this study is as follows:  
 To compare changes in CD19  B cells i n the peripheral blood following treatment with 
obinutuzumab versus placebo  
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
13/Protocol WA29748, Version 4 PHARMACOKINETIC OBJE CTIVES  
The pharmacokinetic (PK) objectives for this study are as follows:  
 To characterize the pharmacokinetics of obinutuzumab in the LN population  
 To assess potential PK interactions between obinutuzumab and concomitant medications, 
including mycophenolate mofetil ( MMF ) 
 
PATIENT -REPORTED OUT COME OBJECTIVES  
The patient -reported outcome (PRO) objective for this study is as follows:  
 To assess the change  from baseline of the patient’s general health over the course of the 
study  by use of the Subject’s Global Assessment  
 
EXPLORATORY OBJECTIV ES 
The exploratory objectives for this study are as follows:  
 To evaluate pre -dose levels of exploratory biomarkers (which may include but are not 
limited to B -cell subsets and levels of protein and mRNA in serum, plasma, blood, and 
urine) and potential associations with outcome  
 To evaluate changes in exploratory biomarkers (which may include but are not limited to 
B-cell subsets and levels of protein and mRNA in serum, plasma, blood, and urine) over 
time in patients dosed with obinutuzumab versus patients dosed with placebo  
 To evaluate the occurrence of extrarenal flares  
 To evaluate the impact of therapy on patient and physician -reported outcomes  
 To assess damage through the Glucocorticoid Toxicity Change Index (GTCI)  
 To assess renal biopsy histopathology (for the presence and depletion of B  cells at the 
screening biopsy and from subsequent biopsies)  
 
Additional explorat ory objectives and outcome measures will be included in a final Statistical 
Analysis Plan (SAP).  
STUDY DESIGN  
DESCRIPTION OF STUDY  
This Phase II study is a parallel -group, double -blind, randomized, placebo -controlled study 
comparing the efficacy and safety  of obinutuzumab plus MMF with placebo plus MMF in Class 
III and IV patients with proliferative LN.  The Sponsor intends to enroll approximately 120 
patients diagnosed with ISN/RPS Class III or IV LN, with a d iagnosis of systemic lupus 
erythematosus  (SLE) based on current American College of Rheumatology  (ACR ) criteria (at 
least 4 criteria must be present, one of which must be a positive anti -nuclear antibody [ANA]), in 
centers throughout the world.  In addition to study treatment, patients will receive 
standard -of-care therapy with angiotensin -converting enzyme 
(ACE)  inhibitors/angiotensin -IIreceptor  blockers, MMF (dosed at 2.0 2.5 g/day) or 
mycophenolic acid ( MPA ) (dosed 1440 1800 mg/day), and a prednisone taper.   Patients must 
be 1875 years of age and have ISN/RPS 2003 Class III or IV proliferative LN as evidenced by 
renal biopsy performed within 6  months prior to or during screening and may have concomitant 
Class V disease (e.g., Class III/V or Class  IV/V).  Patients with Class III (C) or Class IV (C) 
disease will be excluded because of the lower likelihood of response within these categories.  
Patients must exhibit significant proteinuria (urine protein to creatinine ratio  1.0 based on a 
24-hour urine collection).  Key exclusions will be evidence of severe renal impairment 
(estimated glomerular filtration rate  [GFR ]  30 mL/minute per 1.73 m2 of body surface area), 
end-stage renal disease  requiring dialysis or transplantation, evidence of active infections, and 
other safety -related exclusions.  Patien ts will receive an initial 1000 mg of methylprednisolone 
intravenous ( IV) prior to or during screening, and may receive up to a total of 3000  mg 
methylprednisolone IV prior to randomization for severe clinical activity according to guidelines 
of routine care for these patients.  Patients will receive 80  mg methylprednisolone (or 
methylprednisolone placebo) on the day of the obinutuzumab/placebo infusion to reduce 
infusion -related reactions .  Oral corticosteroids will be initiated at a dose of 0.5 mg/kg 
(maximum 60 mg/day) and will be reduced over 10  weeks.  This modified taper, from the 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
14/Protocol WA29748, Version 4 LUNAR study, will be initiated at a lower dose in recognition that prednisone doses above 
10 mg/day are associated with significant adverse events, including increased risk  of 
cardiovascular events.  Prior experience with rituximab suggests that it can potentially enable 
complete and PRRs in the absence of oral prednisone or a prednisone taper, thus allowing the 
use of lower doses of corticoste roids as proposed in this P hase  II protocol.  
Patients will be followed until at least Week 104, with the primary endpoint evaluation at Week 
52.  An interim analysis at 6  months will be performed to evaluate early differences in CRR.  All 
patients will have central reading of the renal biopsy histopathology and will also receive repeat 
renal biopsy as available on the basis of clinical status and local practice.  All patients will be 
evaluated by high -sensitivity flow cytometry (HSFC) to evaluate the ability of obinutuzumab to 
deplete ci rculating peripheral B cells, and an interim PD analysis will be performed to assess 
whether patients do not fully deplete peripheral CD19 B cells as anticipated.  These mechanistic 
studies and more intensive histopathologic reviews are intended to test th e hypothesis that 
greater B -cell depletion in the target organ (kidney) and associated secondary lymphoid 
structures will translate into greater CRR rates.  
NUMBER OF PATIENTS  
The study will enroll approximately 120 patients with active ISN/RPS 2003 Class III or IV LN at 
approximately sixty centers in North America, South America, Europe, and selected other 
countries.  
TARGET POPULATION  
Inclusion Criteria  
Patients must meet the f ollowing criteria for study entry:  
 Signed Informed Consent Form  
 Age 1875 years  
 Ability to comply with the study protocol, in the investigator’s judgment  
 Diagnosis of SLE, according to current ACR criteria (at least four criteria must be present, 
one of wh ich must be a positive ANA)  
 Diagnosis of ISN/RPS 2003 Class III or IV LN as evidenced by renal biopsy performed 
within 6  months prior to or during screening.  Patients may co -exhibit Class V disease in 
addition to either Class III or Class IV disease.  
 Proteinuria (urine protein to creatinine ratio)  1.0, based on a 24 -hour urine collection  
 For women who are not postmenopausal (  12 months of non -therapy -induced amenorrhea) 
or surgically sterile (absence of ovaries and/or uterus):  agreement to remain abstinent or 
use two adequate methods of contraception, including at least one method with a failure 
rate of  1% per year, during t he treatment period and for at least 18 months after the last 
dose of study drug  
Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the 
patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postov ulation 
methods) and withdrawal are not acceptable methods of contraception.  
Barrier methods must always be supplemented with the use of a spermicide.  
Examples of contraceptive methods with a failure rate of  1% per year include tubal 
ligation, male steri lization, hormonal implants, established, proper use of combined oral 
or injected hormonal contraceptives, and certain intrauterine devices.  
 For men:  agreement to remain abstinent or use a condom plus an additional contraceptive 
method that together resul t in a failure rate of  1% per year during the treatment period and 
for at least 12 months after the last dose of study drug and agreement to refrain from 
donating sperm during this same period  
Men with a pregnant partner must agree to remain abstinent or  use a condom for the 
duration of the pregnancy.  
Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the 
patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of contraception.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
15/Protocol WA29748, Version 4 Patients must be willing to practice this method of contraception while taking MMF and 
for 90 days after stopping MMF.  
 
Exclusion Criteria  
Patients who meet any of the following criteria will be excluded from st udy entry:  
 Retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or 
stroke syndrome, cerebellar ataxia, or dementia that is currently active and resulting from 
SLE 
 Presence of rapidly progressive glomerulonephritis define d by 
The presence of crescent formation in  50% of glomeruli assessed on renal biopsy or  
Sustained doubling of serum creatinine within 12 weeks of screening or  
The investigator’s opinion that the patient has rapidly progressive glomerulonephritis.  
 Severe renal impairment as defined by estimated GFR  30 mL/min or the need for dialysis 
or renal transplant  
 Greater than 50% of glomeruli with sclerosis on renal biopsy  
 Treatment with cyclophosphamide or calcineurin inhibitors within the 3  months prior to  
randomization  
 Unstable disease with thrombocytopenia or at high risk for developing clinically significant 
bleeding or organ dysfunction requiring therapies such as plasmapheresis or acute blood or 
platelet transfusions  
 Lack of peripheral venous access  
 Pregnancy or lactation  
 History of severe allergic or anaphylactic reactions to monoclonal antibodies  or known 
hypersensitivity to any component of the obinutuzumab infusion  
 Significant or uncontrolled medical disease in any organ system not related to SLE or  LN, 
which, in the investigator’s opinion, would preclude patient participation  
 Concomitant chronic conditions, excluding SLE, (e.g., asthma, Crohn’s disease) that 
required oral or systemic steroid use in the 52 weeks prior to screening  
 Known HIV infection  
 Known active infection of any kind (excluding fungal infection of nail beds) or any major 
episode of infection requiring hospitalization or treatment with IV anti -infectives within 
8 weeks of the screening visit or oral anti -infectives within 2  weeks prio r to the screening 
visit 
 History of serious recurrent or chronic infection  
 History of cancer, including solid tumors, hematological malignancies, and carcinoma in situ 
(except basal cell carcinomas of the skin that have been treated or excised and have 
resolved)  
 Currently active alcohol or drug abuse or history of alcohol or drug abuse within 52  weeks 
prior to screening  
 Major surgery requiring hospitalization within 4 weeks of randomization (excluding 
diagnostic surgery)  
 Previous treatment with an anti -CD20targeted  therapy within 12 months of randomization  
 Previous treatment with a biologic B -celltargeted therapy (other than anti -CD20) within 
6 months of randomization  
 Treatment with any investigational agent within 28 days of randomization or five half -lives of 
the investigational drug (whichever is longer)  
 Receipt of a live vaccine within 28 days prior to screening  
 Intolerance or contraindication to oral or IV corticosteroids  
 Aspartate aminotransferase or alanine aminotransferase  2.5   upper limit of normal  (ULN) 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
16/Protocol WA29748, Version 4  Amylase or lipase  2  ULN 
 Neutrophils  1.5  103/L 
 Positive hepatitis B surface antigen (HbSAg) or hepatitis C serology.  Patients who are 
HBsAg negative and hepatitis B core antibody positive with no detectable DNA will be 
allowed into the study but will require regular monitoring of hepatitis  B virus  DNA.  
 Hemoglobin  7 g/dL, unless caused by autoimmune hemolytic anemia resulting from SLE  
 Platelet count  10,000/L 
 Positive serum human chorionic gonadotropin  measured prior to the first obinutuzumab 
infusion  
 Known intolerance to MMF and MPA  
 
LENGTH OF STUDY  
The study will follow all patients for a minimum of 78 weeks after the last infusion of 
obinutuzumab at Day 182.  In consideration of recruitment and follo w-up (independent of B-Cell 
follow -up [BCFU] ), the length of study is estimated to be greater than 36 months.  Patients may 
enter BCFU and continue to be evaluated for safety on a limited basis.  
END OF STUDY  
The end of this study is defined as the last patient’s last visit at Week 104. This has been 
selected to enable 78 weeks (~18 months) of safety follow -up after the last dose of study drug 
to assess the occurrence of adverse events and to enable an assessment of peripheral blood 
CD19+ B cell return.  
Additional B -cell follow -up (BCFU) visits will occur until patients have achieved their baseline 
CD19+ count or achieved 25 cells/μL CD19+ count (the lower limit of normal (LLN) of CD19+ B 
cells for this lupus population), whichever occurs first.  B -cell fo llow-up (BCFU) visits for all 
patients will end when the last patient has completed ~18 months of safety follow -up from the 
last dose of blinded obinutuzumab infusion.  
Patients who receive additional therapies that reduce peripheral B -cell counts will not be 
included in BCFU.  
OUTCOME MEASURES  
PRIMARY EFFICACY OUT COME MEASURE  
The primary efficacy outcome measure is the proportion of patients who achieve a CRR, 
evaluated at 52 weeks.  
CRR is defined by attainment of all of the following:  
 Normalization of serum  creatinine as evidenced by the following:  
Serum creatinine  the ULN  range of central laboratory values if baseline (Day 1) serum 
creatinine is above the ULN  
Serum creatinine  15% above baseline and  the ULN range of central laboratory 
values if baselin e (Day  1) serum creatinine is  the ULN range of central laboratory 
values  
 Inactive urinary sediment (as evidenced by   10 RBCs/high -power field (HPF) and the 
absence of red cell casts)  
 Urinary protein to creatinine ratio  0.5 
 
SECONDARY  EFFICACY OUTCOME MEASURES  
The secondary efficacy outcome measures are the following:  
 Proportional analysis of patients who achieve an overall response at Week  52 (CRR   PRR)  
 Time to overall response ( CRR   PRR ) over the course of 52 weeks  
 Percent reduction or increase from baseline and mean andmedian assessments of 
biomarkers of LN disease activity (e.g., reduction in anti -dsDNA antibody levels, increase 
C3 and C4 levels)  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
17/Protocol WA29748, Version 4  Proportion of patients that achieve a PRR at Week  52 as defined by attainment of all of the 
followi ng: 
Serum creatinine  15% above baseline value  
No urinary red cell casts and either RBCs/HPF  50% above baseline or  10 RBCs/HPF  
50% improvement in the urine protein to creatinine ratio, with one of the following 
conditions met:  
If the baseline urine pr otein to creatinine ratio is  3.0, then a urine protein to 
creatinine ratio of  1.0 
If the baseline protein to creatinine ratio is  3.0, then a urine protein to creatinine 
ratio of  3.0 
 Proportion of patients who achieve a CRR at Week 24  
 Time to CRR, over the course of 52 weeks.  
 Proportion of patients that achieve a modified CRR (mCRR1) at Week 52 employing the 
primaryefficacy measure definition and removing the urinary sediment analysis criteria  
mCRR1 is defined by attainment of n ormalization of seru m creatinine as evidenced by 
the following:  
Serum creatinine  the ULN range of central laboratory values if baseline (Day 1) 
serum creatinine is above the ULN  
Serum creatinine  15% above baseline and  the ULN range of central laboratory 
values if baseli ne (Day  1) serum creatinine  the ULN range of central laboratory 
values  
Urinary protein to creatinine ratio  0.5 
 Proportion of patients that achieve a second modified CRR (mCRR2) at Week 52 as 
defined by attainment of the following:  
Normalization of seru m creatinine as evidenced by the following:  
Serum creatinine  15% above baseline if baseline (Day  1) serum creatinine is 
above the normal range of the central laboratory values or  the ULN range of 
central laboratory values if baseline (Day  1) serum crea tinine is  the ULN range of 
central laboratory values  
Inactive urinary sediment (as evidenced by   10 RBCs/HPF and the absence of red cell 
casts)  
Urinary protein to creatinine ratio  0.5 
 Proportion of patients that achieve a third modified CRR (mCRR3) at  Week 52 as defined 
by attainment of the following:  
Normalization of serum creatine as evidenced by serum creatinine  the ULN range of 
central laboratory values  
Urinary protein to creatinine ratio  0.5 
 
The hierarchical ordering of the secondary endpoints will be pre -specified in the SAP.  
SAFETY OUTCOME MEASU RES 
The safety outcome measures for this study are as follows:  
 Incidence, type, and severity of adverse events  
 Abnormal vital signs  
 Abnormal laboratory values  
 
Safety will be monitored through  regular physical examinations, vital signs,  hematologic and 
chemistry laboratory tests, urinalyses, and incidence and severity  of adverse events.  In 
addition, the following will be examined:  
 Circulating B cells, T cells, neutrophils and other cell popula tions  
 Plasma immunoglobulins (total Ig, IgG, IgM, and IgA)  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
18/Protocol WA29748, Version 4  Record of menses  
 Pregnancy  
 Antibody titers for mumps, rubella, Varicella , tetanus, influenza, and Streptococcus 
pneumoniae  
 
PHARMACODYNAMIC OUTC OME MEASURE  
The primary PD outcome measure for this s tudy is as follows:  
 Changes in levels of circulating CD19  B-cells relative to baseline  
 
PHARMACOKINETIC OUTC OME MEASURES  
The obinutuzumab PK outcome measures for this study are as follows:  
Non-linear mixed -effects modeling (with software NONMEM) will be used to analyze the dose -
concentration time data of obinutuzumab.  The PK profile data will be used to further develop a 
PK model, including the effect of major covariates (e.g., sex, race/ethnicity, weight, biochemical 
and hematological parameters at base line, degree of underlying disease), on the main 
parameters (e.g., clearance).  The derivation of individual measures of exposure, such as area 
unde r the concentration -time curve  and maximum concentration observed will depend on the 
final PK model used for  this analysis.  Results of this analysis may be reported separately.  
Serum obinutuzumab will be summarized (mean, minimum, maximum, SD, and geometric 
mean) and reported within this study.  
Exploratory graphical analyses will be performed to assess whethe r the occurrences of serious 
adverse events and abnormalities in the safety laboratory parameters in patients  treated with 
obinutuzumab can be attributed to obinutuzumab exposure.  Also,  exploratory 
graphical  analyses will be performed to assess whether th e variability  in response can be 
attributed to  the variability in obinutuzumab exposure.  Relevant  observed relationships 
between exposure and safety parameters may be  further characterized using different 
approaches such as logistic regression analysis an d indirect response modeling.  
Additional PK and PD analyses may be conducted as appropriate.  
PATIENT -REPORTED OUT COME MEASURE  
The PRO measure for this study is as follows:  
 Subject’s Global Assessment  
This visual analog scale (VAS) will be captured in screening, at the baseline visit, and at 
several timepoints during study conduct.  
 
EXPLORATORY OUTCOME MEASURES  
The exploratory outcome measures for this study are as follows:  
 Changes in levels of circulating B -cell subsets relative to baseline  
 Changes in  levels of exploratory biomarkers, which may include but are not limited to levels 
of protein and mRNA in serum, plasma, blood, and urine, relative to baseline  
 Proportion of patients experiencing a Systemic Lupus Erythematosus Disease Activity 
Index -2K flare 
 Proportion of patients experiencing a renal flare over 52 weeks and 104 weeks  
 Proportion of patients achieving CRR, mCRR1, mCRR2, and mCRR3 at additional 
timepoints, including Week 12 and Week 36  
 Physician’s Global Assessment  
This VAS will be captured in screening, at the baseline visit, and at several timepoints 
during study conduct.  
 GTCI  
 Renal biopsy evaluations  
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
19/Protocol WA29748, Version 4 INVESTIGATIONAL MEDI CINAL PRODUCTS  
TEST PRODUCT (INVEST IGATIONAL DRUG)  
The test product for this study is obinutuzumab  and will be administered by IV infusion at a dose 
of 1000  mg on Days 1, 15, 168, and 182.  The study drug will be administered in a hospital or 
clinic environment where full resuscitation facilities are immediately available and under close 
supervision of  the investigator or designee.  After the end of the first infusion, the IV line will 
remain in place for at least 2 hours to enable administration of IV drugs if necessary.  If no 
adverse events occur during this period of time, the IV line may be removed .  For subsequent 
infusions, access through an IV line should remain in place for at least 30 minutes from the  end 
of the infusion, and if no  adverse events occur after 30 minutes, the IV access may be removed.  
COMPARATOR (PLACEBO)  
The obinutuzumab placebo  (corresponding to the obinutuzumab1000 -mg dose) will be 
administered by IV infusion on Days 1, 15, 168, and 182.  The placebo will be administered in a 
hospital or clinic environment where full resuscitation facilities are immediately available and 
under close supervision of the investigator or designee.  After the end of the first infusion, the IV 
line will remain in place for at least 2 hours to enable administration of IV drugs if necessary.  If 
no adverse events occur during this period of time, the IV  line may be removed.   For 
subsequent infusions, access through an IV line should remain in place for at least 30 minutes 
from the  end of the infusion, and if no  adverse events occur after 30 minutes, the IV access may 
be removed . 
NON -INVESTIGATIONAL MEDIC INAL PRODUCTS  
After screening , patients who were not already receiving MMF  or MPA  will receive 1500  mg/day 
(or equivalent)  in divided doses ( 23 times/day), and all patient doses will be titrated upward to 
a target dose of 2. 02.5 g/day (or equivalent)  in divided doses (2 3 times/day) by Week 4, as 
tolerated.  If reductions in dose are necessary, decreases will be allowed in 250 500 mg (or 
equivalent)  decrements.  During screening or at randomization, if clinically indicated, patients 
may receive 7501000 mg methylprednisolone IV once daily for up to 3 days to treat underlying  
LN clinical activity.  Patients will receive 0. 5 mg/kg oral prednisone, tapering this prednisone 
dose, per protocol, starting on Day  16 and reducing the prednisone dosage to 7.5  mg/day by 
Week  12. 
Prior  to each infusion of either study drug or placebo, patients should receive prophylactic 
treatment with acetaminophen (650 1000 mg) and diphenhydramine (50  mg; or equivalent dose 
of a similar agent) by mouth, given 30 60 minutes before  the start of the infusion period.  The 
patients who are receiving obinutuzumab will receive 80  mg methylprednisolone IV and patients 
who are receiving placebo will receive placebo -methylprednisolone IV given 30 60 minutes 
before the start of the obinutuzu mab/placebo infusion.  
CONCOMITANT THERAPY AND CLINICAL PRACTIC E 
Patients  who are not already taking vitamin D ( 800 IU/day) and calcium supplements 
(1200  mg/day of calcium citrate or 1500 mg/day of calcium carbonate) will begin taking  these 
supplements at randomization.  All patients will take either an ACE inhibitor or an 
angiotensin -receptor blocker titrated to adequate blood pressure control as recommended by 
the National Kidney Foundation for chronic kidney disease.  
Other  agents tha t affect proteinuria will not be allowed to be initiated during the study.  These 
include but are not limited to the following:  
 Non-dihydropyridine calcium antagonists  
 Dihydropyridine calcium antagonists  
 Aldosterone antagonists  
 Direct renin antagonists  
 
STATISTICAL METHODS  
All efficacy outcomes will be analyzed according to the modified intent -to-treat principle and will 
include all randomized patients who have received any amount of study drug.  Patients will be 
grouped according to randomized (assigned) t reatment, rather than treatment received.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
20/Protocol WA29748, Version 4 Treatment period data will be locked after all patients have completed the Week 52 visit.  The 
primary efficacy and safety analyses will be performed on data for all patients through the Week 
52 assessments or earl y discontinuation.  
Safety assessments will be performed on patients who receive study medication.  In all safety 
analyses, patients will be grouped according to the treatment that patients actually received 
rather than the treatment assigned.  
The primary a nd secondary efficacy analyses will include all randomized patients who received 
any study medication, with patients grouped according to the treatment assigned at 
randomization.  
PRIMARY ANALYSIS  
The primary assessment of efficacy of obinutuzumab,  to induc e a clinically significant 
improvement in renal function in patients with ISN/RPS 2003 class III or IV LN, will be assessed 
by attainment of CRR.  
CRR is defined as achievement of all of the following:  
 Normalization of serum creatinine as evidenced by the f ollowing:  
Serum creatinine  the ULN range of central laboratory values if the baseline (Day  1) 
serum creatinine is above the ULN  
Serum creatinine  15% above baseline and  the ULN range of central laboratory 
values if baseline (Day 1) serum creatinine is  the ULN range of central laboratory 
values  
 Inactive urinary sediment (as evidenced by   10 RBCs/HPF and the absence of red cell 
casts)  
 Urinary protein to creatinine ratio  0.5 
 
Any patient who switches to rescue medication prior to Week 52 will be considered a 
non-responder.  
The proportions of patients achieving CRR across treatment  groups will be compared using a 
Cochrane -Mantel -Haenzel ( CMH ) test with race (Afro -Caribbean/ African American versus 
others) and region (United States versus non -United States) as stratification factors.  If the test 
result is in favor of the obinutuzumab group at   0.1-level (one -sided), it will be concluded that 
there is a shift toward better renal response associated with the obinutuzumab group.  
DETERMINATION OF SAM PLE SIZE   
This Phase II study is a proof -of-concept study that is designed to detect an improvement in 
CRR.  The primary efficacy endpoint of this study is the proportion of patien ts that achieve CRR.  
It is estimated that approximately 30% of patients with proliferative LN who are receiving MMF 
(or equivalent) will achieve a CRR at Week 52 and that the addition of obinutuzumab to MMF 
(or equivalent) will induce an overall CRR rate o f 50% at Week 52.  On the basis of these 
assumptions, a total of 120  patients randomized to obinutuzumab - and placebo -treated groups 
in a 1:1  ratio (60  patients in each of the obinutuzumab - and placebo -treated groups) will yield 
approximately 83% power at the two -sided   0.2 significance level using a CMH  test, 
assuming the same CRR proportions across the strata.  
INTERIM ANALYSES  
Pharmacody namic Futility Interim Analysis  
Given the rationale for this st udy, including the results from the LUNAR and BELONG studies, 
an interim analysis for futility is planned on the basis of CD19 B -cell counts after 30 patients 
have been assigned to the obinutuzumab arm and have had their Day 28 blood CD19 B -cell 
counts ass essed by HSFC.  
The effect of rituximab on CD19 B -cell counts has been measured by HSFC in an investigator -
sponsored study in which  peripheral B -cell depletion below the lower limit of quantification  
(LLOQ ) of the assay  occurred in 46% of patients.  Slightly less than half of these rituximab -
treated patients with  full peripheral B -cell depletion  achieved a major clinical response, with the 
remainder of the patients having partial clinical responses.  Therefore, it is hypothesized that an 
improved outc ome over rituximab is achievable for a LN patient population with  full peripheral B -
cell depletion, with the assumption that improved tissue depletion with treatment will parallel the 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
21/Protocol WA29748, Version 4 peripheral depletion.  To test the hypothesis in this study, we will req uire at least 50% of the 
obinutuzumab -treated patients to have  peripheral B -cell depletion below the LLOQ of the HSFC 
assay  in order to have a realistic chance of a positive primary endpoint analysis for the 
treatment arm.  Quantification of the link betwe en this biomarker and the study’s primary 
analysis has not been established; therefore predictive probabilities for study statistical 
significance cannot be provided.  Consequently, the study will be terminated if the 5% one -sided 
Clopper -Pearson upper con fidence limit for the proportion of patients who achieve B -cell 
depletion is not greater than 0.5.  Assuming that there are 30 patients at the time of the interim 
analysis, this will effectively require that  11 obinutuzumab patients have complete B -cell 
depletion below the LLOQ of the HSFC assay  at the time of the interim analysis.  
The interim analysis will be performed by the independent Data Monitoring Committee ( iDMC ), 
which may recommend that the study be stopped for futility if the futility criterion  is satisfied.  
Additional criteria for recommending that the study be stopped for futility may be added to the 
iDMC Charter.  
As this interim analysis will only result in termination of the study due to futility, and not for 
efficacy, an adjustment to the -level is not required.  Although the outcome of the interim 
analysis may reduce the power of this study to below the estimated 83%, a sample size 
adjustment has not been made.  
Renal Response Interim Analysis  
The iDMC will conduct an interim efficacy anal ysis to evaluate renal response when the last 
patient has achieved the 6 -month visit.  The interim analysis will be performed and interpreted 
by members of the iDMC, who may recommend to the Sponsor the initiation of future study 
planning, according to rul es outlined in the iDMC Charter.  If the iDMC does recommend that 
future study planning can begin, then the summary of renal response data at Week 24 will be 
shared with appropriate Sponsor senior management personnel who will be unblinded at the 
treatment  group level.  
This interim analysis is for planning purposes only and will have no impact on the progression of 
this study.  Consequently, an adjustment to the -level is not required.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
22/Protocol WA29748, Version 4 LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
Abbreviation  Definition  
ACE angiotensin -converting enzyme  
ACR  American College of Rheumatology  
ADA anti-drug antibody  
ADCC  antibody -dependent cell -mediated cytotoxicity  
ALMS  Aspreva Lupus Management Study  
ANA  anti-nuclear antibody  
ARB angiotensin -receptor blocker  
AUC  area under the concentration –time curve  
BAFF  B-cell activating factor  
BCFU  B-cell follow -up 
CDC  complement -dependent cytotoxicity  
CLL chronic lymphocytic leukemia  
Cmax maximum concentration observed  
CMH  Cochrane -Mantel -Haenzel  
CRR  complete renal response  
EC Ethics Committee  
eCRF  electronic case report form  
EDC  electronic data capture  
ESRD  end-stage renal disease  
GC germinal center  
GFR  glomerular filtration rate  
GI gastrointestinal  
GTCI  Glucocorticoid Toxicity Change Index  
HBcAb  hepatitis B core antibody  
HBsAg  hepatitis B surface antigen  
HBV hepatitis B virus  
HIPAA  Health Insurance Portability and Accountability  Act 
HPF high-power field  
HSFC  high-sensitivity flow cytometry  
ICH International Conference on Harmonisation  
iDMC  independent Data Monitoring Committee  
IMP investigational medicinal product  
IRB Institutional Review Board  
IRR infusion -related reaction  
ISN International Society of Nephrology  
IV intravenous  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
23/Protocol WA29748, Version 4 Abbreviation  Definition  
IxRS  interactive voice/Web response system  
LLN lower limit of normal  
LLOQ  lower limit of quantification  
LN lupus nephritis  
mAb monoclonal antibody  
mCRR1  modified complete renal response  
mCRR2  second modified complete renal response  
mCRR3  third modified complete renal response  
MMF  mycophenolate mofetil  
MOA  mechanism of action  
MPA  mycophenolic acid  
NaCl  sodium chloride  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for 
Adverse Events  
NHL non-Hodgkin’s lymphoma  
NK natural killer  
NSAID  nonsteroidal anti -inflammatory drug  
PD pharmacodynamic  
PK pharmacokinetic  
PML progressive multifocal leukoencephalopathy  
PRO  patient -reported outcome  
PRR  partial renal response  
RCR  Roche Clinical Repository  
RPS Renal Pathology Society  
SAP Statistical Analysis P lan 
SLE systemic lupus erythematosus  
SLEDAI  Systemic Lupus Erythematosus Disease Activity Index  
SLICC  Systemic Lupus International Collaborating Clinics  
TI tubulointerstitial inflammation  
ULN upper limit of normal  
VAS visual analog scale  
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
24/Protocol WA29748, Version 4 1. BACKGROUND  
1.1 BACKGROUND ON LUPUS NEPHRITIS  
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease that occurs 
primarily in women of childbearing age.  It is characterized by multisystem involvement 
and immunological abnormalities, and much of the tissue damage is thought to occur 
through autoantibody formation and immune complex deposition.  The disease is 
heterogeneous in its clinical presentation, course, and prognosis.  However, most 
patients present with joint involvement, skin rashes, mouth ulcers, Raynaud’s 
phenomenon, and/or severe fatigue.  Inflammation of pericardial and pleural tissues may 
also be present.  The most serious manifestations include CNS and renal invo lvement, 
which correlate with poor outcomes that include temporary or permanent disability or 
death.  Typically, the disease follows a relapsing -remitting course with intermittent 
periods of disease activity (flare) interspersed with periods of relative qu iescence.  
The incidence and prevalence of SLE varies with sex, race, and ethnicity.  The 
estimated prevalence of SLE in the United States ranges between 65 and 155 per 
100,000  (Walsh  et al. 2001 ; Ward  2004 ; Naleway  et al. 2005 ; Chakravarty  et al. 2007 ; 
Molina et al. 2007 ; Sacks  et al. 2010 ; Feldman  et al. 2013 ; Furst  et al. 2013 ; 
Lim et al. 2014 ).  In adulthood, approximately nine times as many women as men are 
affected.  The disease has a higher incidence and worse outcome among 
African -Americans, Afro -Caribbeans, Hispanics, and Asians compared with Caucasians.  
Medications for the successful treatment of SLE as measured by long -term remission 
are limited, and on ly one new medication for SLE treatment has been approved in more 
than 50 years (Burness and McCormack 2011 ).  Analgesi cs and nonsteroidal 
anti-inflammatory drugs  (NSAIDs)  provide partial symptomatic relief.  Anti -malarial drugs 
are gen erally well tolerated by patients with SLE and appear to have a beneficial effect 
on the prevention of lupus flare s, increasing long -term survival, and possibly 
ameliorating certain types of organ damage ( Ruiz-Irastorza  et al. 2009 ).  However, these 
agents are generally regarded as having insufficient efficacy for moderate to severe 
manifestations of SLE.  
The mainstay s of therapy for more significant manifestations of SLE are corticosteroids 
and off -label use of immunosuppressive drugs (e.g., methotrexate, myco phenolic acid 
[MPA] [as either mycophenolate mofetil (MMF)  or Myfortic (MPA  as sodium salt) ], 
azathioprine, and cyclophosphamide), which have profound and diverse effects on the 
immune system in patients with lupus.  However, the use of these immunosuppressant 
agents is limited by their safety profiles.  Corticosteroids, for example, are effective for 
many of th e manifestations of SLE but have significant short - and long -term adverse 
effects, including infections, osteoporosis, hyperglycemia, and hyperlipidemia.  
Lupus nephritis (LN) is a common manifestation of SLE and continues to be a major 
cause of morbidity a nd mortality in this patient population.  Of unselected patients with 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
25/Protocol WA29748, Version 4 SLE, 25% 50% have abnormalities of urine or renal function early in the course of their 
disease, and up to 60% of adults and 80% of children may eventually develop overt
renal abnormalities (Cameron 1999).  Proteinuria is the most common feature of LN, 
often in the nephrotic range, and is frequently accompanied by a worsening of renal 
function.  The clinical course of LN varies from mild subclinical disease to an aggressive 
course that may progress to end-stage renal disease (ESRD)  (Flanc et al. 2004).  This is 
particularly concerning because patients with LN, despite having a decrease in clinical 
lupus activity after they begin renal replacement therapy, have been noted to have
poorer outcomes than other patients with non-lupus causes of ESRD (Lee et al. 2003).
The nature and severity of the clinical features do not always predict the underlying 
histological severity, and renal biopsy is necessary for a precise diagnosis.  The findings 
from a consensus conference in 2002 on renal pathology in LN were adopted by the 
International Society of Nephrology (ISN) and the Renal Pathology Society (RPS)
leading to the ISN/RPS 2003 classification system (Weening et al. 2004).  This 
classification scheme grades LN on the basis of histological features seen using light 
microscopy (see Table 1 ).
Table 1 International Society of Nephrology/Renal Pathology Society
2003 Classification of Lupus Nephritis
Class I Minimal mesangial LN
Class II Mesangial proliferative LN
Class III Focal LN (  50% of glomeruli)
III (A):  active lesions
III (A/C):  active and chronic lesions 
III (C):  chronic lesions
Class IV Diffuse LN (  50% glomeruli)
Diffuse segmental (IV-S) or global (IV-G) LN 
IV (A):  active lesions
IV (A/C):  active and chronic lesions
IV (C):  chronic lesions
Class V Membranous LN
Class VI Advanced sclerosing LN (  90% globally sclerosed glomeruli without
residual activity)
LN   lupus nephritis.
Note:  Class V may occur in combination with Class III or IV, in which case both will be 
diagnosed.
Source:  Markowitz GS, D’Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an 
assessment at 3 years. Kidney Int 2007;71:491 –5.
 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
26/Protocol WA29748, Version 4 Cyclophosphamide, MMF or MPA, and azathioprine, along with corticosteroids, have 
been used in the treatment of proliferative Class III/IV LN with varying degrees of
success and varying adverse effects (Houssiau et al. 2004).  Cyclophosphamide
became a dominant standard of care in the 1980s, yet acute and dose-limited toxicity 
prompted the investigation of lower-dose regimens such as the Euro-lupus regimen 
(Houssiau et al. 2002).  Toxicity also prompted the search for new therapies, including 
MMF (Chan et al. 2000; Ginzler et al. 2005), and a study that directly compared the two 
therapies (Contreras et al. 2004).  Given the organ-threatening severity of LN, 
placebo-controlled studies were not considered to be appropriate to prove the efficacy of 
either agent, and both cyclophosphamide and MMF became unapproved standards of 
care (Hahn et al. 2012).
A major advance in the treatment of patients with LN was the demonstration that MMF 
was comparable in efficacy and safety to cyclophosphamide in the Aspreva Lupus 
Management Study (ALMS) (Appel et al. 2009) and potentially superior to azathioprine
in remission maintenance (Dooley et al. 2011).  These critical studies solidified the place 
of MMF as a potentially effective therapy for LN, although MMF was not found to be 
superior to cyclophosphamide.  Both MMF and cyclophosphamide are considered to be 
first-line therapies for the treatment of patients with proliferative LN, as outlined in the 
American College of Rheumatology (ACR) Lupus Nephritis Guidelines
(Hahn et al. 2012).
As a measure of unmet need, the risk of mortality remains elevated for patients with 
lupus.  In the modern era, on the basis of a multisite international cohort of 9500 patients 
with lupus, the standardized mortality ratio was 2.4, with particularly high mortality seen 
with renal disease (Bernatsky et al. 2006). Among patients with LN, 10%-30% of 
patients progress to ESRD despite aggressive immunosuppressive therapy
(Costenbader et al. 2011).  Whereas these outcomes have improved over the past
30 years, continued risk of treatment failure remains (as defined by death, ESRD, 
sustained doubling of serum creatinine, LN flare, or need for rescue medications), which 
ranges 14.5%-20.1% per 100 patient-years over the course of follow-up
(Dooley et al. 2011; Rovin et al. 2012).
1.2 BACKGROUND ON OBINUTUZUMAB
Obinutuzumab (also known as GAZYVA or GA101) is a recombinant, monoclonal, 
humanized, and glycoengineered type II CD20 antibody of the IgG1 isotype that 
specifically targets the extracellular loop of the CD20 transmembrane antigen that is 
expressed on the surface of non-malignant and malignant pre-B and mature
B lymphocytes but not on hematopoietic stem cells, pro-B cells, normal plasma cells, or 
other normal tissue (Mössner et al. 2010; Niederfellner et al. 2011; Klein et al. 2013). 
Glycoengineering of the Fc portion of obinutuzumab results in a higher affinity for 
FcgRIII receptors on immune effector cells such as natural killer (NK) cells and 
macrophages/monocytes (Mössner et al. 2010).

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
27/Protocol WA29748, Version 4 Obinutuzumab in combination with chlorambucil is currently approved in multiple 
countries worldwide for the treatment of patients with previously untreated ch ronic 
lymphocytic leukemia (CLL).  
Data from an estimated 3284 patients, up to 31 October 2014, are available for safety 
analysis of obinutuzumab in clinical studies.  These data include patients with CLL or 
non-Hodgkin’s lymphoma  (NHL) from doses of 502000 mg in monotherapy or in 
combination with cyclophosphamide, doxorubicin, vincristine, and prednisone ; 
fludarabine plus cyclophosphamide; bendamustine; or chlorambucil.  
Nonclinical in vitro studies show that obinutuzumab mediates superior induction of dire ct 
cell death and effector cell -mediated antibody -dependent cell -mediated cytotoxicity 
(ADCC) and antibody dependent cellular phagocytosis on a panel of NHL cell lines 
compared with the type I CD20 antibodies rituximab and ofatumumab.  Conversely, its 
potency to mediate complement -dependent cytotoxicity (CDC) is significantly reduced 
compared with these two antibodies.  In ex vivo autologous whole -blood B -cell depletion 
studies with blood from healthy volunteers as well as patients with CLL, obinutuzumab 
mediated superior B -cell depletion when compared with rituximab.  
These properties of obinutuzumab translated into superior anti -tumor efficacy in direct 
comparison with rituximab against a number of aggressive subcutaneous and 
disseminated NHL xenograft mod els.  The efficacious and optimal dose range of 
obinutuzumab in xenograft models ranged 10 30 mg/kg, corresponding to trough levels 
of 300600 g/mL.  Treatment with obinutuzumab resulted in potent and superior 
depletion of B -cells in the peripheral blood and in lymphoid tissues of hCD20 transgenic 
mice and cynomolgus monkeys.  Vaccination studies in cynomolgus monkeys and 
human CD20 transgenic mice showed that the enhanced efficacy in terms of the B -cell 
depletion of obinutuzumab translated into suppressio n of de novo antibody responses 
but left the protective humoral memory responses intact.  
The data generated to date imply that obinutuzumab represents a novel therapeutic 
anti-CD20  antibody with outstanding efficacy compared with classical type I and 
non-ADCC -enhanced anti -CD20 antibodies, such as rituximab, ocrelizumab and 
ofatumumab.  
See the immunology Obinutuzumab Investigator's Brochure for additional details on 
nonclinical and clinical studies of obinutuzumab.  
1.3 STUDY RATIONALE AND BENEFIT -RISK ASSESSM ENT 
Multiple studies have demonstrated histopathologic involvement of B and T cells in LN 
pathogenesis.  A temporal model established from lupus -prone mice strains with 
nephritis suggests that autoantibodies and immune complexes deposit within the 
glomerular  basement membrane of the kidney, fix complement, and cause local 
inflammation.  Lymphocytes, macrophages, and neutrophils migrate into the kidney and 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
28/Protocol WA29748, Version 4 establish continued tubulointerstitial inflammation (TI) that triggers proliferative 
mesangial changes in  the glomeruli with resultant proteinuria, hematuria, and altered 
renal function.  This experimental nonclinical model demonstrates antibody -producing 
cells (APCs) that mature into plasma cells ( Cassese et al. 2001 ).  As an organized 
immunologic reaction i nvolving B cells, T cells, macrophages, and supporting dendritic 
cells becomes amplified, renal function further deteriorates and is fatal in multiple mouse 
models.  
The presence of B cells in LN has been better characterized over the past 10  years 
(Steinme tz et al. 2008 ; Lee and Ballow 2010 ).  Recently, Chang et al. ( 2011 ) published 
an extensive histopathologic review of LN biopsy samples from a longitudinal series of 
patients at the University of Chicago.  This review confirms the presence of B  cells in LN  
biopsies and describes their organization into T:B -cell aggregates and germinal centers 
(GCs).  The review also confirmed that TI is an important pivotal variable and an 
independent risk factor in predicting renal outcomes in patients with LN ( Hill et al.  2000 ; 
Alsuwaida et al. 2013 ).  On renal biopsy, the presence and degree of TI is prognostic 
and may identify those patients with LN who are at risk for progression to renal failure 
(Schwartz et al. 1982 ; Esdaile et al. 1989 ; Hsieh et al. 2011 ).  As such, TI is a central 
manifestation of LN that might arise from different pathogenic mechanisms from those 
implicated in glomerulonephritis, and it may serve as a potential therapeutic target in this 
disease.  
These data, demonstrating the presence of B cells in LN, implicate tertiary lymphoid 
neogenesis in the pathogenesis of lupus TI.  The presence of lymphoid -like structures 
strongly correlated with detectable tubular basement membrane immune complexes.  
These observations suggested that in LN, GCs , and T:B aggregates select for cells that 
locally secrete pathogenic antibodies in the tubulointerstitium.  Furthermore, the data 
indicated that such plasmablast foci are a usual feature of LN that is complicated by 
severe TI.  Although interstitial inflam mation often correlates with the extent of 
glomerular injury in LN, there are several lines of evidence that these processes may be 
distinct.  Chang et al. (2011 ) hypothesized that identification of the in situ antigens and 
factors promoting local B -cell s election and expansion of organized immunological 
structures in the interstitium should yield important biomarkers and could lead to novel 
therapeutic strategies in LN.  Anti -vimentin autoantibodies are being investigated as a 
potentially pathogenic autoan tibody produced by vimentin expression in the damaged 
interstitium ( Kinloch  et al. 2014 ).  
Genentech and Roche have experience conducting LN clinical studies with two 
anti-CD20 compounds:  rituximab and ocrelizumab.  Study U2790g (the LUNAR study; 
Rovin  et al. 2012 ) was a randomized, parallel arm, add -on double -blind 
placebo -controlled study in patients with Class III and IV proliferative LN.  The study 
evaluated the regimen of rituximab plus MMF versus MMF in combination with 
methylprednisolone infusions a nd a prednisone taper and enrolled 144  adult patients in 
North and South America.  The study failed to meet its primary endpoint of overall 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
29/Protocol WA29748, Version 4 response (weighted toward complete renal response  [CRR] ); no major new safety 
signals were identified.  The LUNAR st udy determined that the combination of 
rituximab   MMF was more effective at reducing anti -dsDNA autoantibody levels and 
increasing complement levels than MMF alone.  In addition, there was a 15.3% increase 
of partial renal response (PRR) with rituximab, a nd fewer patients in the rituximab arm 
required rescue with cyclophosphamide (n   1) versus the MMF -alone arm (n   8).  A pre -
specified sub -analysis of African American patients (n   40) demonstrated that 70% of 
these patients responded (PRR   CRR ) in the rituximab arm versus 45% in the 
MMF -alone arm (p   0.2) ( Rao et al. 2012 ).  This analysis clarified that non -responders 
had higher mean serum creatinine levels, a higher degree of proteinuria, and higher 
mean blood pressure than did responders.  
The partial  response observed in the LUNAR study, in addition to the multiple 
publications that suggest partial response in patients with more refractory disease 
(Lu et al. 2009 ; Jónsdóttir  et al. 2010 ; Roccatello  et al. 2011 ; Turner -Stokes  et al. 2011 ; 
Díaz-Lagares  et al. 2012 ; Gregersen  and Jayne  2012 ; Furtado and Isenberg  2013 ), 
particularly with the combination of rituximab and cyclophosphamide ( Ng et al. 2007 ), 
has suggested that rituximab has a place in the treatment of these patients and led to its 
incorporatio n into the ACR LN Treatment Guidelines in 2013 ( Hahn et al. 2012 ).  This 
partial response difference along with the improvement in anti -dsDNA antibody and 
complement levels suggests that the drug has activity, but not at the level of CRR.  
These findings, in addition to lupus -related factors described below that might impair 
rituximab’s ability to deplete B cells in SLE, are consistent with the hypothesis that 
incomplete local B -cell depletion contributed to a partial response and that a more 
efficient B -cell depleting agent (obinutuzumab) might be associated with greater efficacy.  
A PRR improvement was also observed in a second company -sponsored study of LN, 
Study WA20500 (the BELONG study; Mysler et al. 2013 ).  The BELONG study was a 
Phase III dose -ranging  study that evaluated ocrelizumab, a humanized anti -CD20 
monoclonal antibody  (mAb)  therapy with 3 5-fold greater ADCC than rituximab.  The 
BELONG study enrolled 350  patients in an international, double -blind, randomized, 
controlled dose -ranging study enrolling Class  III and Class  IV patients with LN who were 
treated with a background therapy of either MMF or Euro -Lupus -regimen 
cyclophosphamide ( 500 mg intravenous [ IV] every 2  weeks   6 doses).  This study was 
terminated because of a minor imbalance of serious infectious events (largely confined 
to countries in Asia) and after the LUNAR study data became available, suggesting that 
the likelihood of a positive outcome had decreased significantly.  
There were several notable findings from the BELONG study.  Ocrelizumab was 
associated with a 12.2% increase in overall response (66.9%) across both doses and 
background treatments compared with controls (54.7%).  In the Euro -Lupus 
regimen -cyclophosphamide treated  patients, ocrelizumab was associated with a 22.7% 
increase in overall response (65.6%) across both doses compared with the control 
(42.9%).  Serious infectious events were clustered within the first 12  weeks of the study, 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
30/Protocol WA29748, Version 4 consistent with the time of maximal prednisone exposure.  Lastly, ocrelizumab was 
associated with a significant decrease in anti -dsDNA antibody levels and an 
improvement in complement levels compared with the controls.  These findings replicate 
the efficacy and immunologic outcomes from the LUNAR study and are consistent with 
the hypothes is that patients with LN are resistant to B -cell depletion and that anti -CD20 
therapy is associated with PRR.  
There are available data that demonstrate that achievement of CRR is prognostic of a 
good long -term outcome ( Chen et al. 2008 ); however, across th e LUNAR and BELONG 
studies, only 30 %40% of patients were able to achieve CRR at 12  months.  In the 
LUNAR study ( Rovin et al. 2012 ), 54% of the patients who were randomized to the 
high-dose MMF/high -dose prednisone arm achieved no response, defined as fail ure to 
achieve PRR or CRR or having met another definition of treatment failure.  Recently, 
efforts have been made to identify subsets of patients treated with either Euro -Lupus  
cyclophosphamide ( Houssiau et al. 2004 ) or MMF ( Dall’Era  et al. 2011 ) who achieve a 
short -term favorable outcome and are of potentially lower unmet medical need.  The 
putative biomarkers from the ALMS database that predict good response are baseline 
C4 level, duration of diagnosis, baseline estimated glomerular filtration rate ( GFR), early 
normalization of complement, and reduction of proteinuria by  25% from baseline 
(Dall’Era et al. 2011 ).  Other clinical prognostic factors such as non -Caucasian race, 
poor socioeconomic status, uncontrolled hypertension, high activity and chro nicity score 
(on biopsy), baseline renal impairment, nephritic relapses, and poor initial therapy 
response have been associated with a poor outcome and thus higher unmet need.  With 
these factors in mind, a significantly high proportion of patients have po or prognostic 
factors and exhibit major unmet medical needs despite currently available therapies.  A 
recent review of 73  patients undergoing renal biopsy for LN concluded that persistence 
of interstitial inflammation is also associated with poor long -term outcome, yet few 
patients receive repeat renal biopsies, suggesting that unrecognized, uncontrolled 
inflammation may be present in many patients ( Alsuwaida 2013 ).  Existing therapies 
have known toxicities that can limit their use, and prednisone toxicity is increasingly 
recognized as a major concern with standard induction regimens ( Petri et al. 2014 ).  
Higher rates of CRR, faster achievement of CRR, improved tolerability of drugs, 
significant reduction of prednisone exposure, and reduction of flares in ma intenance 
stages have currently not been achieved.  
The scientific rationale for the experimental use of obinutuzumab in LN is supported by 
multiple experiments that suggest that patients with SLE are resistant to B -cell depletion 
with rituximab, as descri bed below.  SLE is considered a classic autoimmune disease 
marked by a loss of B -cell tolerance ( Rahman  and Isenberg  2008 ).  There are multiple 
publications that document the presence of B cells in active LN, both from experimental 
mouse models of lupus ( Cassese  et al. 2001 ) and also from more recent surveys of LN 
histopathology ( Chang  et al. 2011 ).  This evidence demonstrates a primary role for 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
31/Protocol WA29748, Version 4 B cells in disease pathogenesis; however, two studies using anti -CD20 therapies in LN 
(the LUNAR and BELONG studi es) demonstrated only partial responses.  
Recent data suggest that B cells are resistant to and are incompletely depleted by 
rituximab in the peripheral blood of patients with SLE ( Vital et al. 2011 ).  The explanation 
for this finding may be related to the putative mechanisms of actions (MOAs) of 
rituximabthe indirect depletion of CD20  B cells by ADCC and CDC and via apoptotic 
mechanisms, as well as new information that all three may be impaired in patients with 
lupus.  
ADCC and the interaction between the Fc portion of rituximab and the effector cell may 
be altered in SLE ( Ahuja et al. 2011 ).  CDC may be impaired by the 
hypocomplementemic environment of LN, and the role of complement in B -cell depletion 
of patients with SLE has not been formally studied ( Leffler et al. 2014 ).  Apoptotic 
defects are known to occur in SLE ( Bouts  et al. 2012 ), and this resistance to normal 
cellular death may translate to incomplete B -cell killing with rituximab via this 
mechanism.  In addition, the elevated human anti -chimeric antibody rates that were 
observed in the rituximab lupus studies and the early peripheral B -cell return that was 
repeatedly demonstrated in patients with SLE who were treated with rituximab is further 
evidence that rituximab may not have fully depleted B c ells in these studies.  
Obinutuzumab is a humanized, type II  anti-CD20 mAb  that has been approved for CLL 
and was demonstrated in clinical studies to be superior to rituximab ( Dooley et al. 2011 ).  
Obinutuzumab exhibits direct B -cell killing through a type  II mechanism 
(Honeychurch  et al. 2012 ) and has significantly higher ADCC compared with either 
rituximab or ocrelizumab, a type I humanized anti -CD20 mAb (see the Obinutuzumab 
Investigator’s Brochure).  Obinutuzumab has lower CDC and less dependence on 
complement for its MOA.  There are recent data that suggest that obinutuzumab may 
show depletion of B cells superior to rituximab in lupus -prone mouse models 
(unpublished data on file) and in patients with lupus (in an in vitro peripheral blood 
mononuclear ce lls analysis of B  cells) ( Reddy et al. 2014 ).  With consideration of these 
combined data, this scientific rationale supports the Phase II evaluation of obinutuzumab 
in patients with LN.  
Given the high unmet medical need of patients with LN for an improved CRR rate and 
therefore reduced risk of ESRD, achievement of this benefit is desirable.  The known risk 
of obinutuzumab, as characterized in the CLL -11 Stage  2 head -to-head study of 
obinutuzumab versus rituximab ( Goede  et al. 2014 ), suggests that its risk p rofile is 
comparable to rituximab, with the exception of worsened infusion -related reactions  
(IRRs) .  In this setting, the benefit -risk assessment favors conducting this Phase II 
randomized clinical study.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
32/Protocol WA29748, Version 4 2. OBJECTIVES  
2.1 EFFICACY OBJECTIVES   
The primary effica cy objective for this study is as follows:  
 To evaluate the efficacy of obinutuzumab compared with placebo in patients with 
ISN/RPS Class III or IV LN as measured by CRR at 52 weeks  
 
The secondary efficacy objectives for this study are as follows:  
 To assess  overall renal response (defined as CRR plus PRR)  
 To evaluate the ability of obinutuzumab to improve time -to-response (CRR plus 
PRR) over the course of 52 weeks  
 
2.2 SAFETY OBJECTIVES  
The safety objectives for this study are as follows:  
 To evaluate the safety of obinutuzumab compared with placebo in patients with 
Class III or IV LN, focusing on the nature, frequency, and severity of serious and 
non-serious adverse events, as well as effects on laboratory values, vital signs, or 
other safety biomarkers  
 To charac terize the immunogenic potential of obinutuzumab by measuring human 
anti-drug antibodies (ADA s) and assessing their relationship with other outcome 
measures  
 To fully characterize adverse events of special interest, including infusion reactions, 
infections,  thrombocytopenia, and neutropenia  
 
2.3 PHARMACODYNAMIC OBJE CTIVE  
The pharmacodynamic (PD) objective for this study is as follows:  
 To compare changes in CD19  B cells in the peripheral blood following treatment 
with obinutuzumab versus placebo  
 
2.4 PHARMACOKINETIC  OBJECTIVES  
The pharmacokinetic (PK) objectives for this study are as follows:  
 To characterize the pharmacokinetics of obinutuzumab in the LN population  
 To assess potential PK interactions between obinutuzumab and concomitant 
medications, including MMF  
 
2.5 PATIENT -REPORTED OUTCO ME OBJECTIVE  
The patient -reported outcome (PRO) objective for this study is as follows:  
 To assess the change from baseline of the patient’s general health over the course 
of the study  by use of the Subject’s Global Assessment  
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
33/Protocol WA29748, Version 4 2.6 EXPLORATO RY OBJECTIVES  
The exploratory objectives for this study are as follows:  
 To evaluate pre -dose levels of exploratory biomarkers (which may include but are 
not limited to B -cell subsets and levels of protein and mRNA in serum, plasma, 
blood, and urine) and po tential associations with outcome  
 To evaluate changes in exploratory biomarkers (which may include but are not 
limited to B -cell subsets and levels of protein and mRNA in serum, plasma, blood , 
and urine) over time in patients dosed with obinutuzumab versus  patients dosed 
with placebo  
 To evaluate the occurrence of extrarenal flares  
 To evaluate the impact of therapy on patient and physician -reported outcomes  
 To assess damage through the Glucocorticoid Toxicity Change Index  (GTCI)  
 To assess renal biopsy histopathology (for the presence and depletion of B  cells at 
the screening biopsy and from subsequent biopsies)  
 
Additional exploratory objectives and outcome measures will  be included in a final 
Statistical Analysis P lan (SAP) . 
3. STUDY DESIGN  
3.1 DESCRIPTION OF  STUDY  
This Phase II study is a parallel -group, double -blind, randomized, placebo -controlled 
study comparing the efficacy and safety of obinutuzumab plus MMF with placebo plus 
MMF in Class III and IV patients with proliferative LN.  The Sponsor intends to enroll 
approximately 120 patients diagnosed with ISN/RPS Class III or IV LN, with a d iagnosis 
of SLE based on current ACR criteria (at least 4 criteria must be present, one of which 
must be a positive anti -nuclear antibody  [ANA] ), in centers throughout the  world.  In 
addition to study treatment, patients will receive standard -of-care therapy with 
angiotensin -converting enzyme (ACE)  inhibitors/angiotensin -IIreceptor  blockers, MMF 
(dosed at 2.0 2.5 g/day)  or MPA (dosed 1440 1800 mg/day) , and a prednisone tap er.  
Patients must be 18 75 years of age and have  ISN/RPS 2003 Class III or IV proliferative 
LN (see  Table  1) as evidenced by renal biopsy performed within 6  months prior to or 
during screening and may have concomitant Class V disease (e.g., Class III/V or 
Class  IV/V).  Patients with Clas s III (C) or Class IV (C) disease will be excluded because 
of the lower likelihood of response within these categories.  Patients must exhibit 
significant proteinuria (urine protein to creatinine ratio  1.0 based on a 24-hour urine 
collection ).  Key exclusions will be evidence of severe renal impairment (estimated GFR 
 30 mL/minute per 1.73 m2 of body surface area), ESRD requiring dialysis or 
transplantation, evidence of active infections, and other safety -related exclusions.  
Patients will recei ve an initial 1000 mg of methylprednisolone IV prior to or during 
screening, and may receive up to a total of 3000  mg methylprednisolone IV prior to 
randomization for severe clinical activity according to guidelines of routine care for these 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
34/Protocol WA29748, Version 4 patients.  Pat ients will receive 80  mg methylprednisolone (or methylprednisolone 
placebo) on the day of the obinutuzumab/placebo infusion to reduce IRRs.  Oral 
corticosteroids will be initiated at a dose of 0.5  mg/kg (maximum 60 mg/day) and will be 
reduced over 10 weeks  (see Appendix  5).  This modified taper, from the LUNAR study, 
will be initiated at a lower dose in recognition that prednisone  doses above 10  mg/day 
are associated with significant adverse events, including increased risk of cardiovascular 
events (Bichile  and Petri 2014).  Prior ex perience with rituximab suggests that it can 
potentially enable complete and PRRs  in the absence of oral prednisone or a prednisone 
taper, thus allowing the use of lower doses of corti costeroids as proposed in this P hase 
II protocol ( Condon  et al. 2013 ). 
Patients will be followed until at least Week 104, with the primary endpoint evaluation at 
Week 52.  An interim analysis at 6  months will be performed to evaluate early 
differences in CRR.  All patients will have central reading of the renal biopsy 
histopathology and will also receive repeat renal biopsy as available on the basis of 
clinical status and lo cal practice.  All pat ients will be evaluated by high -sensitivity flow 
cytometry (HSFC) to evaluate the ability of obinutuzumab to deplete circulating 
peripheral B cells, and an interim PD analysis will be performed to assess whether 
patients do not fully deplete peripheral CD19 B cells as anticipated.  These mechanistic 
studies and more intensive histopathologic reviews are intended to test the hypothesis 
that greater B -cell depletion in the target organ (kidney) and associated secondary 
lymphoid structure s will translate into greater CRR  rates.  
Figure  1 Study Schema  
 
EP   endpoint; MMF   mycophenolate mofetil.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
35/Protocol WA29748, Version 4  
3.2 END OF STUDY  
The end of this study is defined as the last patient’s last visit at Week 104. This has 
been selected to  enable 78 weeks (~18 months) of safety follow -up after the last dose of 
study drug to assess the occurrence of adverse events and to enable an assessment of 
peripheral blood CD19+ B cell return.  
Additional B -cell follow -up (BCFU) visits will occur until p atients have achieved their 
baseline CD19 + count  or achieved 25 cells/μL CD19 + count  (the lower limit of normal 
(LLN) of CD19+ B cells for this lupus population), whichever occurs first.  B-cell 
follow -up (BCFU) visits for all patients will end when the last patient has completed 
~18 months of safety follow -up from the last dose of blinded obinutuzumab infusion.  
 
Patients who receive additional therapies that reduce peripheral B -cell counts  will not 
be included in BCFU.  
 
3.3 RATIONALE FOR STUDY DESIGN  
3.3.1  Rationale for Obinutuzumab Dose and Schedule  
The Phase II dose selection for obinutuzumab is based on experimental documentation 
of the drug’s potency relative to rituximab in head -to-head in vitro  nonclinical 
experiments and primate experiments and by partial efficacy demonstrated in the 
LUNAR study with rituximab.  The most relevant in vitro experiments demonstrated a 
5-to 50-fold greater ADCC potency for obinutuzumab in a Z138 lymphoma cell line 
experiment and in a nonclinical xenograft mouse tumor volume experiment 
(Mössner  et al. 2010 ).  A related primate study ( Mössner  et al. 2010 ) evaluated the 
depletion of B cells in cynomolgous monkeys evaluating rituximab at 2   10 mg/kg versus 
obinutuzumab  at 2   10 mg/kg and at 2   30 mg/kg.  This controlled experiment 
demonstrated a significantly greater B -cell depletion (CD40 CD21) with obinutuzumab 
versus rituximab at the 2   10 mg/kg dose level in lymph nodes and splenic tissue, and 
no significant dif ference in depletion between the two obinutuzumab doses.  
Glycoengineered modifications resulting in significantly higher ADCC and the direct 
type II cell -killing mechanism translate into results from mouse and primate experiments 
that confirm greater pote ncy for obinutuzumab.  These findings were confirmed in the 
CLL11  Stage 2 head -to-head study of obinutuzumab versus rituximab 
(Goede  et al. 2014 ), which demonstrated greater progression -free survival and also 
greater minimal residual disease negativity for  obinutuzumab even in protected 
micro -environments such as the bone marrow.  
In the LUNAR study, rituximab was dosed at 1000 mg on Days 1, 15, 168, and 182 with 
a PD goal of peripheral blood CD19  B-cell depletion by use of normal sensitivity flow 
cytometry  up to and including Week 52, the primary endpoint of the study.  This dosing 
schema may not have accomplished the PD goal of B -cell depletion in the kidney, and 
the degree of B -cell depletion in the kidney remains unknown since routine renal 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
36/Protocol WA29748, Version 4 biopsies are not part of clinical practice and there are no existing blood or urine 
biomarkers capable of evaluating this question.  For these reasons, obinutuzumab will 
be studied at a comparable dose (1000 mg) and comparable interval (on Days 1, 15, 
168, and 182) to assess whether the achieved CRR differs from the CRR rate observed 
in the LUNAR Study.  
3.3.2  Rationale for Patient Population  
The population to be enrolled in this protocol will be patients with ISN/RPS Class III or IV 
LN with active inflammatory processes as evidenced by a renal biopsy within 6 months 
of screening or during screening and elevated proteinuria.  Class III and IV LN was 
selected because these patients have proliferative disease, which has a poor prognosis 
and requires significant immunosuppressive therapy.  Patients with Class V 
membranous nephritis will be allowed protocol entry if the Class V membranous 
nephritis is detected on a renal biopsy and concurrent with Class III or IV disease.  
Patients entering the protocol may have either relapsing or newly diagnosed disease .  
The population selected for this study has the highest unmet medical needs, and prior 
data suggesting partial responses in this population with anti -CD20 mAbs  rituximab and 
ocrelizumab suggest that enrollment is feasible and that a greater response may be 
achieved with the more potent drug obinutuzumab.  
3.3.3  Rationale for Control Group  
Study WA29748 will be a placebo -controlled study provided on top of background 
immunosuppression with MMF.  Add -on study designs are appropriate in this population, 
and the provision of no background immunosuppression in a placebo -controlled study 
would represent inadequate therapy for a population at risk for severe renal damage.  
3.3.4  Rationale for Biomarker Assessments  
The variability in response to previous  B-cell targeting therapies in LN is incompletely 
understood.  This variability may reflect the heterogeneity of this disease as it relates to 
varying degrees of B -cell involvement among patients, but it may also point to 
incomplete B -cell depletion.  Pred ictive and PD biomarkers have the potential to 
differentiate between these possible explanations and will be collected in this study to 
improve understanding of any variability seen for clinical outcome to obinutuzumab 
treatment.  Predictive biomarker samp les will be collected prior to dosing in an effort to 
identify those patients with B -cell driven pathogenesis who are most likely to respond to 
obinutuzumab.  PD biomarker assessment will evaluate the modulation of B -cell 
numbers and activity by obinutuzum ab, and may additionally inform PK/PD modeling to 
support the dose and dose regimen.  As these biomarkers may also have prognostic 
value, their association with disease progression will also be explored.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
37/Protocol WA29748, Version 4 3.4 OUTCOME MEASURES  
3.4.1  Efficacy Outcome Measures  
Primary Efficacy Outcome Measure  
The primary efficacy outcome measure is the proportion of patients who achieve a CRR, 
evaluated at 52 weeks.  
CRR is defined by attainment of all of the following:  
 Normalization of serum creatinine as evidenced by the following:  
Serum creatinine  the upper limit of normal (ULN) range of central laboratory 
values  if baseline (D ay 1) serum creatinine is above the ULN  
Serum creatinine  15% above baseline and  the ULN range of central 
laboratory values if baseline (Day  1) serum creatinine is  the ULN range of 
central laboratory values  
 Inactive urinary sediment (as evidenced by   10 RBCs/ high-power field ( HPF) and 
the absence of red cell casts)  
 Urinary protein to creatinine ratio  0.5 
 
Secondary Efficacy Outcome Measure s  
The secondary efficacy outcome measures are the following:  
 Proportional analysis of patients who achieve an overall response at Week  52 
(CRR   PRR)  
 Time to overall response ( CRR   PRR ) over the course of 52 weeks  
 Percent reduction or increase from baseline and mean and median assessments of 
biomarkers of LN disease activity (e.g., reduction in anti -dsDNA antibody levels, 
increase C3 and C4 levels)  
 Proportion of patients that achieve a PRR at Week  52 as defined by attainment of all 
of the following:  
Serum creatinine  15% above baseline value  
No urinary red cell casts and either RBCs/HPF  50% above baseline or  10 
RBCs/HPF  
50% improvement in the urine protein to creatinine ratio, with one of the following 
conditions met:  
If the baseline urine protein to creatinine ratio is  3.0, then a urine protein to 
creatinine ratio of  1.0 
If the baseline protein to creatinine ratio is  3.0, then a urine protein to 
creatinine ratio of  3.0 
 Proportion of patients who achieve a CRR a t Week 24  
 Time to CRR, over the course of 52 weeks.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
38/Protocol WA29748, Version 4  Proportion of patients that achieve a modified CRR (mCRR1) at Week 52 employing 
the primary efficacy measure definition and removing the urinary sediment analysis 
criteria  
mCRR1 is defined by attainment of normalization of serum creatinine as 
evidenced by the following:  
Serum creatinine  the ULN range of central laboratory values  if baseline 
(Day 1) serum creatinine is above the ULN  
Serum creatinine  15% above baselin e and  the ULN range of central 
laboratory values  if baseline (Day  1) serum creatinine  the ULN range of 
central laboratory values  
Urinary protein to creatinine ratio  0.5 
 Proportion of patients that achieve a second m odified CRR (mCRR2) at Week 52 as 
defined by attainment of the following:  
Normalization of serum creatinine as evidenced by the following:  
Serum creatinine  15% above baseline if baseline (Day  1) serum creatinine 
is above the normal range of the central laboratory values or  the ULN range 
of central laboratory value s if baseline (Day  1) serum creatinine is  the ULN 
range of central laboratory values  
Inactive urinary sediment (as evidenced by   10 RBCs/HPF and the absence of 
red cell casts)  
Urinary protein to creatinine ratio  0.5 
 Proportion of patients that achieve a third modified CRR (mCRR3) at Week 52 as 
defined by attainment of the following:  
Normalization of serum creatine as evidenced by serum creatinine  the ULN 
range of central laboratory values  
Urinary protein to creatini ne ratio  0.5 
 
The hierarchical ordering of the secondary endpoints will be pre -specified in  the SAP . 
3.4.2  Safety Outcome Measures  
The safety outcome measures for this study are as follows:  
 Incidence, type, and severity of adverse events  
 Abnormal vital signs  
 Abnormal laboratory values  
 
Safety will be monitored through regular physical examinations, vital signs,  hematologic 
and chemistry laboratory tests, urinalyses, and incidence and severity  of adverse events.  
In addition, the following will be examined:  
 Circulating B cells, T cells, neutrophils and other cell populations  
 Plasma immunoglobulins (total Ig, IgG, IgM, and IgA)  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
39/Protocol WA29748, Version 4  Record of menses  
 Pregnancy  
 Antibody titers for mumps, rubella, Varicella , tetanus, influenza, and Streptococcus 
pneumoniae  
 
3.4.3  Pharmacodynamic Outcome Measure  
The primary PD outcome measure for this study is as follows:  
 Changes in l evels of circulating CD19  B-cells relative to baseline  
 
3.4.4  Pharmacokinetic Outcome Measures  
The obinutuzumab PK outcome measures for this study are as fo llows:  
Non-linear mixed -effects modeling (with software NONMEM) will be used to analyze the 
dose -concentration time data of obinutuzumab.  The PK profile data will be used to 
further develop a PK model, including the effect of major covariates (e.g., sex, 
race/ethnicity, weight, biochemical and hematological parameters at baseline, degree of 
underlying disease), on the main parameters (e.g., clearance).  The derivation of 
individual measures of exposure, such as area under the concentration -time curve 
(AUC)  and maximum concentration observed (C max) will depend on the final PK model 
used for this analysis.  Results of this analysis may be reported separately.  Serum 
obinutuzumab will be summarized (mean, minimum, maximum, SD, and geometric 
mean) and reported within this study.  
Exploratory graphical analyses will be performed to assess whether the occurrences of 
serious adverse events and abnormalities in the safety laboratory parameters in 
patients  treated with obinutuzumab can be attributed to obinutuzumab e xposure.  
Also,  exploratory graphical  analyses will be performed to assess whether the 
variability  in response can be attributed to  the variability in obinutuzumab exposure.  
Relevant  observed relationships between exposure and safety parameters may 
be further characterized using different approaches such as logistic regression analysis 
and indirect response modeling.  
Additional PK and PD analyses may be conducted as appropriate.  
3.4.5  Patient -Reported Outcome Measure  
The PRO measure for this study is as follows:  
 Subject’s Global Assessment  
This visual analog scale  (VAS)  will be captured in screening, at the baseline visit, 
and at several timepoints during study conduct.  
 
3.4.6  Exploratory Outcome Measures  
The exploratory outcome measures for this study are as follows:  
 Changes in l evels of circulating B -cell subsets relative to baseline  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
40/Protocol WA29748, Version 4  Changes in l evels of exploratory biomarkers, which may include but are not limited 
to levels of protein and mRNA in serum, plasma, blood , and urine , relative to 
baseline  
 Propor tion of patients experiencing a Systemic Lupus Erythematosus Disease 
Activity Index  (SLEDAI) -2K flare  
 Proportion of patients experiencing a renal flare over 52 weeks and 104 weeks  
 Proportion of patients achieving CRR, mCRR1 , mCRR2 , and mCRR3  at additional 
timepoints, including Week 12 and Week 36  
 Physician’s Global Assessment  
This VAS will be captured in screening, at the baseline visit, and at several 
timepoints during study conduct.  
 GTCI  
 Renal biopsy evaluations  
 
All patients will be asked to undergo an optional repeat renal biopsy after completion of 
the treatment portion of the study (after Week 52).  If a patient agrees to a repeat renal 
biopsy, one should be performed within 4 weeks of completion of the treatme nt portion 
of the study.  Biopsies performed at other times, for clinical reasons, will also be 
submitted for central review.  Because examination of the biopsy sample may potentially 
unblind the study treatment, investigators and study site personnel shou ld examine the 
biopsy sample for routine histology to enable clinical decisions but should not review 
immunohistopathology results that evaluate the presence or absence of B cells or be 
informed of their results.  
It is important to ensure that patients’ r enal biopsy samples are classified in a consistent 
manner.  As with other quantitative histopathology procedures, there can be significant 
inter-personal variation in the scoring of renal biopsy samples.  Therefore, the biopsy 
sample used for entry qualifi cation will be collected (where possible) and sent for reading 
at a specialist review laboratory before being returned to the study site.  This will allow 
accurate analysis  and will enhance the scientific credibility of the study.  Determination 
of eligibi lity, however, will be made based on the local renal biopsy review.  
The original microscopic sections from each patient’s biopsy sample will be re -read by a 
panel of renal histopathologists.  Additional slides for investigating disease 
characteristics are also requested as described in the Laboratory Manual.  The biopsy 
consensus evaluation process will be as follows:  
 A panel of independent nephro -pathologists will be used for the study.  
 A consensus reading of each renal biopsy will be made by two of the pa thologists.  
 Discrepancies will be resolved at periodic consensus meetings.  
 
However, reading at the specialist review laboratory is not required prior to study entry.  
Any subsequent biopsies (i.e., following treatment) will also undergo the same analysis 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
41/Protocol WA29748, Version 4 at the specialist review laboratory.  Lack of availability of a biopsy sample specimen will 
not preclude enrollment in the study, as long as the pathology report confirming eligibility 
is available.  Follow -up repeat biopsies may be performed as clinically  required by the 
investigator and also provided for analysis by the centralized facility.  
All repeat biopsy samples will be read with a central reading methodology.  The baseline 
biopsy sample that was used to determine the eligibility of the patient will be sent to the 
central reading site, as this will allow comparison between pre - and post -treatment 
samples.  An operational manual that outlines processes for the acquisition of renal 
biopsy data will be implemented as part of this protocol.  
4. MATERIALS AND METHODS   
4.1 PATIENTS  
All patients will be screened for conformance with the following inclusion and exclusion 
criteria.  The study will enroll approximately 120 patients with active ISN/RPS 2003 
Class III or IV LN at approximately sixty centers in North America, South America, 
Europe, and selected other countries.  
4.1.1  Inclusion Criteria  
Patients must meet the following criteria for study entry:  
 Signed Informed Consent Form  
 Age 1875 years  
 Ability to comply with the study protocol, in the inv estigator’s judgment  
 Diagnosis of SLE, according to current ACR criteria (at least four criteria must be 
present, one of which must be a positive ANA) 
 Diagnosis of ISN/RPS 2003 Class III or IV LN as evidenced by renal biopsy 
performed within 6  months prior to or during screening .  Patients may co -exhibit 
Class V disease in addition to either Class III or Class IV disease.  
 Proteinuria (urine protein to creatinine ratio)  1.0, based on a 24 -hour urine 
collection  
 For women who are not postmenopausal ( 12 months of non -therapy -induced 
amenorrhea) or surgically sterile (absence of ovaries and/or uterus):  agreement to 
remain abstinent or use two adequate methods of contraception, including at least 
one method with a failure rate of  1% per year, during the tre atment period and for 
at least 18 months after the last dose of study drug  
Abstinence is only acceptable if it is in line with the preferred and usual lifestyle 
of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or 
postovulatio n methods) and withdrawal are not acceptable methods of 
contraception.  
Barrier methods must always be supplemented with the use of a spermicide.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
42/Protocol WA29748, Version 4 Examples of contraceptive methods with a failure rate of  1% per year include 
tubal ligation, male sterilization, hormonal implants, established, proper use of 
combined oral or injected hormonal contraceptives, and certain intrauterine 
devices.  
 For men:  agreement to remain abstinent or use a condom plus an additional 
contraceptive method that together result in a failure rate of  1% per year during the 
treatment period and for at least 12 months after the last dose of study drug and 
agreement to refrain from donating sperm during this same period  
Men with a pregnant partner must agree to remain abstine nt or use a condom for 
the duration of the pregnancy.  
Abstinence is only acceptable if it is in line with the preferred and usual lifestyle 
of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or 
postovulation methods) and withdr awal are not acceptable methods of 
contraception.  
Patients must be willing to practice this method of contraception while taking 
MMF and for 90 days  after stopping MMF.  
 
4.1.2  Exclusion Criteria  
Patients who meet any of the following criteria will be excluded fr om study entry:  
 Retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke 
or stroke syndrome, cerebellar ataxia, or dementia that is currently active and 
resulting from SLE  
 Presence of rapidly progressive glomerulonephritis defined by  
The p resence of crescent formation in  50% of glomeruli assessed on renal 
biopsy or  
Sustained doubling of serum creatinine within 12 weeks of screening  or 
The i nvestigator ’s opinion that the patient has rapidly progressive 
glomerulonephritis . 
 Severe renal impairment as defined by estimated GFR  30 mL/min or the need for 
dialysis or renal transplant  
 Greater than 50% of glomeruli with sclerosis on renal biopsy  
 Treatment with cyclophosphamide or calcineurin inhibitors within the 3  months prior 
to randomization  
 Unstable disease with thrombocytopenia or at high risk for developing clinically 
significant bleeding or organ dysfunction requiring therapies such as 
plasmapheresis or acute blood or platelet transfusions  
 Lack of peripheral venous access  
 Pregnancy or lactation  
 History of severe allergic or anaphylactic re actions to mAbs  or known 
hypersensitivity to any component of the obinutuzumab infusion  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
43/Protocol WA29748, Version 4  Significant or uncontrolled medical disease in any organ system not related to SLE 
or LN, which, in th e investigator’s opinion, would preclude patient participation  
 Concomitant chronic conditions, excluding SLE, (e.g., asthma, Crohn’s disease) that 
required oral or systemic steroid use in the 52 weeks prior to screening  
 Known HIV infection  
 Known active inf ection of any kind (excluding fungal infection of nail beds) or any 
major episode of infection requiring hospitalizati on or treatment with IV  
anti-infectives within 8  weeks of the screening visit or oral anti -infectives within 
2 weeks prior to the screening visit  
 History of serious recurrent or chronic infection  
 History of cancer, including solid tumors, hematological malignancies, and 
carcinoma in situ (except basal cell carcinomas of the skin that have been treated or 
excised and have resolved)  
 Currently active alcohol or drug abuse or history of alcohol or drug abuse within 
52 weeks prior to screening  
 Major surgery requiring hospitalization within 4 weeks of randomization (excluding 
diagnostic surgery)  
 Previous treatment with an anti -CD20targeted  therapy within 12  months of 
randomization  
 Previous treatment with a biologic B-celltargeted therapy  (other than anti -CD20)  
within 6 months of randomization  
 Treatment with any investigational agent within 28 days of randomization or five 
halflives  of the investigational drug (whichever is longer)  
 Receipt of a live vaccine within 28 days prior to screening  
 Intolerance or contraind ication to oral or IV  corticosteroids  
 Aspartate aminotransferase or alanine aminotransferase  2.5   ULN 
 Amylase or lipase  2  ULN 
 Neutrophils  1.5  103/L 
 Positive hepatitis  B surface antigen (HbSAg) or hepatitis C serology.  Patients who 
are HBsAg negative and hepatitis B core antibody (HBcAb) positive with no 
detectable DNA will be allowed into the study but will require regular monitoring of 
hepatitis B virus (HBV) DNA.  
 Hemoglobin  7 g/dL, unless caused by autoimmune hemolytic anemia resulting 
from SLE  
 Platelet count  10,000 /L 
 Positive serum human chorionic gonadotropin  measured prior to the first 
obinutuzumab infusion  
 Known intolerance to MMF and MPA  
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
44/Protocol WA29748, Version 4 4.2 METHOD OF TREATMENT ASSIGNMENT AND BLIND ING 
The investigator or the investigator’s research staff will provide patient eligibility 
information through the interactive voice/Web response system  (IxRS) at randomization.  
Each patient will be randomized and assigned a unique identification number.  As 
confirmation, the investigator will be provided with written verification of each patient’s 
registration.  
Patients will be randomized to receive obi nutuzumab or placebo in a 1:1 ratio.  
The randomization of patients into treatment and control groups will be managed by a 
central IxRS vendor by use of a block design.  The factors for balancing between the 
treatment groups will be the following:  
 Treatment  balance within each race stratum for the following:  
Region (Afro Caribbean/African American versus others)  
United States versus non -U.S. sites  
 
Because it is important to maintain blinding to preserve the integrity of the data collected, 
all laboratory st udies of blood specimens, with unblinding potential, will be performed by 
a central laboratory.  Therefore, site personnel and the Sponsor’s staff involved with the 
conduct of the study will not receive unblinded data related to peripheral B -cell counts, 
PK results, specific immunoglobulin levels, or ADA results during the study, as listed 
below, until all eligible patients have completed their Week 52 visit.  
While PK samples must be collected from patients assigned to the comparator arm to 
maintain the bli nding of treatment assignment, PK  assay results for these patients are 
generally not needed for the safe conduct or proper interpretation of this study.  Sponsor 
personnel responsible for performing PK assays will be unblinded to patients’ treatment 
assign ments to identify appropriate PK samples to be analyzed.  Samples from patients 
who are assigned to the comparator arm will not be analyzed except by request (e.g., to 
evaluate a possible error in dosing).  
If unblinding is necessary for patient management (e.g., in the case of a serious adverse 
event for which patient management might be affected by knowledge of treatment 
assignment), the investigator will be able to break the treatment code by contacting the 
IxRS.  Treatment codes should not be broken exce pt in emergency situations.  If the 
investigator wishes to know the identity of the study treatment for any other reason, he 
or she should contact the Medical Monitor directly.  The investigator should document 
and provide an explanation for any premature unblinding (e.g., accidental unblinding, 
unblinding due to a serious adverse event).  
For regulatory reporting purposes and if required by local health authorities, the Sponsor 
will break the treatment code for all serious, unexpected suspected adverse reac tions 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
45/Protocol WA29748, Version 4 (see Section  5.7) that are considered by the investigator or Sponsor to be related to the 
study drug.  
4.3 STUDY TREATMENT  
4.3.1  Formulation, P ackaging, and Handling  
4.3.1.1  Obinutuzumab and Placebo  
Obinutuzumab is provided as a single -dose, sterile liquid formulation in a 50 -mL 
pharmaceutical grade glass vial containing a nominal 1000 mg of obinutuzumab 
(G3 material).  The formulated drug product consis ts of 25  mg/mL drug substance (G3) 
formulated in histidine, trehalose, and poloxamer 188.  The vials contain 41  mL (with 
2.5% overfill).  
Handling and Storage  
The recommended storage conditions for the obinutuzumab drug product are between 
2C and 8C and p rotected from light.  Chemical and physical in -use stability for 
obinutuzumab dilutions in 0.9% sodium chloride (NaCl) have been demonstrated for 
24 hours at 2 C8C and at ambient temperature and ambient room lighting.  
The prepared diluted product should  be used immediately.  If not used immediately, 
in-use storage times and conditions prior to use are the responsibility of the user and 
would normally not be longer than 24 hours at 2 C8C.  Obinutuzumab should not be 
frozen or shaken.  It should be mixed  gently.  All transfer procedures require strict 
adherence to aseptic techniques.  An additional in -line filter should not be used because 
of potential adsorption.  
For further details see the Obinutuzumab Investigator’s Brochure, pharmacy manual, 
and local  prescribing information.  
The placebo employed in this study will be a generic placebo of normal saline, and the 
double -blinded format will utilize an unblinded pharmacist to enable delivery of 
obinutuzumab and obinutuzumab placebo.  
4.3.1.2  Methylprednisolone and Placebo  
Methylprednisolone and methylprednisolone placebo may be reimbursed by the Sponsor 
as per local requirements.  Local supply of commercially available stock should be used 
or matching saline solution – prepared by the unblinded pharmacist  to mainta in the 
double blind status of the study .  For information on the formulation and handling of 
methylprednisolone, see the pharmacy manual and the local prescribing information for 
methylprednisolone.  
4.3.1.3  Mycophenolate Mofetil /Mycophenolic Acid  
For information on the formulation of and the packaging and handling requirements for 
MMF  and MPA , see the local prescribing information.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
46/Protocol WA29748, Version 4 4.3.2  Dosage, Administration, and Compliance  
4.3.2.1  Obinutuzumab and Placebo  
Obinutuzumab will be administered by IV infusion at a dose of 1000  mg on Days  1, 15, 
168, and 182.  
Obinutuzumab must be administered in a hospital or clinic environment where full 
resuscitation facilities are immediately available and under close supervision of the 
investigator or designee.  Although study drug may be admini stered on an outpatient 
basis, patients may be hospitalized for observation at the discretion of the investigator.  
See the Obinutuzumab Administration section below for detailed study drug 
administration instructions for the first infusions (Day 1) and subsequent  infusions 
(Day  15, Day  168, and Day  182) of the two dosing intervals.  
Obinutuzumab vials are biologically and chemically stable at 2 C8C (36F46F).  Do 
not use beyond the expiration date stamped on the carton.  Obinutuzumab should be 
protected from direct sunlight.  
For further details, see the immunology Obinutuzumab Investigator’s Brochure and the 
local prescribing information.  
Obinutuzumab Dose and Schedule  
Obinutuzumab will be administered by IV infusion as an absolute (flat) dose of 1000  mg 
for four infusions on Days 1, 15, 168, and 182.  Placebo infusion will be infused in the 
same volume and on the same scheduled days in the control arm.  
Obinutuzumab Preparation  
Obinutuzumab drug product that is intended for IV infusion is prepared by dilut ion of the 
drug product into an infusion bag containing 0.9% NaCl to the final drug concentration of 
4 mg/mL.  Using a 250 -mL infusion bag containing 0.9% NaCl, withdraw and discard 
40 mL of the NaCl.  Withdraw 40 mL of obinutuzumab from a single glass via l and inject 
it into the infusion bag (discard any unused portion of obinutuzumab remaining in the 
vial).  Gently invert the infusion bag to mix the solution; do not shake.  
Administration sets with polyvinyl chloride, polyurethane, or polyethylene as produ ct 
contact surface and IV bags with polyolefin, polypropylene, polyvinyl chloride, 
or polyethylene as product contact surface are compatible and may be  used.  Use of  a 
port or a peripherally inserted central catheter ( PICC  line) is acceptable.  
Do not use o binutuzumab beyond the expiration date stamped on the carton.  
Obinutuzumab Administration  
Obinutuzumab should be administered to patients in a clinical setting (inpatient or 
outpatient) where full emergency resuscitation facilities are immediately availabl e and 
patients should be under close supervision of the investigator at all  times.  Do not 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
47/Protocol WA29748, Version 4 administer as  an IV push or bolus.  After the end of the first  infusion, the  IV line should 
remain in place for  2 hours in order to  be able to  administer IV drugs if necessary.  If no 
adverse events occur after 2  hours, the  IV line may be removed.  For subsequent 
infusions, access through an IV line should remain in  place for at least 30  minutes from 
the end of the infusion, and if no adverse events occur after 30 m inutes, the  IV access 
may be removed.  
Patients should receive prophylactic treatment with acetaminophen ( 6501000  mg) and 
diphenhydramine (50  mg; or equivalent dose of a similar agent) by mouth 30 60 minutes 
prior to the study drug infusion.  Methylprednis olone  80 mg IV must be given 
3060 minutes prior to the start of infusions on Days 1, 15, 168, and 182.  
Patients who are administered an antihistamine (e.g., diphenhydramine) for the 
treatment or prevention of IRRs should be given appropriate warnings prio r to the 
patients’ discharge about drowsiness and impairment of ability to drive.  
Instructions for administration of obinutuzumab infusions are provided in Table  2 and 
Appendix  7. 
Table  2 Administration of Obinutuzumab Infusions  
First Infusion (Day 1)  Subsequent Infusions  (Days 15 , 168,  and 182)  
Begin infusion at an initial rate of 50 mg/hr.  
If no infusion reaction occurs, increase the 
infusion rate in 50-mg/hr increments every 
30 minutes to a maximum of 400 mg/hr.  
If an infusion reaction develops, stop or slow 
the infusion.  Administer infusion -reaction 
medications and supportive care in 
accordance with institutional protocol.  
Resume the infusion at a  50% reduction in 
rate (the rate being used at the time that the 
hypersensitivity or IRR occurred) if the 
reaction has resolved.  If a patient experienced an infusion reaction 
during the prior infusion, start at the same  rate 
as the first infusion (50  mg/hr ) and follow those 
directions as noted.  
If the patient tolerated the prior infusion well, 
begin infusion at a rate of 100 mg/hr.  
If no infusion reaction occurs, increase the 
infusion rate in 100 -mg/hr increments every 
30 minutes to a maximum of 400 mg/hr.  
If an infusion reaction develops, stop or slow 
the infusion.  Administer infusion -reaction 
medications and supportive care in accordance 
with institutional  protocol.  Resume the infusion 
at a 50% reduction in rate (the rate being used 
at the time that the hypersensitivity or IRR 
occurred) if the reaction has resolved.  
IRR   infusion -related reaction.  
 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
48/Protocol WA29748, Version 4 Table  3 Management of Infusion -Related Reactions  
Infusion -Related 
Symptoms a 
Grade  Guidance  
12 Slow or hold infusion.  
Give supportive treatment b. 
Upon symptom resolution, may resume infusion rate escalation at the 
investigator’s discretion c. 
3 Discontinue infusion.  
Give supportive treatment b. 
Upon symptom resolution, may resume infusion rate escalation, at 
investigator dis cretion c. 
Note:  If the same adverse event recurs with the same severity, treatment 
must be permanently discontinued.  
4 Discontinue infusion immediately, treat symptoms aggressively, and do 
not restart drug.  
IV  intravenous.  
Note:  These recommendations do not address life -threatening events, including 
anaphylaxis, for which all appropriate standard measures (including full resuscitation 
medications and equipment) must be available and should be used as clinically 
indicated.  For further details see Section  5.1.1 . 
a Refer to National Cancer Institute Common Terminology Criteria for Adverse Events, v4.0, 
for the grading of symptoms.  This table does not refer to management of immunoglobulin 
E-mediated allergic reactions.  
b Supportive treatment:  Patients should be treated with acetaminophen/paracetamol and an 
antihistamine such as diphenhydra mine if they have not been received in the last 4 hours. 
IV saline may be indicated.  For bronchospasm, urticaria, or dyspnea, patients may require 
antihistamines, oxygen, corticosteroids (e.g., 100 mg of IV prednisolone or equivalent), 
and/or bronchodilat ors.  For hypotension, patients may require vasopressors.  
c Infusion rate escalation after re -initiation:  Upon complete resolution of symptoms, the 
infusion may be resumed at 50% of the rate achieved prior to interruption. In the absence of 
infusion -related symptoms, the rate of infusion may be escalated in increments of 50 mg/hr 
every 30 minutes to a maximum rate of 400 mg/hr.  
 
4.3.2.2  Mycophenolate Mofetil /Mycophenolic Acid  
All patients will either continue on or initiate use of MMF (or MPA ) during screening or  no 
later than Day 1.  The initial dosage will be 1500  mg/day by mouth  (or equivalent) , given 
in two or three divided doses and titrated upward to 2.0 2.5 g/day  (or equivalent)  in 
divided doses by Week 4.  The dose  may be increased by 500  mg/wk  (or equival ent), as 
tolerated up to a maximum dosage of 2. 5 g/day (or equivalent) .  Reductions, as outlined 
in Appendix  4, will be allowed because of adverse effects.   Investigators, at t heir 
discretion, may use MPA  as a substitute for MMF , with a 360-mg dose  being equivalent 
to a 500 -mg dose of MMF . 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
49/Protocol WA29748, Version 4 Based on ran domized  controlled clinical studies,  approximately 30 40% of patients with 
LN may achieve a CRR  with initial therapy with either cyclophosphamide or MMF in 
combination with corticosteroids  (Dall’Era et al. 2011 ).  In this group, the benefit of 
added therapy may be minimal, and the risks of added therapy may be unwarranted.   
The investigator should assess whether eligible patients may benefit from a n initial  trial 
of standard -of-care therapy prior to enrollment into the study.  
For those patien ts who enter the study already receiving a dosage of MMF (or MPA ) 
higher than 1500  mg/day  (or equivalent) , MMF (or MPA ) will be titrated upward, as 
tolerated, to a goal of 2.5 g/day  (or equivalent) , given in divided doses, by Week 4.  A 
patient’s current d ose of MMF  (or equivalent)  will be given in two or three divided doses 
and will be increased by 500  mg/wk  (or equivalent)  as tolerated.  Refer to Appendix  4 for 
further details.  
Use of MMF  (or equivalent)  during pregnancy is associated with increased risks of 
spontaneous  abortion and congenital malformations , especially external ear and other 
facial abnormalities , including cleft lip and palate, and anomalies of the distal limbs, 
heart, esophagus, kidney , and nervous system .  Because of this, women of reproductive 
potential must be counseled regarding pregnancy prevention and planning and must use 
effective contrac eption prior to initiation of this therapy.    
Because MMF  (or equivalent)  may have an interaction with oral contraceptives that 
could theoretically  decrease its effectiveness, if patients (or partners of patients) 
enrolling in this study use hormonal contr aceptives as their primary method of 
contraception, th ese must be supplemented by either a barrier method of contraception 
or an intra -uterine contraceptive device  (see Section  4.1.1 , and MMF /MPA  U.S. Package 
Insert ). 
Guidelines for dosage modification and treatment interruption or discontinuation are 
provided in Section  5.1. 
Any overdose or incorrect administration of MMF  (or equivalent)  should be noted on the 
MMF /MPA  Administration electronic case report form ( eCRF ).  Adverse events 
associated with an overdose or incorrect administration of MMF /MPA  should be 
recorded on the Adverse  Event eCRF.  
4.3.2.3  Corticosteroid Administration  
Initial Study Corticosteroid Dose  
All patients will receive a combination of IV and oral corticosteroids as part of their initia l 
therapy for LN.  Methylprednisolone (Solu -Medrol) will be implemented in this protocol 
for two purposes:  as part of the usual care for patients with active Class III or IV LN and 
also to red uce IRRs  on the days of obinutuzumab/placebo infusions.  Up to three doses 
of IV methylprednisolone 1000  mg will be given on the basis of investigator judgment 
and local practice.  Up to three 1000  mg infusions may have been initiated prior to 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
50/Protocol WA29748, Version 4 screening or during the screening interval, and proper documentation of the number and 
date of infusions must occur.  
On Days  1, 15, 168, and 182, patients will receive  80mg IV methylprednisolone or 
placebo 30 60 minutes prior to study drug infusion  to prevent IRRs . 
Additional ly, oral prednisone may be initiated before or during the screening interval, and 
a taper will commence on Day 16 of the protocol.  From Days  2 to 16, 0.50  mg/kg/day 
oral prednisone will be given (maximum dose of 60 mg), except on the day of 
IV methylpredn isolone/placebo infusions, and will continue until Day  16.  From Day 16 
onward, a prednisone taper will commence as directed in  Appendix  5.  See Appendix  8 
for list of corticosteroid equivalence.  
Corticosteroid Taper  
All patients will undergo a scheduled  corticosteroid taper commencing on Day  16.  
Patients will fractionally reduce their prednisone dose over 1 0 weeks until the dose is 
7.5 mg/day by Week 12 (see Appendix  5).  Deviations from the scheduled primary 
prednisone taper for any reason other than SLE disease activity will confound 
interpretation, so every attempt should be made to adhere to the tapering schedule.  
After th e 10 weeks of tapering, patients will continue on prednisone at 7.5  mg/day.  In 
patients whose disease is too clinically active for the patient to make the first step in their 
prednisone taper, as evidenced by active urinary sediment, rising serum creatini ne, or 
moderate -to-severe extra renal symptoms, these patients may continue to receive their 
initial prednisone dose for up to an additional 28  days.  Patients who have started their 
taper and whose disease is too clinically active to continue tapering, may , using the 
same criteria as above, remain at the taper dose achieved for up to an additional 
28 days.  The prednisone dose may not be increased beyond the taper dose achieved.  
Patients will be discouraged from making adjustments to their prednisone dose and 
should contact the investigator and be examined before altering the prednisone taper so 
that deviations from the schedule can be justified and its relationship to lupus activity can 
be ascertained.  
After patients complete their Week 52 visit, investiga tors at their discretion may taper the 
oral prednisone further, if they believe it is clinically warranted.  
Corticosteroid Dosing for Renal Flares  
To maintain consistency in the treatment of renal flares, retreatment with higher doses of 
corticosteroids is  permitted if judged clinically appropriate by the investigator and if 
patients meet criteria for a renal flare (see Appendix  5).  Patients may be treated with 
prednisone (up to 0.5 mg/kg; not to exceed 60  mg/day) for 2 weeks.  Prednisone will 
then be tapered to achieve 10 mg/day within 6  weeks after the initial corticosteroid 
increase  and may further be taper ed to 7.5 mg/day at the d iscretion of the investigator .  
Patients who do not exhibit a response to the initial 2 -week course of increased 
corticosteroids and who initiate a new immunosuppressive therapy will be deemed 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
51/Protocol WA29748, Version 4 treatment failures and will continue regular visits and will no t receive additional study 
drug.  
Corticostero id Dose Increases Due to Extrar enal Disease Flare  
Patients will be allowed to receive corticosteroids for emergent illness (trauma,  severe 
asthma) or surgery, if clinically warranted; the corticosteroid use shou ld be limited to a 
total of  7 days, if possible.  Investigators will be allowed to increase the prednisone 
dose by  2.5 mg/day to treat symptoms of adrenal insufficiency or corticosteroid 
withdrawal.  
Patients who experience a severe extra renal SLE flare  may receive treatment with 
additional oral corticosteroids, if judged clinically appropriate by the investigator (see 
Appendix  5).  Thes e patients may be retreated with prednisone (up to 1.0  mg/kg) for up 
to 2 weeks on the basis of the severity of disease and organ system involvement and the 
dosage should be tapered to 7.5  mg/day, following a separate tapering schedule as 
listed in Appendix  5.  Patients experiencing a mild or moderate extrarenal flare may 
temporarily increase their prednisone dose by up to 20 mg per day and taper this dose  
over 4 weeks, if judged clinically appropriate by the investigator.  IV  corticosteroids in 
equivalent doses are allowed if gastrointestinal  (GI) involvement temporarily precludes 
treatment with oral corticosteroids.  Patients who do not show improvement in their 
symptoms after 2  weeks of increased corticosteroid treatment are considered to be 
nonresponsive to corticosteroids.  Efforts should be ma de to reduce corticosteroid 
exposure to the minimally effective level to reduce corticosteroid -associated toxicity.  
If patients require a new immunosuppressive drug (other than corticosteroid s) for 
treatment of their extra renal SLE flare, those patients wi ll be counted as treatment 
failures and will not receive further study drug but will continue their protocol -mandated 
study visits.  
Any overdose or incorrect administration of prednisone or methylprednisolone should be 
noted on the Corticosteroid Administ ration eCRF .  Adverse events associated with an 
overdose or incorrect administration of corticosteroids should be recorded on the 
Adverse  Event eCRF.  
4.3.3  Dosage Modification  
Dose modification is not permitted during this study; however, the rate of infusion may 
be adjusted in the event of an IRR. 
If a patient experiences an IRR that requires interruption of the infusion and the 
investigator determines it should not be restarte d, the patient should continue to be 
followed in the study for safety.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
52/Protocol WA29748, Version 4 4.3.4  Investigational Medicinal Product Accountability  
Obinutuzumab will be provided by the Sponsor.  The study site will acknowledge receipt 
of investigational medicinal products (IMPs) usin g the IxRS to confirm the shipment 
condition and content.  Any damaged shipments will be replaced.  Study sites will 
maintain adequate records for receipt and disposition of study drug and maintain 
adequate drug dispensing and return records for monitor in spection.  
IMPs will either be disposed of at the study site according to the study site’s institutional 
standard operating procedure or returned to the Sponsor with the appropriate 
documentation.  The site's method of IMP destruction must be agreed to by t he Sponsor.  
The site must obtain written authorization from the Sponsor before any IMP is destroyed, 
and IMP destruction must be documented on the appropriate form.  
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of 
by the study site should be recorded on the Drug Inventory Log.  
4.3.5  Post -Study Access to Obinutuzumab  
The Sponsor will offer post -study access to the study drug, obinutuzumab, free of charge 
to eligible patients in accordance with the Roche Global Policy on Conti nued Access to 
Investigational Medicinal Product , as outlined below.  
A patient will be eligible to receive study drug after completing the study if all of the 
following conditions are met:  
 The patient has a life -threatening or severe medical condition and requires 
continued study drug treatment for his or her well -being  
 There are no appropriate alternative treatments available to the patient  
 The patient and his or her doctor comply with and satisfy any legal or regulatory 
requirements that apply to them  
 
A patient will not be eligible to receive study drug after completing the study if any of the 
following conditions are met:  
 The study drug is commercially marketed in the patient's country and is reasonably 
accessible to the patient (e.g., is covered by the  patient's insurance or wouldn't 
otherwise create a financial hardship for the patient)  
 The Sponsor has discontinued development of the study drug or data suggest that 
the study drug is not effective for LN.  
 The Sponsor has reasonable safety concerns regar ding the study drug as treatment 
for LN.  
 Provision of study drug is not permitted under the laws and regulations of the 
patient's country  
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
53/Protocol WA29748, Version 4 The Roche Global Policy on Continued Access to Investigational Medicinal Product is 
available at the following Web si te: 
http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf  
 
4.4 CONCOMITANT THERAPY  
4.4.1  Permitted Therapy  
Concomitant therapy includes any medication (e.g., prescription drugs, over -the-counter 
drugs, herbal or homeopathic remedies, nutritional supplements) used by a patient from 
7 days prior to screening to the study completion/discontinuation visit.   All such 
medications should be reported to the investigator and recorded on the Concomitant 
Medications eCRF.  
4.4.1.1  Other Concomitant Therap y 
Antimalarial Medications  
Antimalarial medications may influence the development of subsequent lupus flares 
(Canadian Hydroxychloroquine Study Group 1991 ).  Patients taking antimalarial 
medications at study entry should maintain a constant dosage througho ut the study.  
Patients not previously on antimalarial medications may be enrolled in the study but 
should not initiate antimalarial medications unless experiencing a disease flare that is 
unresponsive to corticosteroids.  Table  4 lists the antimalarial medications and dose 
ranges expected to be used during the course of the study.  
Table  4 Antimalarial Medi cations  
Antimalarial Medication  Dose Range (Oral)  
Hydroxychloroquine  200400 mg daily  
Chloroquine  500 mg every day or every other day  
Quinacrine  100 mg every day  
 
Antihypertensive Therapy  
All patients who are not currently taking either an ACE inhibitor or an 
angiotensin -receptor blocker  (ARB)  should be started on one at screening.  Patients 
should be on either an ACE inhibitor or ARB for at least 10  days prior to randomization.  
Combination therapy with the two agents will not be allowed.  
Durin g screening, every effort should be made to adequately control patients’ blood 
pressures.  The dose of the ACE inhibitor or ARB may be titrated upward to the 
maximum recommended dose in the current package insert to achieve adequate blood 
pressure control as recommended by the Eighth Report of the Joint National Committee 
on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure ( James 
et al. 2014 ).  If adequate blood pressure control is not achieved, patients may be started 
on addition al antihypertensive agents but not on agents that affect proteinuria 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
54/Protocol WA29748, Version 4 (e.g.,  nondihydropyridine calcium channel blockers, aldosterone antagonists, direct renin 
antagonists).  Additional agents that specifically target the renin -angiotensin system 
cannot be initiated during the study.  Suggested dose ranges for specific  ACE inhibitors 
and ARBs  are listed in  Table  5.   
ACE inhibitor  and ARB therapy exposure during the second and third trimesters is 
known to induce human fetotoxicity  (decreased renal function, oligohydramnios, skull 
ossification retardation) and neonatal toxicity (renal failure, hypotension  and 
hyperkalemia) .  The use  of ACE inhibitors and ARBs  is not recommended during the first 
trimester of pregnancy and is contra -indicated during the 2nd and 3rd trimester of 
pregnancy.  
If patients are intolerant to ACE inhibitors and ARBs , they may use either a direct renin 
inhibitor or aldosterone antagonists, but not in combination.  
Table  5 Suggested Dose Ranges for Angiotensin -Converting En zyme 
Inhibitors and Angiotensin -Receptor Blockers  
ACE Inhibitor or  
ARB Dose Range (Oral)  
(mg/day)  
ACE inhibitors   
Benazepril  1080 
Ramipril  2.510 
Lisinopril  1080 
Enalapril  1040 
Quinapril  1080 
Captopril  75450 
Perindopril  416 
Trandolapril  18 
Moexipril  7.530 
ARBs   
Eprosartan  400600 
Valsartan  80320 
Olmesartan  2040 
Candesartan  832 
Telmisartan  2080 
Losartan  25100 
Irbesartan  75300 
ACE   angiotensin -converting enzyme ; 
ARB   Angiotensin -Receptor Blockers . 
 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
55/Protocol WA29748, Version 4 Vitamins and Supplements  
Patients who are not already taking vitamin  D (800  IU/day) and calcium supplements 
(1200  mg/day calcium citrate or 1500  mg/day calcium carbonate) should start taking 
these supplements during screening.  Investigators should follow current ACR guidelines 
for the prevention and treatment of glucocorticoid -induced osteoporosis ( ACR 2001 ) or, 
for female patients in Canada  50 years of age, Canadian guidelines for the prevention 
and treatment of glucocorticoid -induced osteoporosis ( Cheung et al. 2004 ). 
4.4.1.2  Withdrawal of Immunosuppression after Week 52  
Patients who enter the Study Extension Period at Week 52 w ill remain on background 
standard -of-care immunosuppressant treatment until they have maintained their best 
achieved response, which must be at least an adequate clinical benefit for at least 
6 months.  After Week 52, the investigator may elect to continue  MMF at a reduced dose 
or switch the patient to receive azathioprine at 2mg/kg/day on the basis of local practice.  
If this response is achieved and the patient’s condition is considered to be stable, an 
attempt may be made to reduce or discontinue immunos uppressive treatment while 
closely monitoring renal parameters.  
The following reduction strategy is recommended:  
Azathioprine:  Reduce by 50 mg/day every 4 weeks.  
MMF  (or equivalent) :  Reduce by 500 mg/day (or equivalent)  every 4 weeks.  
 
Patients whose conditions deteriorate on withdrawal of background therapy in this phase 
may receive re -induc tion therapy, which can include  high-dose corticosteroid s, 
immunosuppressant treatment such as MMF /MPA  or obinutuzumab , or a combination of 
these as considered app ropriate by the investigator.  
After Week 52, any treatment changes are entirely at the discretion of the investigator.  
4.4.2  Concomitant Therapy and Clinical Practice  
Concomitant medications such as HMG -coA-reductase inhibitors and bisphosphonates 
will be record ed but not initiated during the study unless considered clinically indicated 
by the treating investigator after discussion with the Medical Monitor.  If patients enter 
the study taking these medications, every effort will be made to keep their dosage stabl e 
to prevent confounding of study results.  
4.4.3  Immunization during Peripheral B -Cell Depletion  
The efficacy and safety of immunization during periods of peripheral B -cell depletion 
have not been adequately studied.  It is recommended that a patient’s vaccinati on record 
and the need for immunization be carefully evaluated prior to receiving study drug.  For 
patients who are likely to require immunization in the foreseeable future, such as 
patients planning to travel to countries where specific immunization is re quired or 
patients requiring a vaccination/booster for their professional activity, any required 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
56/Protocol WA29748, Version 4 vaccination/booster must be given at least 28  days prior to randomization.  Review of a 
patient’s immunization status or need for the following vaccinations in  advance of 
randomization is recommended:  tetanus; diphtheria; influenza; pneumococcus 
polysaccharide; Varicella ; measles, mumps, and rubella (MMR); and hepatitis  B 
vaccines.  
The safety and efficacy of immunization with a live or attenuated live vaccine i n 
B cell-depleted patients are not known.  For this reason, the use of live or attenuated 
vaccines (e.g.,  measles, mumps, rubella, oral polio vaccine, Bacillus  Calmette -Guérin 
[BCG], typhoid, yellow fever, vaccinia, or any other vaccines not yet licensed b ut 
belonging to this category) is specifically excluded for 28  days prior to screening through 
the end of study participation.  
Vaccines that do not contain live organisms (e.g.,  influenza, Pneumovax, tetanus) are 
not prohibited; however, vaccines received  during peripheral B -cell depletion may be 
ineffective.  
4.4.4  Prohibited Therapy  
Use of the following therapies is prohibited during the study:  
 Investigational therapies from within 28 days or 5 half -lives of randomization  
(whichever is longer) and throughout th e study  
 Exposure to a n anti -CD20 targeted biologic therapy from the 12  months prior to 
randomization and throughout the study  
 Treatment with a biologic B -cell-targeted therapy other than anti -CD20 within 
6 months of randomization and throughout the study  
 Live virus vaccines from 28 days before the screening visit and throughout the study  
 NSAIDs , calcineurin inhibitors, or other nephrotoxic drugs during the study conduct  
 
The use of NSAIDs , with the exception of aspirin when used for cardiovascular 
protecti on, is prohibited in this study, given the potential effect of NSAIDs on renal 
function and proteinuria.  If patients are taking NSAIDs prior to enrollment, these 
medications must be discontinued during screening (at least 5 half -lives prior to 
randomizati on).  If the investigator believes that it is necessary to prescribe NSAIDs for a 
patient during the study, he or she should inform the Medical Monitor, and every attempt 
should be made to limit the use of NSAID treatment.  If used, the use of NSAIDs and 
other symptomatic medications that are both prescribed and available over the counter 
will be recorded at each visit.  Patients will be asked by the investigator whether these 
medications were used for a SLE -related symptom (e.g.,  pericarditis) or for sympt oms 
not attributed to lupus (e.g.,  menstrual discomfort).  
Other immunosuppressive agents not specifically allowed in the study as described 
above will not be allowed during the study and must be discontinued during the 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
57/Protocol WA29748, Version 4 screening period when patients become  eligible for study participation and fulfill 
exclusion criteria.  
4.5 STUDY ASSESSMENTS  
See Appendix  1 for the schedule of assessme nts performed during the study.  
4.5.1  Informed Consent Forms and Screening Log  
Written informed consent for participation in the study must be obtained before 
performing any  study -specific screening tests or evaluations.  Informed Consent Forms 
for enrolled pati ents and for patients who are not subsequently enrolled will be 
maintained at the study site.  
All screening evaluations must be completed and reviewed to confirm that patients meet 
all eligibility criteria before randomization.  The investigator will maint ain a screening log 
to record details of all patients screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
4.5.2  Medical History and Demographic Data  
Medical history includes clinically significant diseases, surgeries, canc er history 
(including prior cancer therapies and procedures), reproductive status, smoking history, 
use of alcohol and drugs of abuse, and all medications (e.g.,  prescription drugs, 
over-the-counter drugs, herbal or homeopathic remedies, nutritional supple ments) used 
by the patient within 7 days prior to the screening visit.  
Demographic data will include age, sex, and self -reported race/ethnicity.  The collection 
of information on race is important in the context of this protocol because multiple 
studies ha ve confirmed that patients with an African descent tend to have the worst 
prognosis for renal function.  For this reason, African heritage will be a stratification 
variable.  
4.5.3  Physical Examinations  
A complete physical examination should include an evaluation  of the head, eyes, ears, 
nose, and throat and the cardiovascular, dermatological, musculoskeleta l, respiratory, 
GI, genitourinary, and neurological systems.  Any abnormality identified at baseline 
should be recorded on the General Medical History and Base line Conditions eCRF.  
At subsequent visits (or as clinically indicated), limited, symptom -directed physical 
examinations should be performed.  Changes from baseline abnormalities should be 
recorded in patient notes.  New  or worsened clinically significant abnormalities should be 
recorded as adverse events on the Adverse Event eCRF.  
A chest x -ray, if not done within 3 months prior to screening, will also be done at 
screening.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
58/Protocol WA29748, Version 4 4.5.4  Vital Signs  
Vital signs will include measurements of respiratory rate, body tempera ture, pulse rate, 
and systolic and diastolic blood pressures while the patient is in a seated position for 
5 minutes.  The same arm for blood pressure measurements should be used 
consistently throughout the study, if possible.  
4.5.5  Systemic Lupus Erythematosus Disease Activity Index 
(SELENA -SLEDAI) Assessment  
The SLEDAI -2K instrument (see Appendix  13) will be employed in this study to  assess, 
at baseline, the occurrence of organ involvement other than the kidney.  It will be 
employed at regular visits and at unscheduled visits to capture changes in lupus -related 
disease activity after randomization.  The SLEDAI -2K instrument was select ed for its 
ease of use, validation, and employment in the BELONG study.  SLEDAI -2K is assessed 
for the 10  days prior to the patient’s visit and has 24 items and a total score of 105.  
4.5.6  Systemic Lupus International Collaborating Clinics/ American 
College of R heumatology Damage Index for Systemic Lupus 
Erythematosus  
The Systemic Lupus International Collaborating Clinics (SLICC)/ACR Damage Index for 
SLE (see Appendix  10) will be utilized to assess organ damage as opposed to the 
collection of disease activity.  Damage is defined as non -reversible change not related to 
active inflammation.  
4.5.7  Glucocorticoid Toxicity Change Index  
The GT CI is an exploratory standardized measure of damage related to use of 
glucocorticoids  (see Appendix  14).  The GT CI will be incorporat ed into this study to 
better quantify the accrual of damage linked to corticosteroid use in patients with LN and 
may allow for an improved understanding of standard of care and patient phenotype.  
4.5.8  Laboratory, Biomarker, and Other Biological Samples  
The foll owing laboratory tests will be recorded at the timepoints indicated in the 
Schedule of Assessments (see Appendix  1). It is requ ired that sample specimens be 
sent to the central laboratory at all study timepoints, with the exception of urinalysis and 
hematology samples collected for safety monitoring of MMF.  Full details of the sample 
handling can be found in the Laboratory Manual . 
The full laboratory assessments that will be assessed according to the study schedule of 
assessments are described below:  
 Hematology :  To include CBC, hemoglobin, hematocrit, RBC, mean corpuscular 
volume, mean corpuscular hemoglobin, WBC (absolute and differential), and 
quantitative platelet count.  If a test is required to assess hemolytic anemia, it will be 
performed locally.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
59/Protocol WA29748, Version 4  Blood chemistry :  AST/SGOT, ALT/SGPT, alkaline phosphatase, amylase, lipase, 
total protein, albumin, cholesterol, total bilirub in, urea, uric acid, creatinine, random 
glucose, potassium, sodium, chloride, calcium, phosphorus, lactic dehydrogenase, 
CPK and triglycerides.  
 Urinalysis :  Including dipstick for blood, nitr ite, protein, and glucose and urine 
microscopy.  Preferably, urin ary protein to creatinine ratio should be performed on a 
first morning urine sample (see Appendix  9) 
 24-hour urine collection :  To be analyzed for total protein, total creatinine , creatinine 
clearance , and protein to creatinine ratio .  To be performed  at screening , 
randomizatio n, and at Months 3, 6, 9, and 12.  
 Flow cytometry :  B cell (including CD19, CD27, CD38, and IgD), T cell (CD3, 4, 8) 
and NK cells (CD16, CD56).  Flow cytometry results will remain blinded until the 
study is unblinded.  
 Autoantibody profile :  To include ANA , anti-dsDNA, anti -Sm, anti -RNP, anti -Ro, 
antiLa , anti -C1q.  
 Anti-ds-DNA antibody :  To be measured by ELISA at all visits as part of SLEDAI2K  
assessment  
 Quantitative immunoglobulin :  Total Ig levels including IgG, IgM, and IgA isotypes  
 Complement :  Including C3, C4, and CH50  
 Antibody titers :  Measurement of antibody titers to common antigens ( mumps, 
Varicella,  rubella, tetanus, influenza, and S. pneumoniae ) will be performed 
according to the schedule of assessments.  This information is used to assess the 
effect of obinutuzumab on specific humoral immunity to bacterial and viral antigens.  
 Viral hepatitis:  Measurement of HBsAg,  HBcAb, and hepatitis C antibody.   Patients 
who are HBsAg negative and HBcAb positive will also be evaluated for HBV DNA.  
 Pregnancy test:  All women of childbearing potential (including those who have had 
a tubal ligation)  will have a pregnancy test at each visit.  Positive test results will be 
confirmed with a serum pregnancy test.   The infusion must not be administered 
unless the pre gnancy test is negative.  
 Pharmacokinetic s and ADA:  To be measured as outlined in the schedule of 
assessments.  
 
The following samples will be sent to the Sponsor or a designee for analysis:  
 Cells from blood and urine for B -cell and lupus -related biomarkers , which may 
include but are not restricted to CD19  B cells and mRNA associated with B -cell 
activity  
 Serum , plasma , and urine for B -cell and lupus -related biomarkers, which may 
include but are not restricted to B -cell activating factor (BAFF)  
 Renal biopsy slides  and/or formalin -fixed paraffin -embedded  blocks  for 
immunohistopathology assessment  
 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
60/Protocol WA29748, Version 4 Any leftover material from pharmacokinteics , ADA, and biomarker samples may be used 
for additional assay development and assay validation purposes during the development 
of study - or compound -related assays and exploratory research in addition to the 
mentioned intended uses.  These samples will be stored until the study results have 
been reported, with the exception of some blood, tissue, and urine samples that  might 
be stored for 5  years after all study data have been collected.  For patients who agree to 
take part in optional long -term storage at Roche Clinical Repository (RCR), unused 
blood, urine, and kidney biopsy samples will be stored and destroyed no lat er than 
15 years after the date of final closure of the associated clinical database.  
4.5.9  Electrocardiograms  
Twelve lead ECGs should be taken at the timepoints indicated in the schedule of 
assessments.  Lead placement should be as consistent as possible.  ECG recordings 
must be performed after the patient has been resting in a supine position for at least 
10 minutes.  All ECGs are to be obtained prior to other procedures scheduled at that 
same time (e.g.,  vital sign measurements, blood draws) and should not be obtained 
within 3  hours after any meal.  Circumstances that may induce changes in heart rate, 
including environmental distractions (e.g., television, radio, conversation) should be 
avoided during the pre -ECG resting period and during ECG recording.  
For saf ety monitoring purposes, the investigator must review, sign, and date all ECG 
tracings.  Paper copies of ECG tracings will be kept as part of the patient's permanent 
study file at the site.  
If, at a particular post -dose timepoint, the mean QTcF is  500 ms  and/or  60 ms 
longer  than the baseline value, another ECG must be recorded, ideally within the next 
5 minutes, and ECG monitoring should continue until QTcF has stabilized on two 
successive ECGs.  The Medical Monitor should be notified.  Standard -of-care treatment 
may be instituted per the discretion of the investigator.  If a PK sample is not scheduled 
for that timepoint, an unscheduled PK sample should be obtained.  A decision on study 
drug discontinuation should be made, as described in Section  5.1.9 .  The investigator 
should also evaluate the patient for potential concurrent risk factors (e.g.,  electrolyte 
abnormalities, co -medications known to prolong the QT interval, severe bradycardia).  
Comments generated automatically by the ECG machine should not be recorded unless 
confirmed by a physician.  An ECG is also required if the patient discontinues from the 
study.  
4.5.10  Patient - and Physician -Reported Outcomes  
The Subject’s  Global Assessment of Disease Activity is the patient’s overall assessment 
of his or her current disease activity will be measured on a 100  mm horizontal VAS .  The 
left-hand extreme of the line is described as “ none ” (symptom -free) and the right -hand 
extreme as “ severe ”. 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
61/Protocol WA29748, Version 4 The Physician’s Global Assessment of Disease Activity is the physician’s overall 
assessment of the patient’s current disease activity.  It is measured on a 100  mm 
horizontal VAS .  The left -hand extreme  of the line is described as “none” (symptom -free) 
and the right -hand extreme as “severe”.  
4.5.11  Samples for Roche Clinical Repository  
4.5.11.1  Overview of the Roche Clinical Repository  
The RCR  is a centrally administered group of facilities used for the long -term storag e of 
human biologic specimens, including body fluids, solid tissues, and derivatives thereof 
(e.g., DNA, RNA, proteins, peptides).  The collection and analysis of RCR specimens will 
facilitate the rational design of new pharmaceutical agents and the develo pment of 
diagnostic tests, which may allow for individualized drug therapy for patients in the 
future.  
Specimens for the RCR will be collected from patients who give specific consent to 
participate in this optional research. RCR specimens will be used to a chieve the 
following objectives:  
 To study the association of biomarkers with efficacy, adverse events, or disease 
progression  
 To increase knowledge and understanding of disease biology  
 To study drug response, including drug effects and the processes of dru g absorption 
and disposition  
 To develop biomarker or diagnostic assays and establish the performance 
characteristics of these assays  
 
4.5.11.2  Approval by the Institutional Review Board or Ethics 
Committee  
Collection and submission of biological samples to the RCR is contingent upon the 
review and approval of the exploratory research and the RCR portion of the Informed 
Consent Form by each site's Institutional Review Board or Ethics Committee (IRB/EC) 
and, if applicable, an appropriate regulatory body.  If a site ha s not been granted 
approval for RCR sampling, this section of the protocol ( Section  4.5.11 ) will not be 
applicable at that site.  
4.5.11.3  Sample Co llection  
The following samples will be collected for research purposes, including but not limited 
to research on dynamic (non -inherited) biomarkers:  
 Serum , plasma , and urine samples for research purposes, which may include but 
are not limited to research on biomarkers related to CD20 depletion, LN, SLE, or 
other autoimmune disease/inflammatory disorder  
 Whole blood PAXgene samples for RNA extraction for research purp oses, which 
may include but are not limited to research on biomarkers related to CD20 
depletion, LN, SLE, or other autoimmune disease/inflammatory disorder  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
62/Protocol WA29748, Version 4  Tissue samples from kidney biopsies for research on candidate biomarkers, which 
may include but are not limited to research on biomarkers related to 
CD20  depletion, LN, SLE, or other autoimmune disease/inflammatory disorder  
 
The following samples will be collected for research purposes, including but not limited 
to research on genetic (inherited) biomark ers related to obinutuzumab or LN:  
 Whole blood samples for DNA extraction for research purposes, including but not 
limited to research on biomarkers related to CD20 depletion, LN, SLE, or other 
autoimmune disease/inflammatory disorder  
 
For all samples, dat es of consent and specimen collection should be recorded on the 
associated RCR page of the eCRF.  For sampling procedures, storage conditions, and 
shipment instructions, see the laboratory manual.  
RCR specimens will be destroyed no later than 15 years afte r the date of final closure of 
the associated clinical database.  The RCR storage period will be in accordance with the 
IRB/EC -approved Informed Consent Form and applicable laws (e.g., health authority 
requirements).  
The dynamic biomarker specimens will be  subject to the confidentiality standards 
described in Section  8.4.  The genetic biomarker specimens will undergo additional 
processes to ensure confidentiality, as described below.  
4.5.11.4  Confidentiality  
Given the sensitive nature of genetic data, Roche has implemented additional processes 
to ensure patient confidentiality for RCR specimens and associated data.  Upon receipt 
by the RCR, each specimen is "double -coded" by replacing the patient identification 
number with a new independent number.  Data generated from the use of these 
specimens and all clinical data transferred from the clinical database and considered 
relevant are also labeled w ith this same independent number.  A "linking key" between 
the patient identification number and this new independent number is stored in a secure 
database system.  Access to the linking key is restricted to authorized individuals and is 
monitored by audit  trail.  Legitimate operational reasons for accessing the linking key are 
documented in a standard operating procedure.  Access to the linking key for any other 
reason requires written approval from the Pharma Repository Governance Committee 
and Roche's Le gal Department, as applicable.  
Data generated from RCR specimens must be available for inspection upon request by 
representatives of national and local health authorities, and Roche monitors, 
representatives, and collaborators, as appropriate.  
Patient medi cal information associated with RCR specimens is confidential and may be 
disclosed to third parties only as permitted by the Informed Consent Form (or  separate 
authorization for use and disclosure of personal health information) signed by the 
patient, unle ss permitted or required by law.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
63/Protocol WA29748, Version 4 Data derived from RCR specimen analysis on individual patients will generally not be 
provided to study investigators unless required by local law.   The aggregate results of 
any research conducted using RCR specimens will be  available in accordance with the 
effective Roche policy on study data publication.  
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of the RCR data will become and remain the exclusive and unburdened property 
of Roche, except where agreed otherwise.  
4.5.11.5  Consent to Participate in the Roche Clinical Repository  
The Informed Consent Form will contain a separate section that addresses participation 
in the RCR.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential hazards of participation in the RCR.  Patients will be 
told that they are free to refuse to participate and may withdraw their specimens at any 
time and for any reason during the storage period.  A separate, s pecific signature will be 
required to document a patient's agreement to provide optional RCR specimens.  
Patients who decline to participate will not provide a separate signature.  
The investigator should document whether or not the patient has given consen t to 
participate by completing the RCR Research Sample Informed Consent eCRF.  
In the event of an RCR participant's death or loss of competence, the participant's 
specimens and data will continue to be used as part of the RCR research.  
4.5.11.6  Withdrawal from the R oche Clinical Repository  
Patients who give consent to provide RCR specimens have the right to withdraw their 
specimens from the RCR at any time for any reason.  If a patient wishes to withdraw 
consent to the testing of his or her specimens, the investigato r must inform the Medical 
Monitor in writing of the patient's wishes through use of the RCR Subject Withdrawal 
Form and, if the study is ongoing, must enter the date of withdrawal on the RCR 
Research Sample Withdrawal of Informed Consent eCRF.  The patient  will be provided 
with instructions on how to withdraw consent after the study is closed.  A patient's 
withdrawal from Study WA29748 does not, by itself, constitute withdrawal of specimens 
from the RCR.  Likewise, a patient's withdrawal from the RCR does n ot constitute 
withdrawal from Study WA29748.  
4.5.11.7  Monitoring and Oversight  
RCR specimens will be tracked in a manner consistent with Good Clinical Practice by a 
quality -controlled, auditable, and appropriately validated laboratory information 
management system,  to ensure compliance with data confidentiality as well as 
adherence to authorized use of specimens as specified in this protocol and in the 
Informed Consent Form.  Roche monitors and auditors will have direct access to 
appropriate parts of records relatin g to patient participation in the RCR for the purposes 
of verifying the data provided to Roche.  The site will permit monitoring, audits, IRB/EC 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
64/Protocol WA29748, Version 4 review, and health authority inspections by providing direct access to source data and 
documents related to the  RCR samples.  
4.6 PATIENT, TREATMENT, STUDY, AND SITE DISC ONTINUATION  
4.6.1  Patient Discontinuation  
Patients have the right to voluntarily withdraw from the study at any time for any reason.  
The primary (and very uncommon) reason for withdrawal from the study should be the 
patient’s withdrawal of consent.  In addition, the investigator has the right to withdraw a 
patient from the study at any time.  Reasons for withdrawal from the study may include 
but are not limited to the following:  
 Patient withdrawal of con sent at any time  
 Any medical condition that the investigator or Sponsor determines may jeopardize 
the patient’s safety if he or she continues in the study  
 Investigator or Sponsor determines it is in the best interest of the patient  
 Patient non -compliance, defined as the inability to comply with protocol procedures 
despite  repeated interaction with the Principal I nvestigator  
 
If a patient wishes to withdraw from the study, a distinction should be made concerning 
withdrawal from experimental treatment and com plete withdrawal from the study.  
Patients wishing to withdraw from treatment should continue to receive efficacy and 
safety evaluations in the study.  Every effort should be made to obtain information on 
patients who withdraw from the study.  The primary reason for withdrawal from the study 
should be documented on the appropriate eCRF.  However, patients will not be followed 
for any reason after consent has been withdrawn.  Patients who withdraw from the study 
will not be replaced.  
Patients who meet any of  these criteria will not receive any additional study drug, but 
should be monitored for safety for at least 52 weeks after their last dose of study drug , 
unless they have withdrawn consent . 
4.6.2  Study Treatment Discontinuation  
Patients must discontinue study treatment but remain in the study if they experience any 
of the following:  
 Pregnancy  
 Grade 4 IRR the patient should be withdrawn from study treatment immediately  
 Recurrence of Grade 3 IRR at rechallenge  
 Grade 3 or 4 neutropenia that does not resolve to Gra de  2 within 8 weeks  
 Thrombocytopenia that does not resolve to Grade  2 within 8 weeks  
 Hepatitis B reactivation despite the initiation of the appropriate anti -viral therapy  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
65/Protocol WA29748, Version 4  Receipt of rescue cyto -toxic therapy, including cyclophosphamide, an anti -CD20 
mAb other than Obinutuzumab , or other confounding investigational therapies used 
for the primary treatment of lupus or LN 
 
The primary  reason for study treatment discontinuation should be documented on the 
appropriate eCRF.  Patients who discontinue study treatment prematurely will not be 
replaced, but they should continue protocol -mandated visits and procedures.  
4.6.3  Study and Site Discontinuation  
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include but a re not limited to the following:  
 The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to patients.  
 Patient enrollment is unsatisfactory.  
 Data recording is inaccurate or incomplete.  
 Action is deemed necess ary based on recommendations from the independent Data 
Monitoring Committee (iDMC).  
 
The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.  
The Sponsor has the right to close a site at any time.  Reasons for closing a sit e may 
include but are not limited to the following:  
 Excessively slow recruitment  
 Poor protocol adherence  
 Inaccurate or incomplete data recording  
 Non-compliance with the International Conference on Harmonisation (ICH) 
guidelines for Good Clinical Practice  
 No study activity (i.e., all patients have completed and all obligations have been 
fulfilled)  
 
5. ASSESSMENT OF SAFETY   
5.1 SAFETY PLAN  
Obinutuzumab is currently approved in CLL and also has been used in clinical studies 
for other malignancies such as NHL but not for autoimmune diseases.  Thus, the entire 
safety profile is not known at this time.  The safety plan for this study is designed to 
ensure patient safety and will include specific eligibility criteria and monitoring 
assessments as detailed below.  
5.1.1  Infusion -Related Reactions  
The most frequently observed adverse drug reactions in patients who received 
obinutuzumab during clinical studies in CLL and NHL were IRRs, which occurred 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
66/Protocol WA29748, Version 4 predominantly during infusion of the first 1000 mg.  In patients who received the 
combined measures for prevention of IRRs (adequate glucocorticoid, oral 
analgesic/antihistamine, omission of antihypertensive medication in the morning of the 
first infusion, and, for CLL patients only, the Cycle 1 Day 1 dose administered over 
2 days), a de creased incidence of all grade IRRs was observed.  The rates of 
Grades  34 IRRs (which were based on a relatively small number of patients) were 
similar before and after mitigation measures were implemented.  The incidence and 
severity of infusion -related symptoms decreased substantially after the first 1000  mg 
was infused, with most patients having no IRRs during subsequent administrations of 
obinutuzumab.  
In the majority of patients, IRRs were mild to moderate and could be managed by the 
slowing or tempor ary halting of the first infusion, but severe and life -threatening IRRs 
requiring symptomatic treatment have also been reported.  IRRs may be clinically 
indistinguishable from IgE -mediated allergic reactions (e.g., anaphylaxis).  
In studies where patients received either obinutuzumab or rituximab (another 
anti-CD-20), obinutuzumab patients appeared to have more IRRs compared to those 
receiving rituximab.  
Details regarding management of IRRs can be found in Section  5.1.9 . 
5.1.2  Infections  
Serious bacterial, fungal, and new or reactivated viral infections can occur during and 
following the completion of obinutuzumab therapy.  Fatal infections have been reported.  
Obinutuzumab is more potent in B -cell depletion than is rituximab; it is theoretically 
possible that there is an increased risk of infections with obinutuzumab compared with 
rituximab.  Study BO21004/CLL11 provides the most meaningful assess ment of the 
possible risk of infection ( Goede et al. 2014 ).  In Stage 1a (obinutuzumab   chlorambucil 
versus chlorambucil alone) and Stage 2 (obinutuzumab   chlorambucil versus 
rituximab   chlorambucil) of Study BO21004 in patients with CLL, the incidence of 
infections was similar between the treatment arms.  However, the chlorambucil arm 
compared with the obinutuzumab   chlorambucil arm showed a higher incidence of 
serious infections and deaths due to infection; the incidence of serious infections and 
fatal infections was similar in the obinutuzumab   chlorambucil and 
rituximab   chlorambucil arms.  To date, there is no clear evidence of a difference 
between rituximab and obinutuzumab regarding infections.  
5.1.2.1  Hepatitis B Reactivation  
HBV reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and 
death, can occur in patients treated with anti -CD20 antibodies, including obinutuzumab.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
67/Protocol WA29748, Version 4 5.1.2.2  Progressive Multifocal Leukoencephalopathy  
Progressive multifocal leukoencephalopathy (PML) has been report ed in patients treated 
with obinutuzumab.  The diagnosis of PML should be considered in any patient that 
presents with new -onset or changes to preexisting neurologic manifestations.  The 
symptoms of PML are unspecific and can vary depending on the affected  region of the 
brain.  Motor symptoms with corticospinal tract findings (e.g., muscular weakness, 
paralysis, and sensory disturbances), sensory abnormalities, cerebellar symptoms, and 
visual field defects are common.  Some signs/symptoms regarded as “corti cal” (e.g., 
aphasia or visual -spatial disorientation) may occur.  Evaluation of PML includes but is 
not limited to consultation with a neurologist, brain MRI, and lumbar puncture 
(cerebrospinal fluid testing for John Cunningham [JC] viral DNA).  Therapy wi th 
obinutuzumab should be withheld during the investigation of potential PML and 
permanently discontinued in case of confirmed PML.  Discontinuation or reduction of any 
concomitant immunosuppressive therapy should also be considered.  The patient should 
be referred to a neurologist for the evaluation and treatment of PML.  
5.1.3  Immunizations  
The safety of immunization with live or attenuated viral vaccines, following obinutuzumab 
therapy has not been studied, and vaccination with live virus vaccines is not 
recomm ended during treatment and until B -cell recovery.  
5.1.4  Neutropenia  
Severe and life threatening neutropenia, including febrile neutropenia, has been reported 
during treatment with obinutuzumab for hematologic malignancies.  
5.1.5  Thrombocytopenia  
Severe and life threat ening thrombocytopenia, including acute thrombocytopenia 
(occurring within 24 hours after the infusion), has been observed during treatment with 
obinutuzumab for hematologic malignancy.  Fatal hemorrhagic events have also been 
reported during Cycle 1 in pa tients treated with obinutuzumab for hematologic 
malignancy.  
5.1.6  B-Cell Depletion and Recovery  
B-cell recovery has taken place whenever peripheral B cells are no longer depleted.  
B-cell peripheral blood depletion is defined as levels below the lower limit of 
quantification  (LLOQ) of the HSFC assay (1  cell/L).  B -cell repopulation is defined as 
the return of peripheral blood B cells to a level of 10 cells/L.  B-cell recovery is defined 
as peripheral blood B cells at the patient’s pretreatment baseline or at t he LLN for the 
population under study  (25 cells/ µL).  In the majority of cases, B -cell recovery has taken 
longer than 12  months in previous studies of obinutuzumab, with and without 
chemotherapy, for the treatment of hematologic malignancies.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
68/Protocol WA29748, Version 4 5.1.6.1  Obinutuzumab Monotherapy - NHL and CLL Patients  
In the Phase II part of study BO21003 (relapsed indolent NHL), 87 patients were 
included in the obinutuzumab arm and 86 in rituximab arm.  The median level of 
CD19  cells was 0.079   109 cells/L at baseline and decreased rapidly to zero by 
2.5 hours post -infusion on Cycle 1, Day 1.  At the end of the treatment phase, of those 
with a known B -cell status, 80 of the rituximab patients (95%) and 82 of the 
obinutuzumab patients (96%) had B -cell depletion.  At 18 months post -treatment, 
5 of 8 and 17 of 19  patients (who were tested) in the rituximab and obinutuzumab arms, 
respectively, remained B -cell depleted.  
The data from patients with NHL in Studies BO21003 and BO20999 were pooled and 
analyze d for B -cell depletion (a total of 205 patients).  In this population from the pooled 
analysis, 195 of 202 patients (97%) had B -cell depletion at the end of treatment.  At 
12 months, 10 of 56 patients (18%) with known B -cell status had recovered B cells.  
The data from patients with CLL in Studies BO21003 and BO20999 were pooled and 
analyzed for B -cell depletion (a total of 38 patients).  In this CLL population from the 
pooled analysis, 30 of 35 patients with available data (86%) had B -cell depletion at the 
end of treatment.  Twenty -seven of these patients had at least 6 months follow -up 
information (after the last study drug administration), and after 24 months, 
19 of 27 patients (70%) had recovered B cells.  Of note, there were no B -cell count data 
on the r emaining 30% of patients as they had either progressed or died or were lost to 
follow -up before this timepoint.  
5.1.6.2  Obinutuzumab in Combination with Chemotherapy - CLL 
Patients  
In the Phase III Study BO21004/CLL11, 40 of 44 patients (91%) in the 
obinutuzumab   chlorambucil arm with available data had B -cell depletion at the end of 
treatment.  Within 24 months after the end of follow -up, 18 of 40 patients (45%) had 
recovered B -cells, including 5 patients who also experienced disease progression at the 
time of re covery.  
5.1.7  Immunoglobulin Depletion and Recovery  
When obinutuzumab has been used for treatment of hematologic malignancies, 
immunoglobulin depletion and recovery has varied.  In Study BO20999 Phase I, for 
patients with NHL, the levels of IgA, IgG, and IgM imm unoglobulins were either low or 
normal for the duration of the treatment period.  For the patients with CLL, 
immunoglobulin levels were low during the course of treatment.  In Phase II, across 
indications (aggressive NHL, indolent NHL, and CLL), changes in  baseline mean and 
median levels of IgA, IgG, and IgM were observed during the treatment period, but 
baseline levels had been achieved by the end of the treatment period.  
In Study BO21003, in Phase II, in the obinutuzumab arm, mean and median values for 
IgA, IgG, and IgM concentrations were all within the standard reference ranges.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
69/Protocol WA29748, Version 4 In Study BO21000, the serum levels of IgA, IgG, and IgM decreased from baseline to 
Cycle 4 and follow -up (Day 28), but the median levels remained within the corresponding 
normal ranges.  No differences between treatment population or dose groups were 
observed in either treatment arm.  
5.1.8  Gastrointestinal Perforations  
In the pivotal study in NHL , cases of GI perforation have been reported in patients 
treated with obinutuzumab in association with bendamustine.   Patients with NHL may 
have a tumor involvement of the GI tract (very rare in CLL patients), which may shrink 
rapidly and lead to an opening in the GI wall.  
5.1.9  Management of Specific Adverse Events  
Guidelines for management of s pecific adverse events are outlined in Table  6.  
Additional guidelines are provided in the subsections below.  
  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
70/Protocol WA29748, Version 4 Table  6 Guidelines for Management of Specific Adverse Events  
Event  Action to Be Taken  
General IRR   Patients who have pre -existing cardiac or pulmonary conditions 
should be monitored carefully throughout the infusion and the 
post-infusion period.  
 Withholding of antihypertensive treatments should be considered 
for 12 hours prior to and throughout each obinutuzumab infusion 
and for the first hour after administration.  
 Patients at acute risk of hypertensive crisis should be evaluated 
for the benefits and risks of withholding their anti -hypertensive 
medication.  
 Hypersensitivity may be difficult to distinguish from IRRs.  If a 
hypersensitivity reaction is suspected during infusion (e.g., 
symptoms typically occurring after previous exposure and very 
rarely with the first infusion), the infusion should be stopped and 
treatment permanently discontinued.  
 Patients with known IgE mediated hypersensitivity to 
obinutuzumab must not be treated.  
 For additional guidance see Table  3. 
Infections:  General   No patient will be enrolled with an active infection or history of 
chronic or recurring infections.  
 Patients who develop an active infection during the study will have 
study drug withheld until the event has resolved.  
 Patients who require vaccination should be pre -vaccinated 
6 weeks prior to receiving study drug.  
 Vaccination with live vaccine  during study is contra -indicated (see 
Section  4.4.3 ). 
Infections:  Hepatitis B   Hepatitis B screening is required prior to initiation of study drug.  
 Patients with active or chronic hepatitis B (surface Ag ) will be 
excluded from the study.  
 Patients who are HBcAb  with no detectable DNA will be allowed 
into the study but will require regular monitoring of HBV DNA.  If 
reactivation is seen, s tudy drug treatment must be withheld.  
 Patients will be monitored regularly for transaminitis.  
 Patients with transaminitis will be promptly referred to a 
hepatologist for evaluation and treatment.   
 Patients with Hepatitis B reactivation, despite the use of 
appropriate antivirals, will be discontinued from treatment as 
outlined in Section  4.6.2 . 
CSF = cerebrospinal fluid; GI  = gastrointestina l; HBcAb  = hepatitis B core antibody; 
HBV = hepatitis B virus; IRR  = infusion -related reaction; IVIG  = intravenous 
immunoglobulin; JC  = John Cunningham; MRI  = magnetic resonance imaging; 
PML = progressive multifocal leukoencephalopathy.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
71/Protocol WA29748, Version 4 Table  6 Guidelines  for Management of Specific Adverse Events  (cont.)  
Event  Action to Be Taken  
Infections:  suspected 
PML  Stop study drug.  
 Obtain neurological consult.  
 In consultation with a neurologist, we recommend obtaining an 
MRI and performing a lumbar puncture to assess for CSF JC  viral 
DNA.  
 Notify monitors immediately.  
 Study treatment will be withheld for all participants while patient is 
unblinded and investigated for suspected PML.  
Neutropenia   Patients who experience neutropenia should be closely monitored 
with regular laboratory tests until resolution.  
 If treatment is necessary, it should be administered in accordance 
with local guidelines and administration of granulocyte 
colony  stimulating factors should be considered.  
 Any signs of concomitant infection sho uld be treated as 
appropriate.  
 Grade 3 or 4 neutropenia that does not resolve to Grade  2 within 
8 weeks is a treatment -discontinuation criterion.  
 Cases of late onset neutropenia (occurring 28 days after the end 
of treatment) or prolonged neutropenia (las ting more than 28 days 
after treatment has been completed/stopped) have also been 
reported in studies of obinutuzumab for hematologic malignancy.  
Thrombocytopenia   Patients should be closely monitored for thrombocytopenia,  
 If thrombocytopenia occurs, regular laboratory tests should be 
performed until the event resolves, and dose delays should be 
considered in case of severe or life -threatening thrombocytopenia.  
 Transfusion of blood products (i.e., platelet transfusion) acco rding 
to institutional practice is at the discretion of the treating physician.  
 Thrombocytopenia that does not resolve to Grade  2 within 
8 weeks is a treatment -discontinuation criterion.  
 Use of all concomitant therapies, which could possibly worsen 
thrombocytopenia related events such as platelet inhibitors and 
anticoagulants, should also be taken into consideration  
Hypogammaglobulinemia   Ig levels will be monitored throughout the study period.  
 IVIG should be considered for patients with recurrent/severe  
infections despite appropriate treatment, with concomitant 
hypogammaglobulinemia.  
GI perforations   Promptly evaluate patients presenting with new onset abdominal 
symptoms . 
CSF   cerebrospinal fluid; GI   gastrointestinal; HBcAb   hepatitis B core antibody; 
HBV   hepatitis B virus ; IRR   infusion -related reaction; IV IG   intravenous 
immunoglobulin; JC   John Cunningham; MRI   magnetic resonance imaging; 
PML   progressive multifocal leukoencephalopathy.  
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
72/Protocol WA29748, Version 4 5.2 SAFETY PARAMETERS AN D DEFINITIONS  
Safety assessments will consist of monitoring and recording adverse events, including 
serious adverse events and adverse events of special interest, performing 
protocol -specified safety laboratory assessments, measuring protocol -specified vital 
signs, and conduct ing other protocol -specified tests that are deemed critical to the safety 
evaluation of the study.  
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section  5.4. 
5.2.1  Adverse Events  
According to the ICH guidelines for Good Clinical Practice, an adverse event is any 
untoward medical occurrence in a clinical investigation patient administered a 
pharma ceutical product, regardless of causal attribution.  An adverse event can 
therefore be any of the following:  
 Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicin al product, 
whether or not considered related to the medicinal product  
 Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition), except as described in 
Section  5.3.5.10 . 
 Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline  
 Any deterioration in a laboratory value or other clinical tes t (e.g., ECG, Xray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug  
 Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior t o assignment of study treatment (e.g.,  screening invasive 
procedures such as biopsies)  
 
5.2.2  Serious Adverse Events (Immediately Reportable to the 
Sponsor)  
A serious adverse event is any adverse event that meets any of the following criteria:  
 Is fatal (i.e., th e adverse event actually causes or leads to death)  
 Is life threatening (i.e.,  the adverse event, in the view of the investigator, places the 
patient at immediate risk of death)  
This does not include any adverse event that had it occurred in a more severe 
form or was allowed to continue might have caused death.  
 Requires or prolongs inpatient hospitalization (see Section  5.3.5.11 ) 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
73/Protocol WA29748, Version 4  Results in persistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient’s ability to conduct normal life 
functions)  
 Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug  
 Is a significant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the ou tcomes 
listed above)  
 
The terms "severe" and "serious" are not synonymous.  Severity refers to the intensity of 
an adverse event (e.g., rated as mild, moderate, or severe, or according to National 
Cancer Institute Common Terminology Criteria for Adverse Ev ents (NCI CTCAE) criteria; 
see Section  5.3.3 ); the event itself may be of relatively minor medical significance (such 
as severe headache w ithout any further findings).  
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.  
Serious adverse events are required to be reported by the investigator to the Sponsor 
immediately (i.e., no more than 24 h ours after learning of the event; see Section  5.4.2  for 
reporting instructions).  
5.2.3  Adverse Events of Special Interest (Immediately Reportab le to 
the Sponsor)  
Adverse events of special interest are required to be reported by the investigator to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section  5.4.2  for reporting instructions).  Adverse events of special interest for this study 
include the following:  
 Cases of potential drug -induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by Hy’s 
law (see Section  5.3.5.7 ) 
 Suspected transmission of an infectious agent by the study drug, as defined below  
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopa thy), pathogenic or non -pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an infection 
in a patient exposed to a medicinal product.  This term applies only when a 
contamination of the study drug is suspected.  
 IRRs (see Section  5.1.1 ) 
 Grade 3 or higher i nfections  (see Section  5.1.2 ) 
 Any hepatitis B reactivation and PML (see Section  5.1.2 ) 
 Drug -related n eutropenia (see  Section  5.1.4 ) 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
74/Protocol WA29748, Version 4  Drug -related t hrombo cytopenia (see Section  5.1.5 ) 
 GI perforations (see  Section  5.1.8 ) 
 
5.3 METHODS AND TIMING F OR CAPTURING AND ASS ESSING 
SAFETY  PARAMETERS  
The investigator is responsible for ensuring that all adverse events (see Section  5.2.1   
for definition) are recorded on the Adverse Event eCRF and reported to  the Sponsor in 
accordance with instructions provided in this section and in Sections  Sections  5.4  5.6. 
For each adverse event recorded on the Adverse Event eCRF, the investigator will make 
an assessment of seriousness (see Section  5.2.2  for seriousness criteria), severity 
(see Section  5.3.3 ), and causality (see Section  5.3.4  ). 
5.3.1  Adverse Event Reporting Period  
Investigators will seek information on adverse events at each patient contact.  All 
adverse events, whether reported by the patient or noted by study personnel,  will be 
recorded in the patient’s medical record and on the Adverse Event eCRF.  
After informed consent  has been obtained but prior to initiation of study drug , only 
serious adverse events caused by a protocol -mandated intervention (e.g., invasive 
procedures such as biopsies, discontinuation of medications) should be reported (see  
Section  5.4.2  for instructions for reporting serious adverse events).  
After initiation of study drug , all adverse events, regardless of relationship to study  
drug, will be reported until the patient completes his or her last study visit at Week 104 or 
for a period of 76 weeks after the last dose of study drug (whichever is longer).  After this 
period, the investigator should report any serious adverse events t hat are believed to be 
related to prior study drug treatment (see  Section  5.6). 
5.3.2  Eliciting Adverse Event Information  
A consistent methodology of non -directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation time -points.  Examples of 
non-directive questions include the following:  
"How have you felt since your last clinic visit?"  
"Have yo u had any new or changed health problems since you were last here?"  
 
5.3.3  Assessment of Severity of Adverse Events  
The adverse event severity grading scale for the NCI CTCAE (v4.0) will be used for 
assessing adverse event severity.  Table  3 will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
75/Protocol WA29748, Version 4 Table  7 Adverse Event Severity Grading Scale for Events Not Specifically 
Listed in NCI CTCAE  
Grade  Severity  
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
or intervention not indicated  
2 Moderate; minimal, local, or non -invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily living a 
3 Severe or medically significant, but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; or 
limiting  self-care activities of daily living b,c 
4 Life-threatening consequences or urgent intervention indicated d 
5 Death related to adverse event d 
NCI CTCAE  = National Cancer Institute Common Terminology Criteria for Adverse Events . 
Note:  Based on  the most recent version of NCI CTCAE (v4.0), which can be found at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.  
a Instrumental activities of daily living refer to preparing meals, shopping for groceries or 
clothes, using t he telephone, managing money, etc.  
b Examples of self -care activities of daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and taking medications, as performed by patients who are 
not bedridden.  
c If an event is asse ssed as a "significant medical event," it must be reported as a serious 
adverse event (see Section  5.4.2  for reporting instructions), per the definition of serious 
adverse event in Section  5.4.2 . 
d Grade 4 and 5 events must be reported as serious adverse events ( see Section  5.4.2  for 
reporting instructions), per the definition of serious adverse event in Section  5.2.2 . 
 
5.3.4  Assessment of Causality of Adverse Events  
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether or 
not an adverse event is considered to be related to the study drug, indicating "yes" or 
"no" accordingly.  The following guidance should be taken into consideration (see also  
Table  8): 
 Temporal relationship of event onset to the initiation of study drug  
 Course of the event, considering especially the effects of dose reduction, 
discontinuation of study drug, o r reintroduction of study drug (as applicable)  
 Known association of the event with the study drug or with similar treatments  
 Known association of the event with the disease under study  
 Presence of risk factors in the patient or use of concomitant medicatio ns known to 
increase the occurrence of the event  
 Presence of non -treatment -related factors that are known to be associated with the 
occurrence of the event  
 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
76/Protocol WA29748, Version 4 Table  8 Causal Attribution Guidance  
Is the adverse event suspected to be ca used by the study drug on the basis of facts, evidence, 
science -based rationales, and clinical judgment?  
YES There is a plausible temporal relationship between the onset of the adverse event and 
administration of the study drug, and the adverse event cann ot be readily explained by 
the patient's clinical state, intercurrent illness, or concomitant therapies; and/or the 
adverse event follows a known pattern of response to the study drug; and/or the 
adverse event abates or resolves upon discontinuation of the  study drug or dose 
reduction and, if  applicable, reappears upon re -challenge.  
NO An adverse event will be considered related, unless it fulfills the criteria specified below .   
Evidence exists that the adverse event has an etiology other than the study drug 
(e.g.,  preexisting medical condition, underlying disease, intercurrent illness, 
or concomitant medication); and/or the adverse event has no plausible temporal 
relationship to administration of the study drug (e.g., cancer diagnosed 2 days after 
first dose of study drug).  
 
For patients receiving combination therapy, causality will be assessed individually for 
each protocol -mandated therapy.  
5.3.5  Procedures for Recording Adverse  Events  
Investigators should use correct medical terminology/concepts when record ing adverse 
events on the Adverse Event eCRF.  Avoid colloquialisms and abbreviations.  
Only one adverse event term should be recorded in the event field on the Adverse Event 
eCRF.  
5.3.5.1  Infusion -Related Reactions  
Adverse events that occur during or within 24 hours after study drug administration and 
are judged to be related to obinutuzumab infusion should be captured as a diagnosis 
(e.g., "infusion -related reaction") on the Adverse Event eCRF.  If possible, avoid 
ambiguous terms such as "systemic reaction."  A ssociated signs and symptoms should 
be recorded on the dedicated Infusion -Related Reaction eCRF.  If a patient experiences 
both a local and systemic reaction to the same dose of study drug, each reaction should 
be recorded separately on the Adverse Event e CRF, with signs and symptoms also 
recorded separately on the dedicated Infusion -Related Reaction eCRF.  
5.3.5.2  Diagnosis versus Signs and Symptoms  
For adverse events other than IRRs (see Section  5.3.5.1 ), a diagnosis (if known) should 
be recorded on the Adverse Event eCRF rather than individual signs and symptoms 
(e.g., record only liver failure or hepatitis rather than jaundice, aster ixis, and elevated 
transaminases).  However, if a constellation of signs and/or symptoms cannot be 
medically characterized as a single diagnosis or syndrome at the time of reporting, each 
individual event should be recorded on the Adverse Event eCRF.  If a  diagnosis is 
subsequently established, all previously reported adverse events based on signs and 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
77/Protocol WA29748, Version 4 symptoms should be nullified and replaced by one adverse event report based on the 
single diagnosis, with a starting date that corresponds to the starting dat e of the first 
symptom of the eventual diagnosis.  
5.3.5.3  Adverse Events That Are Secondary to Other Events  
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by their primary cause, with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time from the initiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:  
 If vomiting result s in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.  
 If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF.  
 If a severe GI  hemorrhage leads to renal failure, both events should be reported 
separately on the eCRF.  
 If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF.  
 If neutropenia is accompanied by an infection, both events should be reported 
separately on the eCRF.  
 
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.  
5.3.5.4  Persistent or Recurrent Adverse Events  
A persistent adverse event is one that extends continuously , without resolution, between 
patient evaluation time points.  Such events should only be recorded once on the 
Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the event is first reported.  If a persi stent adverse event becomes 
more severe, the most extreme severity should also be recorded on the Adverse Event 
eCRF.  Details regarding any increases (or decreases) in severity will be captured on the 
Adverse Event Intensity or Grade Changes eCRF.  I f the event becomes serious, it 
should be reported to the Sponsor immediately (i.e., no more than 24 hours after 
learning that the event became serious; see Section  5.4.2  for reporting instructions).  
The Adverse Event eCRF should be updated by  changing the event from "non -serious" 
to "serious," providing the date that the event became serious, and completing all data 
fields related to serious a dverse events.  
A recurrent adverse event is one that resolves between patient evaluation time points 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Adverse Event eCRF.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
78/Protocol WA29748, Version 4 5.3.5.5  Abnormal Laboratory Values  
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it meets any of the following criteria:  
 Is accompanied by clinical symptoms  
 Results in a change in study treatment (e.g., dosa ge modification, treatment 
interruption, or treatment discontinuation)  
 Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy  
 Is clinically significant in the investigator’s judgment  
 
It is the investigator’s responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.  
If a clinically significant laborator y abnormality is a sign of a disease or syndrome 
(e.g.,  alkaline phosphatase and  bilirubin 5   ULN associated with cholestasis), only the 
diagnosis (i.e.,  cholestasis) should be recorded on the Adverse Event eCRF.  
If a clinically significant laboratory abn ormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating if the test result is above or below the normal range (e.g., "elevated 
potassium," as opposed to "abnor mal potassium").  If the laboratory abnormality can be 
characterized by a precise clinical term per standard definitions, the clinical term should 
be recorded as the adverse event.  For example, an  elevated serum potassium level of 
7.0 mEq/L should be reco rded as "hyperkalemia."  
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section  5.3.5.4  for 
details on recording persistent adverse events).  
5.3.5.6  Abnormal Vital Sign Values  
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event i f it meets any of the following criteria:  
 Is accompanied by clinical symptoms  
 Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)  
 Results in a medical intervention or a change in concomit ant therapy  
 Is clinically significant in the investigator’s judgment  
 
It is the investigator’s responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
79/Protocol WA29748, Version 4 If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g.,  high blood pressure), only the diagnosis (i.e.,  hypertension) should be recorded on 
the Adverse Event eCRF.  
Observations of  the same clinically significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section  5.3.5.4  for 
details on recording persistent adverse events).  
5.3.5.7  Abnormal Liver Function Tests  
The finding of an elevated ALT or AST ( 3  ULN) in combination with either an elevated 
total bilirub in ( 2  ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as 
defined by Hy's law).  Therefore, investigators must report as an adverse event the 
occurren ce of either of the following:  
 Treatment -emergent ALT or AST  3  ULN in combination with total 
bilirubin   2  ULN 
 Treatment -emergent ALT or AST  3  ULN in combination with clinical jaundice  
 
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see  Section  5.3.5.2 ) 
and reported to the Sponso r immediately (i.e., no more than 24  hours after learning of 
the event), either as a serious adverse event or a n adverse event of special interest (see 
Section  5.4.2 ). 
5.3.5.8  Deaths  
All deaths that occur during the protocol -specified adverse event reporting period (see 
Section  5.3.1 ), regardless of relationship to study drug, must be recorded on the 
Adverse Event eCRF and immediately reported to the Sponsor (see Section  5.4.2 ).  This 
includes death attributed to progression of SLE.  
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to th e fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, "unexplained death"  should be recorded on the Adverse Event eCRF.   If the 
cause of death later becomes available (e.g., after autopsy), "unexplained death" should 
be replaced by the established cause of death.  The term "sudden death" should not be 
used unless combined with the pres umed cause of death (e.g., "sudden cardiac death").  
If the death is attributed to progression of lupus/ SLE, “systemic lupus erythematosus 
progression" should be recorded on the Adverse Event eCRF.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
80/Protocol WA29748, Version 4 5.3.5.9  Preexisting Medical Conditions  
A preexisting medical condit ion is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.  
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of  the condition worsens during the study.  When 
recording such events on the  Adverse Event eCRF, it is important to convey the concept 
that the preexisting condition has changed by including applicable descriptors  
(e.g.,  "more frequent headaches").  
5.3.5.10  Lack of Efficacy or Worsening of Systemic Lupus 
Erythematosus  
Events that are clearly consistent with the expected pattern of progression of the 
underlying disease should not be recorded as adverse events.  These data wi ll be 
captured as efficacy assessment data only.  If there is any uncertainty as to whether an 
event is due to disease progression, it should be reported as an adverse event.  
5.3.5.11  Hospitalization or Prolonged Hospitalization  
Any adverse event that results in ho spitalization (i.e., in -patient admission to a hospital) 
or prolonged hospitalization should be documented and reported as a serious adverse 
event (per the definition of serious adverse event in Section  5.2.2), except as outlined 
below.  
An event that leads to hospitalization under the following circumstances should not be 
reported as an adverse event or a serious adverse event:  
 Hospitalizati on for respite care  
 Planned hospitalization required by the protocol, including initial kidney biopsy 
and/or study drug administration  
 Hospitalization for a preexisting condition, provided that all of the following criteria 
are met:  
The hospitalization wa s planned prior to the study or was scheduled during the 
study when elective surgery became necessary because of the expected normal 
progression of the disease  
The patient has not experienced an adverse event  
 Hospitalization for routine or scheduled repeat  surveillance kidney biopsy  
 
An event that leads to hospitalization under the following circumstances is not 
considered to be a serious adverse event, but should be reported as an adverse event 
instead:  
 Hospitalization for an adverse event that would ordin arily have been treated in an 
outpatient setting had an outpatient clinic been available  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
81/Protocol WA29748, Version 4  
5.3.5.12  Adverse Events Associated with an Overdose or Error in Drug 
Administration  
An overdose is the accidental or intentional use of a drug in an amount higher than the 
dose being studied.  An overdose or incorrect administration of study treatment is not 
itself an adverse event, but it may result in an adverse event.  All adverse events 
associated with an overdose or incorrect administration of study drug should be 
recor ded on the Adverse Event eCRF.   If the associated adverse event fulfills 
seriousness criteria, the event should be reported to the Sponsor immediately 
(i.e., no more than 24  hours after learning of the event; see Section  5.4.2 ). 
No safety data related to overdosing of obinutuzumab are available.  In clinical studies 
with obinutuzumab, doses ranging from 50 mg up to and including 2000 mg per infusion 
have been administered.  The incidence and intensity of adverse reactions reported in 
these studies did not appear to be dose dependent.  
5.4 IMMEDIATE REPORTING REQUIREMENTS FROM 
INVESTIGATOR TO SPON SOR  
Certain events require immediate reporting to al low the Sponsor to take appropriate 
measures to address potential new risks in a clinical study.  The investigator must report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than 24 hours after the investiga tor learns of the event.  The following is a list 
of events that the investigator must report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study drug:  
 Serious adverse events (see Section  5.4.2  for further details)  
 Adverse events of special interest (see Section  5.4.2  for further details)  
 Pregnancies (see Section  5.4.3   for further de tails)  
 
The investigator must report new significant follow -up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information).  New significant information includes the following:  
 New signs or symptoms or a change in the diagnosis  
 Significant new diagnostic test results  
 Change in causality based on new information  
 Change in the event’s outcome, including recovery  
 Additional narrative information on the clinical course of the event  
 
Investigators  must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
82/Protocol WA29748, Version 4 5.4.1  Emergency Medical Contacts  
To ensure the safety of study participants, access to the Medical Monitors is available 
24 hours per day, 7 days per week.  Details will be provided separately. An Emergency 
Medical Call Center will also be available 24 hours per day, 7 days per week. The 
Emergency Medical Call Center will connect the investigator with an Emergency 
Medical Cont act, provide medical translation service if necessary, and track all calls.  
Contact information, including toll -free numbers for the Emergency Medical Call 
Center, will be distributed to investigators.  
5.4.2  Reporting Requirements for Serious Adverse Events and  
Adverse Events of Special Interest  
5.4.2.1  Events That Occur prior to Study Drug Initiation  
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol -mandated intervention should be reported.  
The Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided 
to investigators should be completed and submitted to the Sponsor or its designee 
immediately (i.e., no more than 24 hours after learning of the event), either by faxing o r 
by scanning and emailing the form using the fax number or email address provided to 
investigators.  
5.4.2.2  Events That Occur after Study Drug Initiation  
After initiation of study drug, serious  adverse events and adverse events of special 
interest will be reported for a period of 52 weeks after the last dose.  Investigators should 
record all case details that can be gathered immediately (i.e., within 24 hours after 
learning of the event) on the Adverse  Event eCRF and submit the report via the 
electronic dat a capture (EDC) system.  A  report will be generated and sent to Roche 
Safety Risk Management by the EDC system.  
In the event that the EDC system is unavailable, the Serious Adverse Event/Adverse 
Event of Special Interest Reporting Form provided to investig ators should be completed 
and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours 
after learning of the event), either by faxing or by scanning and emailing the form using 
the fax number or email address provided to investigat ors. Once the EDC system is 
available, all information will need to  be entered and submitted via the EDC system.   
Instructions for reporting post -study adverse events are provided in Section  5.6. 
5.4.3  Reporting Requirements for Pregnancies  
5.4.3.1  Pregnancies in Female Patients  
Female patients of childbearing potential will be instructed to immediately inform the 
investigator if they become pregnant du ring the study or within 18 months after the last 
dose of study drug.  A Clinical Trial Pregnancy Report ing F orm should be completed by 
the investigator immediately (i.e., no more than 24  hours after learning of the pregnancy) 
and submitted either by faxin g or by scanning and emailing the form using the fax 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
83/Protocol WA29748, Version 4 number or email address provided to investigators.   Pregnancy should not be recorded 
on the Adverse Event eCRF.  The investigator should discontinue study drug and 
counsel the patient, discussing the ris ks of the pregnancy and the possible effects on the 
fetus.  Monitoring of the patient should continue until conclusion of the pregnancy.  Any 
serious adverse events associated with the pregnancy (e.g., an event in the fetus, an 
event in the mother during o r after the pregnancy, or a congenital anomaly/birth defect in 
the child) should be reported on the Adverse Event eCRF.   In addition, the investigator 
will submit a Clinical Trial Pregnancy Reporting Form when updated information on the 
course and outcome of the pregnancy becomes available.  
5.4.3.2  Pregnancies in Female Partners of Male Patients  
Male patients will be instructed through the Informed Consent Form to immediately 
inform the investigator if their partner becomes pregnant during the study or within 
12 months after the last dose of study drug.  A Clinical Trial Pregnancy Reporting Form 
should be completed by the investigator immediately (i.e., no more than 24 hours after 
learning of the pregnancy) and submitted either by faxing or by scanning and emailin g 
the form using the fax number or email address provided to investigators.  Attempts 
should be made to collect and report details of the course and outcome of any 
pregnancy in the partner of a male patient exposed to study drug.  To allow the Sponsor 
to collect additional information, the Sponsor will request that the pregnant par tner signs 
an Authorization for Use and Disclosure of Pregnancy Health Information to allow for 
follow -up on her pregnancy.  If the authorization has been signed, the investigator will 
update a Clinical Trial Pregnancy Reporting Form with additional inform ation on the 
course and outcome of the pregnancy.  An investigator who is contacted by the male 
patient or his pregnant partner may provide information on the risks of the pregnancy 
and the possible effects on the fetus, to support an informed decision in cooperation with 
the treating physician and/or obstetrician.  
5.4.3.3  Abortions  
Any abortion should be classified as a serious adverse event (as  the Sponsor considers 
abortions to be medically significant), recorded on the Adverse Event eCRF, and 
reported to the Sp onsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section  5.4.2 ). 
5.4.3.4  Congenital Anomalies/Birth Defects  
Any co ngenital anomaly/birth defect in a child born to a female patient exposed to study 
drug or the female partner of a male patient exposed to study drug should be classified 
as a serious adverse event, recorded on the Adverse Event eCRF, and reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section  5.4.2 ). 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
84/Protocol WA29748, Version 4 5.5 FOLLOW -UP OF PATIENT S AFTER ADVERSE  EVENT S 
5.5.1  Investigator Follow -Up 
The investigator should follow each adverse event until the event has resolved to 
baseline grade or better, the event is assessed as stable by the investigator, the patient 
is lost to follow -up, or the patient withdraws consent.  E very effort should be made to 
follow all serious adverse events considered to be related to study drug or study -related 
procedures until a final outcome can be reported.  
During the study period, resolution of adverse events (with dates) should be documente d 
on the Adverse Event eCRF and in the patient’s medical record to facilitate source data 
verification.  
All pregnancies reported during the study should be followed until pregnancy outcome.  
If the EDC system is not available at the time of pregnancy outco me, follow reporting 
instructions provided in Section  5.4.3.1 . 
5.5.2  Sponsor Follow -Up 
For serious adverse events, adverse events of special interest, and pregnancies, the 
Sponsor or a designee may follow  up by telephone, fax, electronic mail, and/or a 
monitoring visit to obtain additional case details and outcome information (e.g.,  from 
hospital discharge summaries, consultant reports, autopsy  reports) in order to perform 
an independent medical assessment of the reported case.  
5.6 POST -STUDY ADVERSE E VENTS  
Post-study, the investigator is not required to actively monitor patients for adverse 
events; however, the investigator should notify the Sponso r of any death, other serious 
adverse event, or adverse event of special interest occurring after the end of the adverse 
event reporting period, believed to be related  to treatment , if he or she becomes aware 
of them.  
The Sponsor should also be notified if  the investigator becomes aware of the 
development of cancer or a congenital anomaly/birth defect in a subsequently conceived 
offspring of a patient who participated in this study.  
The investigator should report these events directly to the Sponsor or its designee, either 
by faxing or by scanning and emailing the Serious Adverse Event/Adverse Event of 
Special Interest Reporting Form using the fax number or email address provided to 
investigators.  
5.7 EXPEDITED REPORTING TO HEALTH AUTHORITIE S, 
INVESTIGATORS, INS TITUTIONAL REVIEW BO ARDS, AND 
ETHICS COMMITTEES  
The Sponsor will promptly evaluate all serious adverse events and adverse events of 
special interest against cumulative product experience to identify and expeditiously 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
85/Protocol WA29748, Version 4 communicate possible new safety finding s to investigators, IRBs, ECs, and applicable 
health authorities in accordance with applicable legislation.  
To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events using the following ref erence document:  
 Obinutuzumab Investigator's Brochure  
 
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.  
Reporting de cisions will also be based on the investigator's assessment of causality and 
seriousness, with allowance for upgrading by the Sponsor as needed.  
An iDMC will monitor the incidence of anticipated adverse events during the study.  An 
aggregate report of any clinically relevant imbalances that do not favor the test product 
will be submitted to health authorities.  
6. STATISTICAL CONSIDER ATIONS AND ANALYSIS PLAN  
All efficacy outcomes will be analyzed according to the modified intent -to-treat principle 
and will include all randomized patients who have received any amount of study drug.  
Patients will be grouped according to randomized (assigned) treatment, rather than 
treatment received.  
Treatment period data will be locked after all patients have completed the W eek 52 visit.  
The primary efficacy and safety analyses will be performed on data for all patients 
through the Week 52 assessments or early discontinuation.  
Safety assessments will be performed on patients who receive study medication.  In all 
safety analy ses, patients will be grouped according to the treatment that patients actually 
received rather than the treatment assigned.  
6.1 DETERMINATION OF SAM PLE SIZE  
This Phase II study is a proof -of-concept study that is designed to detect an 
improvement in CRR.  The  primary efficacy endpoint of this study is the proportion of 
patients that achieve CRR.  
It is estimated that approximately 30% of patients with proliferative LN who are receiving 
MMF  (or equivalent)  will achieve a CRR at Week 52 and that the addition of 
obinutuzumab to MMF  (or equivalent)  will induce an overall CRR rate of 50% at 
Week  52.  On the basis of these assumptions, a total of 120  patients randomized to 
obinutuzumab - and placebo -treated group s in a 1:1  ratio (60  patients in each of the 
obinutuzumab - and placebo -treated groups) will yield approximately 83% power at the 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
86/Protocol WA29748, Version 4 two-sided   0.2 significance level using a Cochrane -Mantel -Haenzel (CMH) test, 
assuming the same CRR proportions across the s trata.  
6.2 SUMMARIES OF CONDUCT  OF STUDY  
The numbers of patients, who enroll, discontinue, and complete the study, will be 
tabulated by treatment group and study period (treatment or BCFU).  Reasons for 
premature study discontinuation will be listed and summar ized by treatment group and 
study period.  Eligibility criteria exceptions and other major protocol deviations will also 
be summarized by treatment group.  
6.3 SUMMARIES OF TREATME NT GROUP COMPARABILI TY 
Demographic and pretreatment characteristics such as age, sex, serum creatinine, 
proteinuria, MMF /MPA  use, treatment, LN class, SLE and nephritis duration, 
race/ethnicity, weight, British Isles Lupus Assessment Group (BILAG) score, and 
background therapies for SLE will be summarized by treatment group.  
Continuous  data (e.g., age, body weight, and height) will be summarized using 
descriptive statistics (mean, standard deviation, median, minimum, and maximum).  
For categorical data (e.g., race/ethnicity and sex), the number and percentage of 
participants in each cat egory will be presented.  
6.4 EFFICACY ANALYSES  
The primary and secondary efficacy analyses will include all randomized patients who 
received any study medication, with patients grouped according to the treatment 
assigned at randomization.  
6.4.1  Primary Efficacy Endp oint 
The primary assessment of efficacy of obinutuzumab,  to induce  a clinically significant 
improvement in renal function in patients with ISN/RPS 2003 class III or IV LN, will be 
assessed by attainment of CRR.  
CRR is defined as achievement of all of the f ollowing:  
 Normalization of serum creatinine as evidenced by the following:  
Serum creatinine  the ULN range of central laboratory values if the baseline 
(Day  1) serum creatinine is above the ULN  
Serum creatinine  15% above baseline  and  the ULN range of central 
laboratory values  if baseline  (Day 1)  serum creatinine is  the ULN range of 
central laboratory values  
 Inactive urinary sediment (as evidenced by   10 RBCs/HPF and the absence of red 
cell casts)  
 Urinary protein to creatinine ratio  0.5 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
87/Protocol WA29748, Version 4 Any patient who switches to rescue medication prior to Week 52 will be considered a 
non-responder.  Additional criteria for analyses of patients who are considered 
non-responders will be specified in the SAP.  
The proportions of patients achieving CRR across treatment  groups will be compared 
using a CMH test with race (Afro -Caribbean/African American versus others) and region 
(United States versus non -United States) as stratification factors.  If the test result is in 
favor of the obinutuzumab group at   0.1-level (one -sided), it will be concluded that 
there is a shift toward better renal response associated with the obinutuzumab group.  
6.4.2  Secondary Efficacy Endpoints  
The p roportion of patients who achieve an overall response at Week  52 (CRR   PRR) 
will be analyzed using a CMH test, with race and region as strata.  
The proportion of patients achieving PRR at Week 52 as defined by achievement of all 
of the following:  
 Serum creatinine  15% above baseline value  
 No urinary red cell casts and either RBCs/HPF  50% above baseline 
or  10 RBCs/HPF  
 50% improvement in the urine protein to creatinine ratio, with one of the following 
conditions met:  
If the baseline urine protein to creatinine ratio is  3.0, then a urine protein to 
creatinine ratio of  1.0 
If the baseline protein to creatinine ratio is  3.0, then a urine protein to creatinine 
ratio of  3.0 
 
Time to first overall response ( CRR   PRR ) over the course of 52 weeks will be 
presented using Kaplan -Meier methodology and compared between treatment groups 
using a stratified log -rank test with race and region as strata .  Time to CRR during this 
period will be analyzed similarly.  
The percent ch ange from baseline and mean and median assessments of biomarkers of 
LN disease activity will be analyzed using appropriate statistical methodology.  
The proportions of patients who achieve a CRR at Week 24 will be analyzed using the 
same methodology as the primary analysis.  In addition, the modified definitions, 
mCRR1 , mCRR2,  and mCRR3,  of CRR will be analyzed in this way to assess the 
sensitivity of CRR to its definition.  
Sensitivity analyses will be performed to assess the potential impact on the primary 
endpoint, and possibly also key secondary endpoints, of missing data and possibly also 
changes to background immunosuppressive medication.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
88/Protocol WA29748, Version 4 The secondary, sensitivity, PRO, and exploratory analyses will be fully specified in the 
SAP.  
6.4.3  Exploratory Efficacy E ndpoints  
The exploratory outcome endpoints for this study are:  
 Change in B -cell subsets over the course of the study  
 Change in serum and urine biomarkers over the course of the study  
 Proportion of patients experiencing an extrarenal flare over 52 weeks  
 Proportion of patients experiencing a renal flare over 52 weeks and 104 weeks  
 Proportion of patients achieving CRR, mCRR1, mCRR2 , and mCRR3,  at additional 
timepoints, including Week 12 and Week 36  
 Change in Physician’s Global Assessment over 52 weeks  
 Change in GTCI  over 52 weeks  
 Change in Renal biopsy histopathology over time  
 
6.5 SAFETY ANALYSES  
The safety analyses will include all randomized patients who received any study drug, 
with patients grouped according to the treatment actually received.  
6.5.1  Adverse Events  
Adverse events will be coded according to a standardized thesaurus.  The severity of 
adverse events will be classified using the NCI  CTCAE, Version  4.0. 
The number and percentage of patients who experience an adverse event will be 
summarized by mapp ed term, appropriate thesaurus level, and toxicity grade for each 
treatment group.  Separate summaries will be provided for serious adverse events, 
treatment -related adverse events (defined  as any adverse event occurring during or 
within 24  hours following  the completion of a study drug infusion), infusion -related 
adverse events and adverse events leading to study discontinuation.  
6.5.2  Deaths  
Patient deaths, including the primary cause of death, will be summarized.  
6.5.3  Laboratory Tests  
Descriptive statistics of labo ratory values and the change from baseline (Day  1) will be 
presented for each treatment group.  The number and percentage of patients with 
treatment -emergent laboratory abnormalities will be presented for each treatment group.  
Laboratory measurements will  include serum chemistries; urinalysis; hematology; 
plasma immunoglobulins; and circulating B -cells, T -cells, neutrophils, and other cell 
populations.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
89/Protocol WA29748, Version 4 The number and percentage of patients with positive serum antibodies to obinutuzumab  
at baseline and duri ng the treatment period will be tabulated.  
6.5.4  Vital Signs  
The change from pretreatment (measured just before initiation of the infusion) in vital 
signs recorded during infusion and post -infusion will be summarized.  Vital  signs that are 
obtained during screen ing and the follow -up period will also be summarized.  
6.6 PHARMACODYNAMIC ANAL YSES  
The primary PD marker will be CD19 B-cell counts.  Exploratory  PD markers from 
blood samples will be summarized graphically and descriptively over time by cohort ; 
these markers  include  B-cell subsets, and quantitative Ig levels (total, IgG, IgM, and 
IgA).  In addition, the percent change from baseline for each marker will be computed at 
each sampling timepoint using the Day  1 pre -dose value as the baseline point.  
Potential PD ma rkers specific to SLE/LN will be summarized graphically and 
descriptively as appropriate and may include but are not limited to the following:  
 Markers of inflammation or B -cell activation:  BAFF, proteinuria, and 
C3 and C4 complement  
 Autoantibodies:  ANA, anti-dsDNA, Sm, Ro, La, RNP, and others  
 
Exploratory analyses will be performed to assess the possible relationship between 
obinutuzumab dosing, PD markers, PK measures, and clinical response.  The key 
exploratory analyses will be specified in the SAP. 
6.7 PHA RMACOKINETIC ANALYSE S 
PK parameters derived from serum concentrations of obinutuzumab will be computed by 
the following:  
 Maximum serum concentration  
During the entire study (C max) 
After the first course of study drug (C max1) 
After the second course of stud y drug (C max2) 
 AUC  from 
Time 0 to infinity (AUC 0) based on all four infusions  
Time 0 to 336 days (AUC 0–336) based on all four infusions  
Time 0 to 168 days (AUC 0–168) based on the first two infusions  
Time 168 to 336 days (AUC 168–336) based on the third and fourth infusions  
 Systemic clearance  
 Volume of distribution under steady -state conditions (V ss) 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
90/Protocol WA29748, Version 4  Half-life (t 1/2) for the terminal portion of the serum concentration –time curve after 
both courses of treatment  
 
PK parameters will be determined for all patients with serum concentration data by the 
method that best describes the data.  This may be non -compartmental analysis, 
compartmental analysis for each individual patient, or population PK analysis.  PK 
parameters will be computed for all patients with  serum concentration data except for 
patients who are noncompliant to dosing and/or sampling schedule or whose samples 
have interference by ADA s (which precludes data inclusion); these patients will be 
excluded from the analysis.  
PK analysis will include a n exploratory analysis to identify baseline covariates that affect 
the pharmacokinetics of obinutuzumab in this patient population.  Baseline covariates 
that will be examined include demographics, other patient characteristics (such as 
disease severity), a nd selected laboratory measures.  
No hypothesis testing will be performed using the PK parameters.  PK data will be 
summarized using descriptive statistics, including mean, standard deviation, geometric 
mean, coefficient of variation, median, and range.  
Additional PK analyses will be conducted as appropriate.  
6.8 PATIENT - AND PHYSICIAN -REPORTED OUTCOME ANA LYSES  
The Subject’s Global A ssessment of disease activity VAS and th e Physician’s Global 
Assessment of disease activity VAS are  recorded at baseline and at Wee ks 4, 12, 24, 
36, and 52/Early Termination.  This assessment will be presented separately from 
adverse event data.  Details will be provided in the SAP.  
6.9 EXPLORATORY ANALYSES  
The exploratory analyses include the following:  
 Change from baseline in proteinuri a at Week  52 
 Change from baseline in albumin level  
 Proportion of subjects that experience a doubling of serum creatinine at Week 52  
 Change from baseline in estimated GFR at Week 52  
 Change from baseline in the SLICC/ACR damage index at Week  52 
 Change from baseline in SLE -associated autoantibodies at Week  52 
 Assessment of local versus centralized expert panel assessment of renal biopsies  
 Histopathologic assessment of renal biopsies for the presence of CD19  B cells and 
other immune cells  
 Change in SLEDAI -2K from baseline to Week 52.  
 
Additional exploratory analyses will be pre -specified in the SAP.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
91/Protocol WA29748, Version 4 6.10 INTERIM ANALYSES  
6.10.1  Planned Interim Analyses  
6.10.1.1  Pharmacodynamic Futility Interim Analysis:  
Given the rationale for this study, including the results from the LUNAR 
(Rovin et al. 2012) and BELONG studies ( Mysler et al. 2013 ), an interim analysis for 
futility is planned on the basis of CD19 B -cell counts after 30 patients have been 
assigned to the obinutuzumab arm and have had their Day 28 blood CD19 B -cell counts 
assesse d by HSFC.  
The effect of rituximab on CD19 B -cell counts has been measured by HSFC in an 
investigator -sponsored study in which  peripheral B -cell depletion below the LLOQ of the 
assay  occurred in 46% of patients ( Vital et al. 2011 ).  Slightly less than half  of these 
rituximab -treated patients with  full peripheral B -cell depletion  achieved a major clinical 
response, with the remainder of the patients having partial clinical responses.  
Therefore, it is hypothesized that an improved outcome over rituximab is a chievable for 
a LN patient population with  full peripheral B -cell depletion, with the assumption that 
improved tissue depletion with treatment will parallel the peripheral depletion.  To test 
the hypothesis in this study, we will require at least 50% of th e obinutuzumab -treated 
patients to have  peripheral B -cell depletion below the LLOQ of the HSFC assay  in order 
to have a realistic chance of a positive primary endpoint analysis for the treatment arm.  
Quantification of the link between this biomarker and t he study’s primary analysis has 
not been established; therefore predictive probabilities for study statistical significance 
cannot be provided.  Consequently, the study will be terminated if the 5% one -sided 
Clopper -Pearson upper confidence limit for the p roportion of patients who achieve B -cell 
depletion is not greater than 0.5.  Assuming that there are 30 patients at the time of the 
interim analysis, this will effectively require that  11 obinutuzumab patients have 
complete B -cell depletion below the LLOQ of the HSFC assay  at the time of the interim 
analysis.  
The interim analysis will be performed by the iDMC, which may recommend that the 
study be stopped for futility if the futility criterion is satisfied.  Additional criteria for 
recommending that th e study be stopped for futility may be added to the iDMC Charter.  
As this interim analysis will only result in termination of the study due to futility, and not 
for efficacy, an adjustment to the -level is not required.  Although the outcome of the 
interi m analysis may reduce the power of this study to below the estimated 83%, a 
sample size adjustment has not been made.  
6.10.1.2  Renal Response Interim Analysis:  
The iDMC  will conduct an interim efficacy analysis to evaluate renal response when the 
last patient has a chieved the 6 -month visit.  The interim analysis will be performed and 
interpreted by members of the iDMC, who may recommend to the Sponsor the initiation 
of future study planning, according to rules outlined in the iDMC Charter.  If the iDMC 
does recommen d that future study planning can begin, then the summary of renal 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
92/Protocol WA29748, Version 4 response data at Week 24 will be shared with appropriate Sponsor senior management 
personnel who will be unblinded at the treatment group level.  
This interim analysis is for planning purpose s only and will have no impact on the 
progression of this study.  Consequently, an adjustment to the -level is not required.  
7. DATA COLLECTION AND MANAGEMENT  
7.1 DATA QUALITY ASSURAN CE 
The Sponsor will be responsible for data management of this study, including  quality 
checking of the data.  Data entered manually will be collected via EDC through use of 
eCRFs.  Sites will be responsible for data entry into the EDC system.  In the event of 
discrepant data, the Sponsor will request data clarification from the site s, which the sites 
will resolve electronically in the EDC system.  
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.  Central laboratory data and other 
electronic data will be sent directly to the Sponsor, using the Sponsor’s standard 
procedures to handle and process the electronic transfer of these data.  
eCRFs and correction documentation will be maintained in the EDC system’s audit trail.  
System backups for data stored by the Spon sor and records retention for the study data 
will be consistent with  the Sponsor’s standard procedures.  
7.2 ELECTRONIC CASE REPO RT FORMS  
eCRFs are to be completed through use of a Sponsor -designated EDC system.  Sites 
will receive training and have access to a  manual for appropriate eCRF completion.  
eCRFs will be submitted electronically to the Sponsor and should be handled in 
accordance with instructions from the Sponsor.  
All eCRFs should be completed by designated, trained site staff.  eCRFs should be 
review ed and electronically signed and dated by the investigator or a designee.  
At the end of the study, the investigator will receive patient data for his or her site in a 
readable format on a compact disc that must be kept with the study records.  
Acknowledgement of receipt of the compact disc is required.  
7.3 SOURCE DATA DOCUMENT ATION  
Study monitors will perform ongoing source data verification to confirm that critical 
protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are 
accurate, complete, and verifiable from source documents.  
Source documents (pap er or electronic) are those in which patient data are recorded 
and documented for the first time.  They include, but are not limited to, hospital records, 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
93/Protocol WA29748, Version 4 clinical and office charts, laboratory notes, mem oranda, PRO s, evaluation checklists, 
pharmacy dispen sing records, recorded data from automated instruments, copies  of 
transcriptions that are certified after verification as being accurate and complete, 
microfiche, photographic negatives, microfilm or magnetic media, X -rays, patient files, 
and records kept at pharmacies, laboratories, and medico -technical departments 
involved in a clinical study.  
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol da ta to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.  
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated  or destroyed and must be retained per 
the policy for retention of records described in Section  7.5. 
To facilitate source data verificati on, the investigators and institutions must provide the 
Sponsor direct access to applicable source documents and reports for study -related 
monitoring, Sponsor audits, and IRB/EC review.  The study site must also allow 
inspection by applicable health author ities. 
7.4 USE OF COMPUTERIZED SYSTEMS  
When clinical observations are entered directly into a study site’s computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
as the source document if the system has  been validated in accordance with health 
authority requirements pertaining to computerized systems used in clinical research.  An 
acceptable computerized data collection system allows preservation of the original entry 
of data.  If original data are modif ied, the system should maintain a viewable audit trail 
that shows the original data as well as the reason for the change, name of the person 
making the change, and date of the change.  
7.5 RETENTION OF RECORDS  
Records and documents pertaining to the conduct of this study and the distribution of 
IMP, including  eCRFs, electronic PRO data (if  applicable), Informed Consent Forms, 
laboratory test results, and medication inventory records, must be retained by the 
Principal Investigator for 15  years after completion or  discontinuation of the study, or for 
the length of time required by relevant national or local health authorities, whichever is 
longer.  After that period of time, the documents may be destroyed, subject to local 
regulations.  
No records may be disposed of  without the written approval of the Sponsor.  Written 
notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another location.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
94/Protocol WA29748, Version 4 The Sponsor will retain study data for 25 years after the final Cli nical Study Report 
has been completed or for the length of time required by relevant national or local health 
authorities, whichever is longer.  
8. ETHICAL CONSIDERATIO NS 
8.1 COMPLIANCE WITH LAWS  AND REGULATIONS  
This study will be conducted in full conformance wit h the ICH E6 guideline for Good 
Clinical Practice  and the principles of the Declaration of Helsinki, or the applicable laws 
and regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual.  The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management:  Definitions and Standards for 
Expedited Reporting).  Studies conducted in the United States or under a U.S. 
Investigational New Drug application will co mply with U.S. FDA regulations and 
applicable local, state, and federal laws.   
Studies conducted in the European Union or European Economic Area will comply with 
the E.U. Clinical Trials Directive (2001/20/EC) or Clinical Trials Regulation 
(536/2014) and applicable local, regional, and national laws.  
8.2 INFORMED CONSENT  
The Sponsor’s sample Informed Consent Form (and ancillary sample Informed Consent 
Forms such as a Child’s Informed Assent Form or Home Nursing Informed Consent 
Form, if  applicable) will be pro vided to each site.  If applicable, it will be provided in a 
certified translation of the local language.  The Sponsor or its designee must review and 
approve any proposed deviations from the Sponsor's sample Informed Consent Forms 
or any alternate consent  forms proposed by the site (collectively, the "Consent Forms") 
before IRB/EC submission.  The final IRB/EC -approved Consent Forms must be 
provided to the Sponsor for health authority submission purposes according to local 
requirements.  
If applicable, the Informed Consent Form will contain separate sections for any optional 
procedures.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential risks associated with each optional procedure.  
Patients will be told that they are free to refuse to participate and may withdraw their 
consent at any time for any reason.  A separate, specific signature will be required to 
document a patient's agreement to participate in optional procedures.  Patients who 
decline to p articipate will not provide a separate signature.  
The Consent Forms must be signed and dated by the patient or the patient’s legally 
authorized representative before his or her participation in the study.  The case history or 
clinical records for each pati ent shall document the informed consent process and that 
written informed consent was obtained prior to participation in the study.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
95/Protocol WA29748, Version 4 The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available  that may affect the willingness of the patient 
to participate.  The final revised IRB/EC -approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes.  
Patients must be re -consented to the most current version of the Cons ent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 
IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent Forms, the case history or clinical records for each patient  shall document the 
informed consent process and that written informed consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.  
A copy of each signed Consent Form must be provided to the patient or the patient’ s 
legally authorized representative.  All signed and dated Consent Forms must remain in 
each patient’s study file or in the site file and must be available for verification by study 
monitors at any time.  
For sites in the United States, each Consent Form ma y also include patient authorization 
to allow use and disclosure of personal health information in compliance with the U.S. 
Health Insurance Portability and Accountability Act of 1996 (HIPAA).  If the site utilizes a 
separate Authorization Form for patient  authorization for use and disclosure of personal 
health information under the HIPAA regulations, the review, approval, and  other 
processes outlined above apply except that IRB review and approval may not be 
required per study site policies.  
8.3 INSTITUTIONAL REVIEW BOARD OR ETHI CS COMMITTEE  
This protocol, the Informed Consent Forms, any information to be given to the patient, 
and relevant supporting information must be submitted to the IRB/EC by the Principal 
Investigator and reviewed and approved by the IRB/E C before the study is initiated.  
In addition, any patient recruitment materials must be approved by the IRB/EC.  
The Principal Investigator is responsible for providing written summaries of the status of 
the study to the IRB/EC annually or more frequently in accordance with the 
requirements, policies, and procedures established by the IRB/EC.  Investigators are 
also responsible for promptly informing the IRB/EC of any protocol amendments (see 
Section  9.6). 
In addition to the requirements for reporting  all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety reports 
or other safety -related communications from  the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by their IRB/EC, and 
archived in the site’s study file.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
96/Protocol WA29748, Version 4 8.4 CON FIDENTIALITY  
The Sponsor maintains confidentiality standards by coding each patient enrolled in the 
study through assignment of a unique patient identification number.  This means that 
patient names are not included in data sets that are transmitted to any  Sponsor location.  
Patient medical information obtained by this study is confidential and may be disclosed 
to third parties only as permitted by the Informed Consent Form (or  separate 
authorization for use and disclosure of personal health information) sig ned by the 
patient, unless permitted or required by law.  
Medical information may be given to a patient’s personal physician or other appropriate 
medical personnel responsible for the patient’s welfare, for treatment purposes.  
Data generated by this study must be available for inspection upon request by 
representatives of the U.S.  Food and Drug Administration and other national and local 
health authorities, Sponsor monitors, representatives, and collaborators, and  the IRB/EC 
for each study site, as appropri ate. 
Information technology systems used to collect, process, and store study -related data 
are secured by technical and organizational security measures designed to protect such 
data against accidental or unlawful loss, alteration, or unauthorized disclosu re or 
access.  In the event of a data security breach, appropriate mitigation measures will be 
implemented.  
8.5 FINANCIAL DISCLOSURE  
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for  1 year after completion of the study  (i.e., last patient last 
visit). 
9. STUDY DOCUMENTATION,  MONITORING, AND 
ADMINISTRATION  
9.1 STUDY DOCUMENTATION  
The investigator must maintain adequate and accurate records to enable the conduct of 
the study to be fully docum ented, including but not limited to the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/EC and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, including an audit trail containing a complete record of all changes to 
data.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
97/Protocol WA29748, Version 4 9.2 PROTOCOL DEVIATIONS  
The investigator should document and explain any protocol deviations.  The investigator 
should promptly report any deviations that might have an impact on patient safety and 
data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC 
policies and procedures .  The Sponsor will review all protocol deviations and assess 
whether any represent a serious breach of Good Clinical Practice guidelines and require 
reporting to health authorities.   As per the Sponsor's standard operating procedures, 
prospective requests to deviate from the protocol, including requests to waive protocol 
eligibility criteria, are not allowed.  
9.3 SITE INSPECTIONS  
Site visits will be conduc ted by the Sponsor or an authorized representative for 
inspection of study data, patients’ medical records, and eCRFs.  The investigator will 
permit national and local health authorities, Sponsor monitors, representatives, and 
collaborators, and the IRBs/E Cs to inspect facilities and records relevant to this study.  
9.4 ADMINISTRATIVE STRUC TURE  
During the conduct of this protocol, an IxRS will be implemented to enable appropriate 
randomization and stratification, and a central laboratory will be employed through  a 
central laboratory vendor.  The protocol oversight will include an iDMC, which will meet 
on a regular predefined basis.  Additionally, a centralized renal histopathology reading 
process will be employed to collect renal biopsy data and enable explorator y analyses of 
the pathology findings.  
9.5 DISSEMIN ATION  OF DATA AND PROTECT ION OF TRADE 
SECRETS  
Regardless of the outcome of a study, the Sponsor is dedicated to openly providing 
information on the study to healthcare professionals and to the public, both at s cientific 
congresses and in peer -reviewed journals.   The Sponsor will comply with all 
requirements for publication of study results.   Study data may be shared with others who 
are not participating in this study (see Section 8.4 for details) , and redacted Clinical 
Study Reports and/or other summaries of clinical study results may be available in 
health authority databases for public access, as required by local regulation, and  will be 
made available upon request.  For more information, refer to the Roche Global Policy on 
Sharing of Clinical Study Informations at the following website:  
https://www.roche.com/innovation/process/clinical -trials/data -sharing/   
 
The results of this study may be published or presented at scientific congresses.  For a ll 
clinical studies in patients involving an IMP for which a marketing authorization 
application has been filed or approved in any country, the Sponsor aims to submit a 
journal manuscript reporting primary clinical study results within 6 months after the 
availability of the respective clinical study report.  In addition, for all clinical studies in 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
98/Protocol WA29748, Version 4 patients involving an IMP for which a marketing authorization application has been filed 
or approved in any country, the Sponsor  aims to publish results from ana lyses of 
additional endpoints and exploratory data that are clinically meaningful and statistically 
sound.  
The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior 
to submission for publication or presentation.  This allows t he Sponsor to protect 
proprietary information and to provide comments based on information from other 
studies that may not yet be available to the investigator.  
In accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
center data.  In this case, a coordinating investigator will be designated by mutual 
agreement.  
Authorship will be determined by mutual agreement and in line with International  
Committee of Medical Journal Editors authorship requirements.  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by the investigator and the 
appropriate Sponsor personnel.  
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.  
9.6 PROTOCOL AMENDMENTS  
Any protocol amendments will be prepared by the Sponsor.  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.  
Approval must be obtained from the IRB/EC and re gulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g.,  change in Medical Monitor or  contact information) . 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
99/Protocol WA29748, Version 4 10. REFERENCES  
Ahuja A, Teichmann LL, Wang H, et al. An acquired defect in IgG -dependent 
phagocytosis explains the impairment in antibody -mediated cellular depletion in 
Lupus. J Immunol 2011;187:3888 94. 
Alsuwaida AO. Interstitial inflam mation and long -term renal outcomes in lupus nephritis. 
Lupus 2013;22:1446 54. 
American College of Rheumatology Ad Hoc Committee on Glucocorticoid -Induced 
Osteoporosis. Recommendations for the prevention and treatment of 
glucocorticoid -induced osteoporosis. Arthritis Rheum 2001;44:1496 503. 
Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus 
cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 
2009;20:1103 12. 
Bernatsky S, Boivin JF, Joseph L, e t al. Mortality in systemic lupus erythematosus. 
Arthritis Rheum 2006 ;54:25507. 
Bichile T, Petri M. Prevention and management of co -morbidities in SLE. Presse Med 
2014;43(6 Pt 2):e187 95. 
Bouts YM, Wolthuis DF, Dirkx MF, et al. Apoptosis and NET formation  in the 
pathogenesis of SLE. Autoimmunity 2012;45:597 601. 
Burness CB, McCormack PL. Belimumab: in systemic lupus erythematosus. Drugs 
2011;71:2435 44. 
Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413 24. 
Canadian Hydroxychloroquine Study Group. A  randomized study of the effect of 
withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. 
N Engl J Med 1991;324:150 4. 
Cassese G, Lindenau S, de Boer B, et al. Inflamed kidneys of NZB/W mice are a major 
site for the homeostasis of plasma c ells. Eur J Immunol 2001;31:2726 32. 
Chakravarty EF, Bush TM, Manzi S, et al. Prevalence of adult systemic lupus 
erythematosus in California and Pennsylvania in 2000: estimates obtained using 
hospitalization data. Arthritis Rheum 1 997;56:2092 4. 
Chan TM, L i FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with 
diffuse proliferative lupus nephritis. Hong Kong -Guangzhou Nephrology Study 
Group. N Engl J Med 2000;343:1156 62. 
Chang A, Henderson SG, Brandt D, et al. In situ B cell -mediated immun e responses and 
tubulointerstitial inflammation in human lupus nephritis. J Immunol 
2011;186:1849 60. 
Chen YE, Korbet SM, Katz RS, et al. Value of a complete or partial remission in severe 
lupus nephritis. Clin J Am Soc Nephrol 2008;3:46 53. 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
100/Protocol WA29748, Version 4 Cheung AM, Feig DS, Kapral M, et al. Prevention of osteoporosis and osteoporotic 
fractures in postmenopausal women: recommendation statement from the 
Canadian Task Force on Preventive Health Care. CMAJ 2004;170:1665 7. 
Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single -centre cohort 
study to evaluate the effectiveness of treating lupus nephritis with rituximab and 
mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280 6. 
Contreras G, P ardo V, Leclercq B, et al. Sequential therapies for proliferative lupus 
nephritis. N Engl J Med 2004;350:971 80. 
Costenbader KH, Desai A, Alarcon GS, et al. Trends in the incidence, demographics, 
and outcomes of end -stage renal disease due to lupus nephrit is in the US from 
1995 to 2006. Arthritis Rheum 2011;63:1681 8. 
Dall’Era M, Stone D, Levesque V, et al. Identification of biomarkers that predict response 
to treatment of lupus nephritis with mycophenolate mofetil or pulse 
cyclophosphamide. Arthritis Care Res 2011;63:351 7. 
Díaz-Lagares  C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with 
biopsy -proven lupus nephritis: pooled data from European cohorts. Autoimmun 
Rev 2012;11:357 64. 
Dooley MA, Jayne D, Ginzler EM, et al. and the ALMS Group. Mycophenolate versus 
azathioprine as maintenance therapy for lupus nephri tis. N Engl J Med 
2011;365: 188695. 
Esdaile JM, Levinton  C, Federgreen W, et al. The clinical and renal biopsy predictors of 
long-term outcome in lupus nephritis: a study of 87  patients and review of the 
literature. Q J Med 1989;72:779 833. 
Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic  
lupus  erythematosus and lupus  nephritis among US adults with Medicaid 
coverage, 2000 2004. Arthritis Rheum 2013;65:753 63. 
Flanc RS, Roberts MA, Strippoli GF, et al. Treatment for lupus nephritis. Cochrane 
Database Syst Rev 2004;1:CD002922.  
Furst DE, Clarke AE, Fernandes AW, et al. Incidence and prevalence of adult systemic 
lupus erythematosus in a large US managed -care population. Lupus 
2013;22:99 105. 
Furtado J, Isenberg DA. B cell elimination in systemic lupus erythematosus. Clin 
Immunol 2013;146(2):90 103. 
Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous 
cyclophosphamide for lu pus nephritis. N Engl J Med 2005;353:2219 28. 
Gladman D, Ginzler E, Goldsmith C, et al. The deve lopment  and initial validation of the 
systemic lupus international collaborating clinics/American College of Rhumatology 
Damage Index for systemic lupus erythem atosus. Arthritis Rheum 1996;39:363 9. 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
101/Protocol WA29748, Version 4 Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with 
CLL and coexisting conditions. N Engl J Med 2014;370:1101 10.  
Gregersen JW, Jayne DR. B -cell depletion in the treatment of lupus nephritis. Nat Rev 
Nephrol 2012;8:505 14. 
Hahn B, McMahon MA, Wilkinson A, et al. American College of Rheumatology 
Guidelines for Screening, Treatment, and Management of Lupus Nephritis. Ar thritis 
Care and Research 2012;64:797 808. 
Hill GS, Delahousse M, Nochy D, et al. A new morphologic index for the evaluation of 
renal biopsies in lupus nephritis. Kidney Int 2000;58:1160 73. 
Honeychurch J, Alduaij W, Azizyan M, et al. Antibody -induced nona poptotic cell death in 
human lymphoma and leukemia cells is mediated through a novel reactive oxygen 
species -dependent pathway. Blood 2012;119:3523 33. 
Houssiau FA, Vasconcelos C, D’Cruz D, et al. Early response to immunosuppressive 
therapy predicts good r enal outcome in lupus nephritis: lessons from long term 
followup of patients in the Euro -Lupus Nephritis Trial. Arthritis Rheum 
2004;50:3934 40. 
Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus 
nephritis: the Euro -Lupus Nephritis Trial, a randomized trial of low -dose versus 
high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121 31. 
Hsieh C, Chang A, Brandt D, et al. Predicting outcomes of lupus nephritis with 
tubulointerstitial inflammation and scarring. Art hritis Care Res 2011;63:865 74. 
James PA, Oparil S, Carter BL, et al. 2014 evidence -based guideline for the 
management of high blood pressure in adults: report from the panel members 
appointed to the Eighth Joint National Committee (JNC 8). JAMA 
2014;311:5 0720. 
Jónsdóttir T, Gunnarsson I, Mourão AF, et al. Clinical improvements in proliferative vs 
membranous lupus nephritis following B -cell depletion: pooled data from two 
cohorts. Rheumatology (Oxford) 2010;49:1502 4. 
Kinloch AJ, Chang A, Ko K, et al. Vime ntin is a dominant target of in situ humoral 
immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol 
2014;66:3359 70. 
Klein C, Lammens A, Schäfer W, et al. Response to: monoclonal antibodies targeting 
CD20. MAbs 2013;5:337 8. 
Lee PT, Fang  HC, Chen CL. Poor prognosis of end -stage renal disease in systemic 
lupus erythematosus: a cohort of Chinese patients. Lupus 2003;12:827 32. 
Lee S, Ballow M. Monoclonal antibodies and fusion proteins and their complications: 
targeting B cells in autoimmune  diseases. J Allergy Clin Immunol 
2010;125:814 20. 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
102/Protocol WA29748, Version 4 Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus 
erythematosus: an update. Ann Rheum Dis 2014;73:1601 6. 
Lim SS, Bayakly AR, Helmick CG, et al. The incidence and prevalence of systemic lupus 
erythematosus, 2002 2004. Arthritis Rheumatol 2014;66:357 68. 
Lu TY, Nq KP, Cambridge G, et al. A retrospective seven -year analysis of the use of B 
cell depletion therapy in systemic lupus erythematosus at University College 
London Hospital:  the first fifty patients. Arthritis Rheum 2009;61:482 7. 
Molina MJ, Mayor AM, Franco AE, et al. Prevalence of systemic lupus erythematosus 
and associated comorbidities in Puerto Rico. J Clin Rheumatol 2007;13:202 4. 
Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy 
through the engineering of a new type II anti -CD20 antibody with enhanced direct 
and immune effector cell -mediated B -cell cytotoxicity. Blood 2010;115:4393 402. 
Mysler  EF, Spinkler AJ, Guzman R, et al. Effica cy and safety of ocrelizumab in active 
proliferative lupus nephritis. Results from a randomized, double -blind, phase III 
study. Arthritis Rheum 2013;65:2368 79. 
Naleway AL, Davis ME, Greenlee RT, et al. Epidemiology of systemic lupus  
erythematosus in rural Wisconsin. Lupus 2005;14:862 6. 
Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus 
erythematosus: long -term follow -up and predictors of response. Ann Rhem Dis 
2007;66:1259 62. 
Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal 
structure of GA101 provide insights into the molecular basis for type I/II distinction 
of CD20 antibodies. Blood 2011;118:358 67. 
Petri M, Bechtel B, Dennis G, et al. Burden of corticosteroid use in  patients with systemic 
lupus erythematosus: results from a Delphi panel. Lupus 2014;23:1006 13. 
Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 
2008;358:929 39. 
Rao K, Dall’Era M, Wofsy D, et al. Rituximab in lupus nephritis: Analysis of  clinical 
variables associated with renal response in African -Americans in the LUNAR trial 
[poster]. Amer Soc Nephrol 2012;poster 56.  
Reddy V, Cambridge G, Isenberg D , et al. Fcgamma receptor IIb facilitates rapid 
internalisation of rituximab (type 1 anti -CD20 antibody) in B cells from patients with 
RA and SLE and contributes to less efficient B cell lysis than type 2 anti -CD20 
antibodies, in vitro [abstract and poster]. Amer College of Rheumatol 2014:abstract 
898. 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
103/Protocol WA29748, Version 4 Roccatello D, Sciascia S, Rossi D, et al. Intensive short -term treatment with rituximab, 
cyclophosphamide and methylprednisolone pulses induces remission in severe 
cases of SLE with nephritis and avoids further immunosuppressive maintenance 
therapy. Nephrol Dial Transplant 2011;26:3987 92. 
Rovin B H, Furie R, Latinis K, et al. and the LUNAR Investigator Group. Efficacy and 
safety of rituximab in patients with active proliferative lupus nephritis: the Lupus 
Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215 26. 
Ruiz-Irastorza G, Olivares N, Ruiz -Arruza I, et al. Predictors of major infections in 
systemic lupus erythematosus. Arthritis Res Ther 2009;11:R109.  
Sacks JJ, Luo YH, Helmick CG. Prevalence of specific types of arthritis and other 
rheumatic conditions in the ambulatory health care system in the United States, 
20012005. Arthitis Care Res 2010;62:460 4. 
Schwartz MM, Fennell JS, Lewis EJ. Pathologic changes in the renal tubule in systemic 
lupus erythematosus. Hum Pathol 1982;13:534 47. 
Steinmetz OM, Velden J, Kneissler U, et al. Analysis and classification of B -cell infiltrates 
in lupus and ANCA -associated nephritis. Kidney Int 2008;74:448 57. 
Turner -Stokes T, Lu TY, Ehrenstein MR, et al. The efficacy of repeated treatment with 
B-cell depletion therapy in systemic lupus ery thematosus: an evaluation. 
Rheumatology (Oxford) 2011;50:1401 8. 
Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic 
lupus erythematosus. Arthritis Rheum 2011;63:3038 47. 
Walsh BT, Pope C, Reid M, et al. SLE in a United S tates -Mexico border community. 
J Clin Rheumatol 2001;7:3 9. 
Ward MM. Prevalence of physician -diagnosed systemic lupus erythematosus in the 
United States: results from the third national health and nutrition examination 
survey. J Womens Health 2004;13:713 8. 
Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in 
systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241 50. 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
104/Protocol WA29748, Version 4 Appendix  1  
Schedule of Assessments  
Week   Treatment Period  
 4 to 0  1 2 4 12 24 26 36 52/ET 
Day  28 to   1 1 a 15 28 84 168 182 252 364 
Informed consent  x         
Inclusion/exclusion criteria  x x        
Medical history  x x        
IxRS assignment b x x        
Demographic data  x         
Subject’s  Global Assessment c  x  x x x  x x 
Physical exam (limited)  x x    x   x 
Height  x         
Vital signs and weight d x x x x x x x x x 
12-Lead ECG  x        x 
Chest X -ray e x         
Physician’s Global Assessment   x  x x x  x x 
SLICC/ACR assessment  x     x   x 
SLEDAI -2K x x  x x x  x x 
Glucocorticoid Toxicity Change Index   x   x x   x 
Hematology f x x x x x x x x x 
Serum chemistries g x x x x x x x x x 
Urinalysis h x x  x x x  x x 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
105/Protocol WA29748, Version 4 Appendix  1  
Schedule of Assessments (cont.)  
Week   Treatment Period  
 4 to 0  1 2 4 12 24 26 36 52/ET  
Day  28 to  1 1 a 15 28 84 168 182 252 364 
24-hour urine collection i x x   x x  x x 
Pregnancy test j x x x x x x x x x 
HBsAg k, HBcAb, Hepatitis  C antibody  x         
Autoantibody profile l x x  x x x  x x 
Antibody titers m x     x   x 
Serum PK sampling n  x n x n x x x n x n x x 
Blood sample for flow cytometry o  x x x x x o   x 
Serum ADA s  x o    x o   x  
Quantitative serum Ig  levels (total, IgG, IgM, 
and IgA)  x x   x x   x 
C3, C4, CH50 complement  x x x x x x  x x 
Serum for biomarkers o x x o x x x x o  x x 
Plasma for biomarkers o x x o x x x x o  x x 
Urine for biomarkers p, o x x x x x x  x x 
PAXgene RNA o x x o x x x x o  x x 
Blood DNA q (optional)  x         
Record of menses  x x x X x x x x x 
Adverse events r  x r x r X x x r x r x x 
 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
106/Protocol WA29748, Version 4 Appendix  1  
Schedule of Assessments (cont.)  
Week   Treatment Period  
 4 to 0  1 2 4 12 24 26 36 52/ET  
Day  28 to  1 1 a 15 28 84 168 182 252 364 
Concomitant medications  x x x X x x x x x 
Study  drug infusion   x s x s   x s x s   
Corticosteroid dose/taper t  x x X x     
Renal biopsy (optional) u         (x) 
ADA   anti-drug antibody ; ET   Early Termination Visit; HBcAb   hepatitis B core antibody;  HBsAg   hepatitis B surface antigen;  HBV   hepatitis B 
virus;  IV  intravenous; IxRS   interactive voice/Web response system ; PK   pharmacokinetic; PO   by mouth; SLEDAI -2K   Systemic Lupus 
Erythematosus Disease Activity Index ; SLICC/ACR   Systemic Lupus International Collaborating Clinics/American  College of Rheumatology . 
Notes:  All assessments will be performed pre -infusion unless otherwise specified.  Infusion visits (Days 15, 168, and 182) except for Day 1, should 
be performed within  3 days of the scheduled visit.  Non -infusion visits should be performed within  3 days of the scheduled visit.  
a Day 1, unless otherwise notified.  
b At screening, IxRS will be contacted to obtain assignment of patient screening number.  At Day  1, IxRS will be contacted to obtain patient 
randomization number and drug  assignment.  
c Subject’s  Global A ssessment will be performed prior to other assessments.  
d Blood pressure and pulse rate while patient is seated  for 5 minutes , and respiratory rate and body temperature.  Vital signs should be t aken 
pre-infusion, then every 15 minutes for 1  hour, then every 30 minutes until the end of the infusion, and within 30  minutes post -infusion.  Additional 
readings may be obtained at the discretion of the investigator in the event of an infusion -related re action (e.g.,  hypotension and/or fever) . 
e If a chest X -ray has been obtained within the past 3  months and no clinically significant abnormality was observed and no new pulmonary signs 
or symptoms are exhibited, no  chest X -ray is required.  
f Hematology:  C BC, RBC count, WBC count and differential, hemoglobin, hematocrit, mean corpuscular vo lume, mean corpuscular hemoglobin,  
and quantitative platelet count.  
g Serum chemistries include AST/SGOT, ALT/SGPT, alkaline phosphatase, total protein, albumin, cholesterol, total bilirubin, BUN, uric acid, 
creatinine, random glucose, lactate dehydrogenase, potassium, sodium, chloride, calcium, phosphorus , CPK, and triglycerides .  At screening and 
at unscheduled visits, amylase and lipase will be also included.  
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
107/Protocol WA29748, Version 4 Appendix  1  
Schedule of Assessments (cont.)  
h All urinalyses must include microscopic examination, macroscopic urinalysis, and spot urine protein  to creatinine ratio (preferably done on the 
first morning  urine ).  The spot urine protein  to creatinine ratio on Days 1, 84, 168, 252, and 364 must be done from first -morning urine.  
i To be analyzed for total protein, total creatinine, creatinine clearance, and protein to creatinine ratio.  
j For wome n of childbearing potential, including those who have had a tubal ligationPositive test results will be confirmed with a seru m pregnancy 
test.  Study drug infusion must not be administered unless the pregnancy test result is negative.  
k Patients who are HBsAg negative and HBcAb positive with no detectable DNA will be allowed into the study but will require regular monitoring o f 
HBV DNA (see the Laboratory Manual for further details) . 
l Autoantibodies include anti -nuclear antibody, anti -dsDNA, Sm, Ro, La, RNP , and anti -C1q. 
m Antibody titers include mumps, rubella, Varicella , tetanus, influenza, and  S. pneumoniae.  
n Obtain pre -infusion (within 30  minutes prior to the start of infusion) and at the end of infusion (or within 30  minutes after the end of infusi on). 
o Samples will be drawn before administration of study drug on dosing days.  
p Urine for biomarkers will be processed at the study site.  Instructions will be provided in the laboratory manual.  
q The DNA samples are optional and should only be obtained  from patients who sign the separate Roche Clinical Repository Informed Consent 
Form.   Preferably, samples will be obtained at screening visit, but they may be obtained at subsequent study visits.  
r On Day  1, adverse events will be recorded during infusion  and post -infusion.  For Days  15, 168, and 182, adverse events will be recorded 
pre-infusion, during infusion, and post -infusion.  For all serious infectious adverse events reported, CBC with differentials, quantitative Ig, and 
CD19 B -cell counts should be  determined within 1  week of onset.  
s On Days 1, 15, 168, and 182, administer 80 mg methylprednisolone IV (or placebo), 650 1000  mg acetaminophen PO, and 50  mg 
diphenhydramine PO (or other antihistamine) 30 60 minutes prior to the study -drug infusion.  
t Patients may initiate 0.5 mg/kg/day oral prednisone in screening or at Day 2.  Oral corticosteroid taper will begin on Day 16.  The maximum 
allowable daily dose of prednisone will be 60  mg. 
u All patients will be asked to undergo an optional repeat renal b iopsy after completion of the treatment portion of the study (after Week 52).  If a 
patient agrees to a repeat renal biopsy, one should be performed within 4 weeks of completion of the treatment portion of the  study.  Biopsies 
performed at other times, for  clinical reasons, will also be submitted for central review.  Because examination of the biopsy sample may 
potentially unblind the study treatment, investigators and study site personnel should not examine the biopsy sample for immu nohistochemistry of 
B cells or be informed of its results.  
 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
108/Protocol WA29748, Version 4 Appendix  2  
Follow -Up and B-Cell Follow -Up Assessments  
Evaluation/Procedure  Follow -Up B-Cell Follow -Up 
Week  76 104 Every 6 M onths 
Study Day ( 7 days)  532 728  
SLICC/ACR   x  
Serum chemistries a x x x 
Urinalysis b x x x 
Urine chemistries:  P/C b x x x 
Pregnancy test c x x x 
Autoantibody profile d x x x 
Blood sample for flow cytometry   x x 
Serum ADA s  x x x 
Serum pharmacokinetics  x x x 
Quantitative serum Ig levels (total, IgG, IgM, and IgA)  x x x 
PAXgene RNA  x x x 
Urine  for biomarkers e x x x 
Serum for biomarkers  x x x 
Plasma for biomarkers  x x x 
Adverse events f x x x 
Glucocorticoid Toxicity Change Index  x x  
Concomitant medications  x x x 
ADA   anti-drug antibody ; P/C   protein to creatinine ratio ; SLICC/ACR   Systemic Lupus International 
Collaborating Clinics/American College of Rheumatology . 
Note:  All urine tests should be performed on first -morning urine.  
a Serum chemistries include AST/SGOT, ALT/SGPT, alkaline phosphatase, total protein, albumin, 
cholestero l, total bilirubin, BUN, uric acid, creatinine, random glucose, lactate dehydrogenase, 
potassium, sodium, chloride, calcium, phosphorus, CPK, and triglycerides . 
b Microscopic and macroscopic.  
c For women of childbearing potential, including those who have had a tubal ligation.  Urine pregnancy 
test on Weeks 76 and 104.  If result of urine pregnancy test is positive, confirm with a central 
laboratory serum pregnancy test.  
d Autoantibodies include:  ANA, dsDNA, Sm, Ro, La, RNP, anti -c1q 
e Urine for biomarkers  will be processed at the study site.  Instructions will be provided in the 
laboratory manual.  
f For all serious infectious adverse events reported, CBC with differentials, quantitative Ig, and CD19 
B-cell counts should be determined within 1  week of onset.  
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
109/Protocol WA29748, Version 4 Appendix  3 International Society of Nephrology/Renal 
Pathology Society (ISN/RPS)  
2003 Classification of Lupus Nephritis  
Table  1 Classifications  
Class  Description  
Class I  Minimal mesangial LN  
Normal glomeruli by light microscopy, but mesangial immune deposits by 
immunofluorescence  
Class II  Mesangial proliferative LN  
Purely mesangial hypercellularity of any degree or mesangial matrix 
expansion by light micros copy, with mesangial immune deposits  
A few isolated subepithelial or subendothelial deposits may be visible by 
immunofluorescence or electron microscopy, but not by light microscopy  
Class III  Focal LN  
Active or inactive focal, segmental or global endo - or extracapillary 
glomerulonephritis involving  50% of all glomeruli, typically with focal 
subendothelial immune deposits, with or without mesangial alterations  
Class III (A) Active lesions:  focal proliferative LN  
Class III (A/C)  Active and chronic lesions:  focal proliferative and sclerosing LN  
Class III (C)  Chronic inactive lesions with glomerular scars: focal sclerosing LN  
Class IV  Diffuse LN  
Active or inactive diffuse, segmental or global endo - or extracapillary 
glomerulonephritis involving  50% of all glomeruli, typically with diffuse 
subendothelial immune deposits, with or without mesangial alterations.  
This class is divided into diffuse s egmental (IV -S) LN when  50% of the 
involved glomeruli have segmental lesions, and diffuse global (IV -G) LN 
when  50% of the involved glomeruli have global lesions.  Segmental is 
defined as a glomerular lesion that involves less than half of the 
glomerul ar tuft.  This class includes cases with diffuse wire loop deposits 
but with little or no glomerular proliferation.  
Class IV -S (A)  Active lesions:   diffuse segmental proliferative LN  
Class IV -G (A)  Active lesions:   diffuse global proliferative LN  
Class IV-S (A/C)  Active and chronic lesions:  diffuse segmental proliferative and 
sclerosing LN  
Class IV -G (A/C)  Active and chronic lesions:  diffuse global proliferative and sclerosing LN  
Class IV -S (C)  Chronic inactive lesions with scars:  diffuse segmental sclerosing LN  
Class IV -G (C)  Chronic inactive lesions with scars:  diffuse global sclerosing LN  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
110/Protocol WA29748, Version 4 Appendix  3 International Society of Nephrology/Renal 
Pathology Society (ISN/RPS)  
2003 Classification of Lupus Nephritis (cont.)  
Table  1 Classifications  (cont.)  
Class  Description  
Class V  Membranous LN  
Global or segmental subepithelial immune deposits or their morphologic 
sequelae by light microscopy and by immunofluorescence or electron 
microscopy, with or without mesangial alterations  
Class V LN may occur in combination with class III or IV in which case 
both will be diagnosed.  
Class V LN may show advanced sclerosis  
Class VI  Advanced sclerotic LN  
 90% of glomeruli globally sclerosed without residual activity  
A  active; C   chronic; G  global; LN   lupus nephritis; S   segmental . 
 
  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
111/Protocol WA29748, Version 4 Table  2 Definitions  
Term  Definition  
Diffuse  A lesion involving most ( 50%) glomeruli  
Focal  A lesion involving  50% of glomeruli  
Global  A lesion involving more than half of the glomerular tuft 
Segmental  A lesion involving less than half of the glomerular tuft (i.e., at least half of 
the glomerular tuft is spared)  
Mesangial 
hypercellularity  At least three mesangial cells per mesangial region in a 3 micron thick 
section  
Endocapillary 
proliferation  Endocapillary hypercellularity due to increased number of mesangial 
cells, endothelial cells, and infiltrating monocytes, and causing narrowing 
of the glomerular capillary lumina  
Extracapillary 
proliferation or 
cellular crescent  Extracapilla ry cell proliferation of more than two cell layers occupying one 
fourth or more of the glomerular capsular circumference  
Karyorrhexis  Presence of apoptotic, pyknotic, and fragmented nuclei  
Necrosis  A lesion characterized by fragmentation of nuclei or disruption of the 
glomerular basement membrane, often associated with the presence of 
fibrin -rich material  
Hyaline thrombi  Intracapillary eosinophilic material of a homogeneous consistency by 
which immunofluorescence has been shown to consist of immune 
deposits  
Proportion of 
involved glomeruli  Intended to indicate the percentage of total glomeruli affected by LN, 
including the glomeruli that are sclerosed due to LN, but excluding 
ischemic glomeruli with inadequate perfusion due to vascular pathology 
separ ate from LN  
LN   lupus nephritis.  
Source:  Weening  JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis 
in systemic lupus  erythematosus revisited. J Am Soc Nephrol 2004;15:241 50. 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
112/Protocol WA29748, Version 4 Appendix  3 International Society of Nephrology/Renal 
Pathology Society (ISN/RPS)  
2003 Classification of Lupus Nephritis (cont.)  
DEFINITION OF ACTIVE  AND CHRONIC LESIONS  
Active Lesions  
 Endocapillary hypercellularity with or without leukocyte infiltration and with 
substantial luminal reduction  
 Karyorrhexis  
 Fibrinoid necrosis  
 Rupture of glomerular basement membrane  
 Crescents, cellular or fibrocellular subendothelial deposits identifiable by light 
microscopy (wireloops)  
 Intraluminal immune aggregates (hyaline thrombi)  
 
Chronic Lesions  
 Glomerular sclerosis (segmental, global)  
 Fibrous adhesions  
 Fibrous crescents  
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
113/Protocol WA29748, Version 4 Appendix  4  
Guidelines for Mycophenolate Mofetil (or Equivalent) Dosing  
INITIAL DOSING  
Patients may use either mycophenolate mofetil  (MMF)  or mycophenolic acid  (MPA)  as 
standard of care background therapy in this study.  Dosing guidelines are based o n use 
of MMF  but an equivalent dose of MPA  may be used (MMF 500 mg is equivalent to MPA  
360 mg).  Patients should be initiated on MMF at a dosage of 1500 mg/day (or 
equiva lent) in divided  doses.  The target MMF dosage for the protocol is 
2000  to 2500  mg/day (or equivalent) . 
If patients are already receiving MMF  (or equivalent)  upon entry into the study, their 
current dosage should be  1500  mg/day  (or equivalent) ; if the dosage is 
not  1500  mg/day  (or equivalent) , then it should be increased to that level.  The patient’s 
dose should also be divided into two or three times -a-day dosing.   
ESCALATION OF DOSE  
The dosage of MMF  (or equivalent)  should be increased, as tolerated, by 500  mg/week  
(or equivalent)  with the goal of  reaching 2000 2500 mg/day  (or equivalent) , given in  
divided doses , by Week  4 at the latest .  
ADJUSTMENTS TO MMF  (OR EQUIVALENT)  DOSE  
Investigators will be allowed to adjus t the dosage because of tolerance and adverse 
effects, but the dosage should not be increased to greater than 2500 mg/day  (or 
equivalent) .  The most common adverse effects requiring titration of MMF  (or equivalent)  
are gastrointestinal (GI) intolerance, ne utropenia, and infectious complications 
(CellCept U.S. Package Insert [USPI] , Myfortic USPI ).  To maintain consistency in 
dose adjustments, recommended reductions are listed in  Table  1. 
If a patient develops GI toxicity due to MMF ( or equivalent ), it is recommended to reduce 
the dose according to “step 1,” as listed in Table  1 if other methods/evaluations, as 
outlined below, are not helpful.  If symptoms persist for 2 weeks after the change, the 
investigator may reduce  the dose according to “step 2,” as listed in Table  1.  After the 
symptoms resolve, an attempt should be made to increase MMF  (or equivalent)  to a goal 
of 2000  mg/day  (or equivalent)  per the previous dosing algorithm.  If GI symptoms 
return, then the patient should be continued on the highest tolerable dose.  
GI toxicity may not necessarily require dose reduction of MMF  (or equivalent) .  If 
diarrhea occurs, infectious causes (e.g., C. difficile  and enteropathogens) should be 
ruled out and treated if necessary.  If, in the investigator’s opinion, the diarrhea is non -
infectious, agents such as Lomotil or tincture of  opium may be used to decrease 
diarrhea.  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
114/Protocol WA29748, Version 4 Appendix  4  
Guidelines for Mycophenolate Mofetil (or Equivalent)  Dosing 
(cont.)  
If a patient develops an absolute neutrophil count ( ANC ) between 1000 and 1200, the 
dose should be reduced according to “step 1,” as l isted in Table  1 and the neutrophil 
count should be checked again at the next scheduled visit.  If the ANC cont inues to be 
between 1000 and 1200, the dose should be reduced according to “step 2,” as listed in 
Table  1.  After the ANC increases to   1200, the dose should be titrated towards goal, 
but at a rate of 500  mg per month.  
If the patient’s ANC is  1000, MMF (or equivalent) must be stopped immediately.  The 
patient must return within 14 21 days for repeat measureme nt of ANC.  If ANC 
is  1500, then MMF (or equivalent) may be restarted at the “step 1” dose according to 
what the patient’s previous MMF (or equivalent) dose was.  For example, if the patient’s 
dosage of MMF was 2500  mg/day at the time of interruption of MMF, then MMF should 
be restarted at 2000  mg/day.  
If a patient experiences an infectious complication, MMF (or equivalent) should be 
stopped until the episode has resolved.  MMF (or equivalent) can then be reinstituted at 
the previous dose.  
Regardless of d ose reduction, every attempt must be made to bring the patient’s dosage 
of MMF (or equivalent) to  1500  mg/day (or equivalent).  
Table  1 Protocol -Specified MMF (or Equivalent) Dose Reduction  
MMF dosage  
(mg/day)  Step 1 Reduction  
(mg) Step 2 Reduction  
(mg) 
2500  2000  1500  
2250  1750  1250  
2000  1500  1000  
1500  1000  750 
 
REFERENCE  
Hogg RJ, Wyatt RJ, Scientific Planning Committee of the North American IgA 
Nephropathy Study.  A randomized controlled trial of mycophenolate mofetil in 
patients with IgA nephropathy. BMC Nephrol 2004;5:3.  
 
 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
115/Protocol WA29748, Version 4 Appendix  5  
Initial Prednisone/Prednisolone Tapering Schedule  
Patients will receive both intr avenous (IV) and oral corticosteroids as part of their initial 
course of therapy.  IV methylprednisolone will be dosed at 1000  mg to treat active lupus 
nephritis (LN) according to standard clinical practice, which typically recommends one to 
three infusion s of methylprednisolone at this dose.  Between one and three infusions of 
1000  mg methylprednisolone will be allowed for the inclusion of patients into this 
protocol and can occur at any time before or during the screening interval.  For instance, 
a patien t with LN may have been identified in the community prior to referral to the 
investigator’s site and received 1000  mg of methylprednisolone.  This dose and all doses 
of steroids must be accounted for in the steroid concomitant medications section of the 
case report form.  The target protocol methylprednisolone dose is a single 1000 mg 
infusion, but up to three infusions will be acceptable for study entry.  
The initial oral prednisone dose will be 0.50  mg/kg/day, not to exceed 60  mg, and will be 
given on Days  216, excluding concomitant dosing of IV methylprednisolone.  
Investigators are instructed to round the calculated dose to the nearest 10 -mg increment 
listed in Table  1.  The investigator should instruct the patient to initiate a corticosteroid 
taper beginning on Day  16.  The patient’s initial study prednisone dose (or equivalent) is 
listed on the top line of Table  1, and the subsequent doses, changing every 2 weeks, are 
noted in the column below the selected initial dose.  Patients whose calculated 
prednisone dose would be  60mg/day should use 60 mg/day as their starting dose.  
Table  1 Prednisone Tapering Schedule  
Starting Prednisone Dose 
(mg/day)  30 40 50 60 
Day 16  25 35 40 50 
Day 28  25 30 30 40 
Day 42  20 25 20 30 
Day 56  15 20 15 20 
Day 70  10 15 10 10 
Day 84  7.5 7.5 7.5 7.5 
 
CORTICOSTEROID DOSIN G FOR EXTRAR ENAL FLARES  
To maintain consistency in the u se of corticosteroids for extra renal flares, patients will 
not be allowed to increase their prednisone dose during their participation in the study 
unless it is judged clinically appropriate by the investigator.  A flare is defined as an 
increase in Systemic Lupus Erythematosus Disease Activity Index  (SLEDAI) -2K that is 
not accounted for by either hypocomplementemia or an increase in anti -dsDNA antibody 
level or the initiation of new immunosuppressive therapy or an increase of corticosteroid  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
116/Protocol WA29748, Version 4 Appendix  5  
Initial Prednisone/Prednisolone Tapering Schedule (cont.)  
dose.  On the basis of the severity of the disease, patients may be retreated with 
prednisone up to 1.0 mg/kg.  IV corticosteroids in equivalent doses may be allowed if 
gastrointestinal involvement temporarily precludes oral corticosteroid use.  
Because it is important to maintain a consistent corticosteroid taper to interpret the 
results of this clinical study, it is suggested that investigators round the calculated 
corticosteroid dose (based on the patient’s weight in kilogra ms) to the nearest 10 -mg 
increment listed in Table  2 (not to exceed 60 mg/day) and follow the recommended 
tapering schedule.  T he investigator should instruct the patient to initiate a corticosteroid 
taper 14 days after starting the increased corticosteroid dose.  The patient’s increased 
study prednisone dosage (or equivalent) is listed on the top line of Table  2, and the 
subsequent dosages, changing every 2  weeks, are noted in the column below the 
selected initial dose.  If the investigator determines th at a higher dose or longer 
treatment period is necessary, he or she should first contact the Medical Monitor to 
discuss this.  Patients who do not show improvement in their symptoms after 2  weeks of 
increased corticosteroid treatment are considered to be n onresponsive to 
corticosteroids.  
Patients who initiate a new immunosuppressive or any other new systemic lupus 
erythematosus  medication will return for all protocol -scheduled visits and will not receive 
further study drug.  
Table  2 Prednisone D osing Recommendations for Extrar enal Flares  
Starting Prednisone 
Dose (mg/day)  20 30 40 50 60 
Day 16  15 25 30 40 50 
Day 30  10 20 25 30 40 
Day 44  10 10 15 20 30 
Day 58  7.5 10 10 10 20 
Day 72  7.5 7.5 10 10 10 
Day 86  7.5 7.5 7.5 7.5 7.5 
 
CORTICOSTEROID DOSIN G FOR RENAL FLARES  
To maintain consistency in the treatment of renal flares, retreatment with higher doses of 
corticosteroids is permitted if judged clinically appropriate by the investigator and if 
patients meet the criteria for a rena l flare as defined by all of the following:  
 Stable or increased creatinine  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
117/Protocol WA29748, Version 4 Appendix  5  
Initial Prednisone/Prednisolone Tapering Schedule (cont.)  
 Worsening active urinary sediment from baseline, as defined by a  50% increase in 
RBCs/ high-power field  or the appearance of new RBC casts when none were 
previously present  
 Increase in proteinuria, as evidenced by an increase in the urine protein to 
creatinine ratio to  2, if the most recent urine protein to creatinine ratio was  2.  
 
Patients may be treated with prednisone (up to 0.5 mg/kg; not to exceed 60 mg/day) for 
2 weeks.  Prednisone will then be tapered to achieve  10 mg/day 6  weeks after the 
initial corticosteroid increase (see Table  3).  Patients who do not exhibit a response to 
the initial 2  week course of increased corticosteroids, as evidenced by an improvement 
in urinary sediment and/or a reduction in the urine protein to creatinine ratio, or who 
initiate a new immunosuppressive therapy will be deemed treatment failures and 
continue scheduled protocol visits of the study and will not receive additional study drug.  
Table  3 Prednisone Dosing  Recommendations for Renal Flares  
Days after Initial 
Corticosteroid Increase  Prednisone Dose  
(mg/day)  
20 30 40 50 60 
14 15 25 30 40 50 
21 15 20 25 30 40 
28 10 20 20 20 30 
35 10 15 15 15 20 
42 10 10 10 10 10 
 
 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
118/Protocol WA29748, Version 4 Appendix  6  
Criteria for Classification of Systemic Lupus Erythematosus  
There are 11 criteria for the classification of systemic lupus erythematosus (SLE).  On 
the basis of this classification, a patient would be considered to have “definit e” SLE if 
any 4 or more of the 11  criteria are present, serially or simultaneously, during any 
interval of observation.  
In this study, a patient will be considered to have SLE if he or she has at least four 
criteria present, one of which must be a positive  anti-nuclear antibody (Criterion  11). 
Criterion  Definition  
1.  Malar rash  Fixed erythema, flat or raised, over the malar eminences, tending to spare 
the nasolabial folds  
2.  Discoid rash  Erythematous raised patches with adherent keratotic scaling and follicular 
plugging; atrophic scarring may occur in older lesions  
3.  Photosensitivity  Skin rash as a result of unusual reaction to sunlight, by patient history or 
physician observation  
4.  Oral ulcers  Oral or nasopharyngeal ulceration, usually painless,  observed by 
physician  
5.  Arthritis  Nonerosive arthritis involving  2 peripheral joints, characterized by 
tenderness, swelling, or effusion  
6.  Serositis  a) Pleuritis --convincing history of pleuritic pain or rubbing heard by a 
physician or evidence of  pleural effusion  
  OR  
b) Pericarditis --documented by ECG or rub or evidence of pericardial 
effusion  
7.  Renal disorder  a) Persistent proteinuria  0.5 g/day or  3 if quantitation not performed  
  OR  
b) Cellular casts --may be red cell, hemoglobin, granular, tubular, or 
mixed  
8.  Neurologic disorder  a) Seizures --in the absence of offending drugs or known metabolic 
derangements (e.g., uremia, ketoacidosis, or electrolyte imbalance)  
  OR  
b) Psychosis --in the absence of offending drugs or known metabolic 
derangements (e.g., uremia, ketoacidosis, or electrolyte imbalance)  
 
 
 
 
 
 
 
 
 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
119/Protocol WA29748, Version 4 Appendix  6  
Criteria for Classification of Systemic Lupus Erythematosus 
(cont.)  
Criterion  Definition  
9.  Hematologic 
disorder  a) Hemolytic anemia --with reticulocytosis  
  OR 
b) Leukopenia:   4,000/mm3 total on 2 or more occasions  
 OR  
c) Lymphopenia:   1,500/mm3 on 2 or more occasions  
  OR 
d) Thrombocytopenia:   100,000/mm3 in the absence of offending drugs  
10.  Immunologic  
disorder a a) Anti-DNA:  antibody to native DNA in abnormal titer  
 OR 
b) Anti-SM:  presence of antibody to SM nuclear antigen  
 OR 
c) Positive finding of antiphospholipid antibodies based on (1) an 
abnormal serum level of IgG or IgM anti -cardiolipin antib odies, (2) a positive 
test result for lupus anticoagulant using a standard method, or (3) a false 
positive serologic test for syphilis known to be positive for  6 months and 
confirmed by Treponema pallidum  immobilization or fluorescent treponemal 
antibody  absorption test  
11.  Anti -nuclear 
antibody  An abnormal titer of anti -nuclear antibody by immunofluorescence or an 
equivalent assay at any point in time and in the absence of drugs known to 
be associated with "drug -induced lupus" syndrome  
a The modifications to criterion number 10 were made in 1997 ( Hochberg 1997 ). 
Source:  Tan et al. 1982 . 
 
REFERENCE  
Hochberg MC. Updating the American College of Rheumatology revised criteria for the 
classificiation of systemic lupus erythematosus. Arthritis Rhe um 1997; 40(9) :1725 . 
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of 
systemic lupus erythematosus. Arthritis Rheum 1982;25(11):1271 7. 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
120/Protocol WA29748, Version 4 Appendix  7  
Study Drug Administration  
ADMINISTRATION OF ST UDY DRUG  
Study drug (obinutuzumab or placebo) should be given as a slow intravenous (IV) 
infusion.  It should not be administered as an IV push or bolus.  
Although obinutuzumab may be administered on an outpatient basis, patients may be 
hospitalized for observation at the discretion of the investigator.  Irrespective, 
obinutuzumab must be administered in a hospital or clinic environment where full 
resuscitation facilities are immediately available and under close supervisi on of the 
investigator or designee.  The guidelines below may be slowed at the discretion of the 
investigator based on a patient’s clinical presentation.  
FIRST INFUSION (DAY  1) 
Patients should receive prophylactic treatment of acetaminophen ( 6501000  mg) a nd 
diphenhydramine hydrochloride ( HCl) (50 mg; or equivalent dose of a similar agent) by 
mouth 30 60 minutes prior to the start of an infusion.  Prior to the Day 1 infusion, 
patients must receive 80  mg IV methylprednisolone  or placebo  3060 minutes prior t o 
the start of the study drug infusion . 
NOTE:  Patients should be cautioned not to operate vehicles or hazardous machinery 
until their response to diphenhydramine (or similar antihistamine) has been determined.  
Study drug infusions should be made through a  dedicated line and commence at a rate 
of 50  mg/hr.  This may be escalated at a rate of 50  mg/hr every 30  minutes to a 
maximum of 400  mg/hr.  Table  1 presents the schedule for the first infusion.  
Table  1 Schedule for First Infusion  
Time  
(min)  Infusion Rate  Dose in 30 minutes  
(mg) Cumulative Dose  
(mg) (mg/hr)  (mL/hr)  
030 50 12.5 25 25 
3160 100 25 50 75 
6190 150 37.5 75 150 
91120 200 50 100 250 
121150 250 62.5 125 375 
151180 300 75 150 525 
181210 350 87.5 175 700 
212240 400 100 200 900 
241255 a 400 100 200 1000  
a Should complete at 255 minutes (4 hours, 15 minutes) to complete total dose of 1000  mg. 
 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
121/Protocol WA29748, Version 4 Appendix  7  
Study Drug Administration (cont.)  
If a patient experiences a mild infusion -related reaction (IRR) that is deemed by the 
investigator to be clinically significant, the infusion rate should be reduced to half the 
infusion  rate that was used at the time of the reaction (e.g.,  from 100  mg/hr to 50  mg/hr).  
After the reaction has resolved, the infusion should be kept at the reduced rate for an 
additional 30  minutes.  If the reduced rate is tolerated, then the infusion rate ma y be 
increased to the next closest rate on the infusion schedule.  Patients who experience a 
moderate -to-severe IRR should have their infusion interrupted immediately and should 
receive aggressive symptomatic treatment.  The infusion should not be restarte d before 
all the symptoms have disappeared; after all symptoms have disappeared, the infusion 
may be restarted at half the rate.  If the reduced rate is tolerated for 30  minutes, then the 
infusion rate may be increased to the next closest rate on the infus ion table.  
After the end of the first infusion, the IV line should remain in situ for at least 2  hours to 
be able to administer drugs intravenously if necessary.  At the end of the remaining 
infusions, the IV line should remain in place for at least 30 minutes.  If no adverse events 
occur during this period of time, the IV line may be removed.  
SUBSEQUENT  INFUSION S (DAY S 15, 168, AND 182)  
Patients should receive prophylactic treatment of acetaminophen ( 6501000  mg) and 
diphenhydramine HCl (50  mg; or equivalent dose of similar agent) by mouth 
3060 minutes prior to the start of an infusion.  Patients must receive 80  mg IV 
methylprednisolone  or placebo  3060 minutes prior to the start of the study drug 
infusion.  
Patients who tolerated the first infusion  of study drug well may receive the second 
infusion as detailed in Table  2.  Patients who experienced an IRR to the first infus ion, 
deemed by the investigator to be clinically significant, should receive study drug as per 
the initial infusion schedule, with the starting rate of infusion not exceeding half that 
associated with the prior reactions.  If the infusion reaction during t he first infusion 
occurred at a rate   200 mg/hr, then the second infusion rate should start at 100  mg/hr.  
Study drug infusions should be made through a dedicated line and commence at a rate 
of 100  mg/hr.  This may be escalated at a rate of 100  mg/hr every  30 minutes to a 
maximum of 400  mg/hr.  Table  2 presents the schedule for the second and subsequent 
infusions.  
In the event th at the patient experiences an IRR, the infusion rate should be reduced to 
half that rate (e.g., from 100  mg/hr to 50  mg/hr).  Patients who experience a 
moderate -to-severe IRR should have their infusion interrupted immediately and should 
receive aggressive symptomatic treatment.  The infusion should not be restarted before 
all the symptoms have disappeared (see above).  

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
122/Protocol WA29748, Version 4 Appendix  7  
Study Drug Administration (cont.)  
Note:  These recommendations do not address life -threatening events, including 
anaphylaxis, for  which all appropriate standard measures (including full resuscitation 
medications and equipment) must be available and should be used as clinically 
indicated.  
Table  2 Schedule for Second and Subsequent Infusions  
Time  
(min)  Infusion  Rate  Dose in 30 minutes  
(mg) Cumulative Dose  
(mg) (mg/hr)  (mL/hr)  
030 100 25 50 50 
3160 200 50 100 150 
6190 300 75 150 300 
91120 400 100 200 500 
121150 400 100 200 700 
151180 400 100 200 900 
181195a 400 100 200 1000  
a Should complete at  195 minutes (3 hours, 15 minutes) to complete total dose of 
1000  mg. 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
123/Protocol WA29748, Version 4 Appendix  8  
Corticosteroid Equivalence Chart  
 Equivalent Dose  
(mg) 
Hydrocortisone  20 
Cortisone acetate  25 
Prednisone  5 
Prednisolone  5 
Methylprednisolone  4 
Dexamethasone  0.75 
Betamethasone  0.75 
Triamcinolone  4 
Beclometasone  0.75 
Note:  Cortisol (hydrocortisone) is the standard of 
comparison for glucocorticoid potency.  
Hydrocortisone is the name used for pharmaceutical 
preparations of cortisol.  
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
124/Protocol WA29748, Version 4 Appendix  9  
Instructions for Collecting and Analyzing Urine Samples  
BASED ON THE EUROPEAN URINALYSIS GUIDELINES [2000]  
URINE COLLECTION  
Urine collected at Screening;  Day 1 ; and Week s 12, 24, 36, and 52 should be collected 
in the following manner:  
 A 24-hour urine sample must be initiated prior to the visit , at which  point  it is to be 
collected and include only one first -morning urine.  
 A separate first -morning urine on the day of the visit should be collected .  
 The investigator will take a 30 -mL aliquot of urine from the first -morning urine 
sample for urine sediment analysis (as outlined below), macroscopic analysis, and a 
spot urine protein  to creatinine ratio.  The recommended vo lume of urine collected 
should be 30  mL, but a minimum of 18 mL should be collected.  Please refer to the 
Central Laboratory Manual for details.  
 
It is preferable that all of the urine for the 24 -hour urine collection is collected separately 
from the first  morning sample used for urine sediment analysis, macroscopic ana lysis, 
and a spot urine protein to creatinine ratio.  If the first morning urine on the day of the 
visit is the final urine collected for the 24 -hour urine collection, then aliquots, as 
descr ibed above, should be taken for urine sediment analysis, macroscopic ana lysis, 
and a spot urine protein to creatinine ratio ; the leftover urine should be combined with 
the rest of the 24 -hour urine collection , and an aliquot should be taken and sent for 
creatinine, protein, and pro tein to creatinine measurement.  
For all other visits requiring a urine specimen, every effort should be made to collect a 
first-morning urine sample.  If a first -morning urine sample cannot be collected, then a 
second -morning urine sample should be collected.  If a second -morning urine sample 
cannot be collected, the patient should be asked to come back within the window period 
for that visit to give a first - or second -morning urine sample (first -morning urine is 
preferable).   Aliquots as described above should be taken for these samples as well (i.e. , 
one sample for macroscopic analysis, one for urine sediment analysis, and one for a 
spot protein to creatinine ratio).  
Written instructions should be given to the patient about ho w to collect a morning urine 
sample.  In addition, it is encouraged to remind the patient that strenuous physical 
exercise should be avoided for the 72 hours preceding a urine collection.  
In females, urine collection should be avoided during menstruation.  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
125/Protocol WA29748, Version 4 Appendix  9  
Instructions for Collecting and Analyzing Urine Samples  (cont.)  
URINE EXAMINATION  
Four hours is the maximum recommended time between urine collection and local 
microscopic analysis.   
The recommended volume of urine collected should be 30 mL, bu t a minimum of 18  mL 
should be collected.  
The sample should be split into three equal aliquots.  One aliquot will be used for central 
laboratory macroscopic and microscopic urinalyses, one aliquot will be used for 
measurement of spot urine protein  to creat inine ratio, and the remaining aliquot will be 
used for local microscopic analysis.  Please refer to the Central Laboratory manual for 
details.  
Local urine microscopic analysis should be performed by manual evaluation.  If this 
cannot be done, validated au tomated analysis is acceptable, but the Principal 
Investigator should first discuss the use of the method with the Medical Monitor.  The 
procedure below outlines the recommended process for manual evaluation.  
Preparation for microscopic analysis is as foll ows: 
 The aliquot for microscopic analysis should be centrifuged between 400 and 
1500   g for approximately 5  minutes (1000   g for 5 minutes is preferred).  
 The supernatant should be decanted.  
 After decanting, if supravital staining will be used to aid in p articulate analysis, 
10% volume of the supravital stain to be used should be added and the solution 
mixed gently.  
 The sediment should be gently resuspended and then placed onto a microscope 
slide.  
 A coverslip should be added horizontally to maximize even distribution.  
 
  
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
126/Protocol WA29748, Version 4 Appendix  9  
Instructions for Collecting and Analyzing Urine Samples (cont.)  
VISUAL MICROSCOPIC A NALYSIS  
 Equipment/staining:  If available, it is recommended that phase -contrast microscopy 
be used if supravital stain is not added for particulate analysis.  
 Examination  
The sample should first be viewed under low -power magnification to note the 
presence of casts (red cell casts and white cell casts).  
The sample should then be viewed under high -power magnification, and the 
number of differ ent particles per high -power objective field should be counted.  
The number of specific particles, (specifically RBCs and WBCs) should be 
reported as an average observed in at least 10  fields selected from all areas of 
the coverslip and reported as number of specific particle (either RBC or WBC) 
per high -power field (HPF).  Automated quantification of RBCs and WBCs is 
acceptable.  
In terms of casts, the number and type of casts should be reported as an 
absolute number as seen in the whole sample and not as a n average per HPF.  
If the absolute number of casts cannot be reported, then it is important to note 
whether casts are present or absent and, if casts are present, the type of casts.  
If casts are present, reporting a range is allowed (as long as that rang e does 
not include “0”).  
 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
127/Protocol WA29748, Version 4 Appendix  10  
Systemic Lupus International Collaborating Clinics/  
American College of Rheumatology (SLICC/ACR)  
(Sample Case Report Form; Not to Be Used to Enter Subject Data ) 
 
NOTE:  Damage (nonreversible change, not related to active inflammation) 
occurring since onset of lupus, ascertained by clinical assessment and present 
for at least 6 months  unless otherwise stated.  Repeat episodes must occur 
6 months apart to score 2 . The same  lesion cannot be scored twice.  
 Score  
Item Not Present  Present  
Ocular (either 
eye, by clinical 
assessment)  Any cataract ever   0  1 
Retinal change or optic atrophy   0  1 
Neuropsychiatric  Cognitive impairment (e.g., 
memory deficit, difficulty with 
calculation, poor concentration, 
difficulty in spoken or written 
language, impaired 
performance levels) or major 
psychosis   0  1 
Seizures requiring therapy for 
6 months   0  1 
Cerebrovascular accident 
(CVA) ever (score 2 > 1 CVA)   0  1           2 
Cranial or peripheral 
neuropathy (excluding optic)   0  1 
Transverse myelitis   0  1 
Renal  Estimated or measured 
glomerular filtration 
rate < 50 mL/min   0  1 
Proteinuria ≥ 3.5 gm/24 hours   0  1 
OR 
End-stage renal disease 
(regardless of dialysis or 
transplantation)   0  3 
Pulmonary  Pulmonary hypertension (right 
ventricular prominence, or loud 
P2)  0  1 
Pulmonary fibrosis (physical 
and radiograph)   0  1 
Shrinking lung (radiograph)   0  1 
Pleural fibrosis (radiograph)   0  1 
Pulmonary infarction 
(radiograph)   0  1 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
128/Protocol WA29748, Version 4 Appendix 10   
Systemic Lupus International Collaborating Clinics/  
American College of Rheumatology (SLICC/ACR) (co nt.)  
 Score  
Item Not Present  Present  
Cardiovascular  Angina or coronary artery 
bypass   0  1 
Myocardial infarction (MI) ever 
(score 2 if > 1 MI)   0  1           2 
Cardiomyopathy (ventricular 
dysfunction)   0  1 
Valvular disease (diastolic 
murmur, systolic murmur > 3/6)   0  1 
Pericarditis for 6 months, or 
pericardiectomy   0  1 
Peripheral 
vascular  Claudication for 6 months   0  1 
Minor tissue loss (pulp space)   0  1 
Significant tissue loss ever (e.g., 
loss of digit or limb) (score 2 if > 
1 site)   0  1           2 
Venous thrombosis with 
swelling, ulceration, or venous 
stasis   0  1 
Gastrointestinal  Infarction or resection of bowel 
below duodenum spleen, liver, 
or gall bladder ever, for cause 
any (score 2 if > 1 site)   0  1           2 
Mesenteric insufficiency   0  1 
Chronic peritonitis   0  1 
Stricture or upper 
gastrointestinal tract surgery 
ever  0  1 
Musculoskeletal  Muscle atrophy or weakness   0  1 
Deforming or erosive arthritis 
(including reducible deformities, 
excluding avascular necrosis)   0  1 
Osteoporosis with fracture or 
vertebral collapse (excluding 
avascular necrosis)   0  1 
Avascular necrosis (score 2 if > 
1)  0  1           2 
Osteomyelitis   0  1 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
129/Protocol WA29748, Version 4 Appendix 10   
Systemic Lupus International Collaborating Clinics/  
American College of Rheumatology (SLICC/ACR) (cont.)  
 Score  
Item Not Present  Present  
Skin Scarring chronic alopecia   0  1 
Extensive scarring or panniculum 
other than scalp and pulp space   0  1 
Skin ulceration (excluding 
thrombosis) for > 6 months   0  1 
Premature gonadal failure   0  1 
Diabetes (regardless of 
treatment)   0  1 
Malignancy (exclude dysplasia) 
(score 2 if > 1 site)   0  1           2 
 
REFERENCE  
Gladman D, Ginzler E, Goldsmith C, et al. The deve lopment and initial validation of the 
systemic lupus international collaborating clinics/American College of Rhumatology 
Damage Inde x for systemic lupus erythematosus. Arthritis Rheum 1996;39:363 9. 
 
 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
130/Protocol WA29748, Version 4 Appendix  11  
Subject’s Global Assessment  
Do not reproduce or distribute.  The Sponsor will provide sites with all instruments 
to be completed in this study.  
(Sample Case Report Form; Not to Be Used to Enter Subject Data)
 
 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
131/Protocol WA29748, Version 4 Appendix  12  
Physician’s Global Assessment  
Do not reproduc e or distribute.  The Sponsor will provide sites with all instruments 
to be completed in this study.  
(Sample Case Report Form; Not to Be Used to Enter Subject Data)
 
 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
132/Protocol WA29748, Version 4 Appendix  13  
Systemic Lupus Erythematosus Disease Activity Index -2K 
Do not reproduce or distribute . The Sponsor will  provide sites with all instruments 
to be completed in this study.  
 
 

 
Obinutuzumab —F. Hoffmann -La Roche Ltd  
133/Protocol WA29748, Version 4 Appendix  14  
Glucocorticoid Toxicity Change Index  
COMPOSITE GLUCOCORTICOID TOXIC ITY CHANGE INDEX  
1. Body mass i ndex (BMI) (compared to baseline)  
a) Improvement ( in either direction ) by more than  2 BMI units toward normal BMI 
(normal range   18.524.9 kg/m2) 
b) No significan t change (BMI remains within  2 BMI units compared with 
baseline)  or BMI remains within the normal range  
c) Moderate increase  in BMI (increase by more t han 2 but less than 5 BMI units  to 
above the upper limit of normal BMI [24.9 kg/m2]) 
d) Major increase in BMI (increase by more than 5 BMI units to above normal 
BMI [24.9  kg/m2]) 
2. Glucose t olerance (compared to baseline)  
a) Improvement in glucose tolerance:  
 HbA1c (glycosylated hemoglobin) declined  10% from baseline without 
medication increase  
or 
 Decrease in diabetic medication without an increase in HbA1c of  10% or 
HbA1c  5.7%  
b) No significant change in glucose tolerance:  
 HbA1c within 10% of baseline or HbA1c  5.7% and no change in 
medication  
or  
 HbA1c increased to  10% of baseline due to a decrease in medication  
or  
 Improvement in glucose tolerance  10% due to an increase in medication  
c) Worsening of glucose tolerance o r medication status:  
 HbA1c increased to  10% and HbA1c  5.7% without a change in 
medication  
or  
 Increase in diabetic medication with  10% increase in HbA1c  
d) Worsening of glucose tolerance despite treatment:  
 HbA1c  5.7% and increased to  10% of baseline and an increase in 
diabetic medication  
3. Blood p ressure (BP) (compared to baseline)  
a) Improvement in BP:  
 
Obinut uzumab —F. Hoffmann -La Roche Ltd  
134/Protocol WA29748, Version 4 Appendix 14   
Glucocorticoid Toxicity Change Index (cont.)   
 Decrease in BP of  10% of baseline without medication increase  
or 
 
 Decrease in medication without an increase in BP of  10% or systolic 
BP  120 and diastolic BP  85 
b) No significant change in BP:  
 BP within 10% of baseline or systolic BP  120 and diastolic BP  85 and no 
change in medication  
or  
 Deterioration in either systolic or diastolic BP  10% due to a decrease in 
medication  
or  
 An improvement in either systolic or diastolic BP of  10% due to an 
increase in medication  
c) Worsening of hypertension:  
 Increase in BP of  10% such that the systoli c BP exceeds 120 mmHg or 
the diastolic BP exceeds 85 mmHg without a change in medication  
or  
 Increase in anti -hypertensive medi cation without an improvement in  
BP  10% 
d) Worsening of hypertension despite treatment:  
 Increase in BP of  10% such that the sys tolic BP exceeds 120 mmHg or 
the diastolic BP exceeds 85 mmHg and an increase in medication  
4. Hyperlipidemia (compared to baseline)  
a) Improvement in lipids:  
 Decrease in low -density lipoprotein (LDL) concentration  10% of baseline 
without medication increase toward the target range  
or 
 Decrease in medication without an increase in LDL of  10% or LDL 
remains within target range  
b) No significant change in LDL:  
 LDL within 10% of baseline or within the target range for pa tient and no 
change in medication  
or  
 
Obinut uzumab —F. Hoffmann -La Roche Ltd  
135/Protocol WA29748, Version 4 Appendix 14   
Glucocorticoid Toxicity Change Index (cont.)  
 Increase in LDL  10% due to a decrease in medication  
or  
 Improvement in LDL of  10% due to an increase in medication  
 
c) Worsening of LDL or medication status:  
 Increase in LDL of  10% to above target range without increase in 
medication  
or  
 Increase in medication without  10% change in LDL  
d) Worsening of LDL despite treatment:  
 Increase in LDL of  10% and an increase in medication  
5. Steroid myopathy  
a) No steroid myopathy  
b) Mild steroid myopathy (weakness without  functional limitation)  
c) Moderate steroid myopathy (weakness with functional limitation)  
See steroid myopathy definitions  below . 
6. Skin  
a) No skin toxicity  
b) Mild  
c) Moderate  
See skin definitions  below . 
7. Neuropsychiatric  
a) No neuropsychiatric symptoms  
b) Mild 
c) Moderate  
See neuropsychiatry definitions  below . 
8. Infection (since last assessment)  
a) No significant infection  
b) Specific infections  Grade 3 (oral or vaginal candidiasis, uncomplicated zoster)  
c) Grade 3  
See infection notes  below . 
 
Obinut uzumab —F. Hoffmann -La Roche Ltd  
136/Protocol WA29748, Version 4 Appendix 14   
Glucocorticoid Toxicity Change Index (cont.)   
9. Bone mineral density (BMD) (compared to baseline)  
a) Improvement   increase in BMD by  3% 
b) No significant change (BMD between  3% and  3%) 
c) Deterioation   decrease by   3%  
Percentage ( %) refers to total BMD in gms/cm2. 
If BMD not evaluated, then option “b” should be selected.  
GLUCOCORTICOID -INDUC ED MYOPATHY DEFINITI ONS  
 Glucocorticoid -induced myopathy is defined as mild symmetrical weakness of the 
proximal muscles and/or neck flexors associated with steroid therapy  and not due to 
any other apparent cause.   Muscle enzymes are typically within normal limits.  
 Mild and moderate myopathy are defined by muscl e strength of 4 on the standard 
Medical Research Council strength testing scale.  A 4 means weaker than normal 
but greater than anti -gravity strength.  
 “Mild” is Grade 4 weakness that does not functionally limit the patient.  
 ”Moderate” is Grade 4 weakness  that does impose functional limitations on the 
patient, interfering with normal daily activities.  
 Note that inability to rise from a chair without assistance constitutes severe  
glucocorticoid -induced myopathy  (Specific Domain)  
 
SEVERITY OF GLUCOCOR TICOID TOXICITY IN THE SKIN  
Manifestations to be considered:  
 Acneiform rash  
 Easy b ruising  
 Hirsutism  
 Atrophy/striae  
 Erosions/tears/ulcerations  
 
Skin 6b. Mild  Skin 6c. Moderate  Severe (Specific Domain)  
Acneiform rash (Grades 1 2) Acneiform rash (Grade 3)  Acneiform  rash (Grade 4)  
Easy bruising (Grade 1)  Easy bruising (Grade 2)   
Hirsutism (Grade 1)  Hirsutism (Grade 2)   
Atrophy/s triae (Grade 1)  Atrophy/s triae (Grade 2)  Atrophy/s triae (Grade 3)  
Erosions/tears/u lcerations 
(Grade  1) Erosions/tears/u lcerations 
(Grade  2) Erosions/tears/u lcerations 
(Grade  3) 
 
 
Obinut uzumab —F. Hoffmann -La Roche Ltd  
137/Protocol WA29748, Version 4 Appendix 14   
Glucocorticoid Toxicity Change Index (cont.)   
Acneiform rash  
– Grade 1:  Papules and/or pustules covering  10% body surface area (BSA), which 
may or may not be associated with symptoms of pruritus or tenderness  
– Grade 2:  Papules and/or pustules covering 10% 30% BSA, which may or may not 
be associated with symptoms of pruritus or tenderness; associated with 
psychosocial impact; limiting instrumental activities of daily living (ADL)  
– Grade 3 :  Papules and/or pustules covering  30% BSA, which may or may not be 
associated with symptoms of pruritus or tenderness; limiting self care ADL; 
associated with local superinfection with oral antibiotics indicated  
– Grade 4:  Papules and/or pustules covering any % BSA, which may or may not be 
associated with symptoms of pruritus or tenderness and are associated with 
extensive superinfection with intravenous  (IV) antibiotics indicated; life -threatening 
consequences  
 
Easy bruising  
– Grade 1:  Localized or in a dep endent area  
– Grade 2:  Generalized  
 
Hirsutism :  In women, increase in length, thickness , or density of hair in a male 
distribution  
– Grade 1:  Hirsutism that the patient is able to camouflage by periodic shaving, 
bleaching, or removal of hair  
– Grade 2:  Hirsutism that requires daily shaving or consistent destructive means of 
hair removal to camouflage; associated with psychosocial impact  
Atrophy/s triae  
– Grade 1:  Covering  10% BSA; associated with telangiectasias or changes in skin 
color  
– Grade 2:  Covering 10 %30% BSA; associated with striae or adnexal structure loss  
– Grade 3:  Covering  30% BSA; associated with ulceration  
 
Erosions/t ears/ulcerations  
– Grade 1 :  Combined area of ulcers  1 cm; non -blanchable erythema of intact skin 
associated with war mth or erythema  
– Grade 2 :  Combined area of ulcers 1 2 cm; partial thickness skin loss involving skin 
or subcutaneous fat  
– Grade 3 :  Combined area of ulcers  2 cm; full -thickness skin loss involving damage 
to or necrosis of subcutaneous tissue that may extend down to fascia  
 
 
Obinut uzumab —F. Hoffmann -La Roche Ltd  
138/Protocol WA29748, Version 4 Appendix 14   
Glucocorticoid Toxicity Change Index (cont.)   
SEVERITY OF NEUROPSY CHIATRIC GLUCOCORTIC OID TOXICITY  
Manifestations to be considered:  
 Insomnia  
 Mania  
 Cognitive impairment  
 Depression  
 
7b. MildNo Functional 
Impairment  7c. Moderate Functional 
Impairment  Severe (Specific Domain)  
Insomnia  Insomnia   
Mania (Grade 1)  Mania (Grade 2)  Mania (Grade 3)  
Cognitive impairment 
(Grade  1) Cognitive impairment (Grade 
2) Cognitive impairment 
(Grade  3) 
Depression (Grade 1)  Depression (Grade 2)  Depression (Grade 3)  
  
DEFINITIONS OF SEVER ITY WITHIN THE NEURO PSYCHIATRIC DOMAIN  
Insomnia :  Dissatisfaction with sleep quality and difficulty initiating or maintaining 
sleep or early morning awakening  
– Grade 1:  N ot associated with functional impairm ent 
– Grade 2:  A ssociated with functional impairment;  recorded as moderate toxicity  
 
Mania  
– Grade 1:   Slightly or occasionally elevated or irritable mood and 0 1 mild or 
occasional additional symptoms of inflated self -esteem, decreased need for sleep,  
increased talkativeness, feeling that thoughts are faster than usual, distractibility, 
increased activity or ag itation, and impulsive actions  
– Grade 2:  Frequent or moderately elevated or irritable mood and 2 3 mild additional 
symptoms of inflated self -esteem, decreased need for sleep, increased 
talkativeness, feeling that thoughts are faster than usual, distractibility, increased 
activity or agitation, and impulsive actio ns 
– Grade 3:  Severe or constantly elevated or irritable mood and 4 or more additional 
symptoms of inflated self -esteem, decreased need for sleep, increased 
talkativeness, feeling that thoughts are faster than usual, distractibility, increased 
activity or agitation, and impulsive actions  
 
 
Obinut uzumab —F. Hoffmann -La Roche Ltd  
139/Protocol WA29748, Version 4 Appendix 14   
Glucocorticoid Toxicity Change Index (co nt.)  
Cognitive impairment  
– Grade 1:  Minor cognitive complaints, no objective findings on mental status 
examination (i.e., not apparent to the examiner) that were not present before 
initiating steroids  
– Grade 2:  New moderate cognitive deficits that were no t present before initiating 
steroids  
– Grade 3:  Frank delirium  
 
Depression  
– Grade 1:  Feeling slightly down or depressed and 0 2 mild or occasional additional 
symptoms of loss of interest, low energy, guilt, poor concentration, insomnia, 
restlessness, or ch ange in appetite  
– Grade 2:  Frequent or moderate feelings of being down or depressed and/or 
34 symptoms of loss of interest, low energy, guilt, poor concentration, insomnia, 
restlessness, or change in appetite  
– Grade 3: Severe constant feeling of being down  or depressed  and/or 5 or more 
symptoms of loss of interest, low energy, guilt, poor concentration, insomnia, 
restlessness, or change in appetite and/or suicidal thoughts  
 
INFECTION NOTES  
 No significant infection :  No specific infec tions or serious infections  Grade 3 or 
greater  
 Specific i snfections :  Oral or vaginal candidiasis or zoster infections without 
postherpetic neuralgia or eye involvement  
Grade 3:  IV antibiotic, anti -fungal, or anti -viral interventi on or hospitalization 
indicated or radiologic or o perative intervention indicated or herpes zoster 
complicated by postherpetic neuralgia or eye involvement  
Grade 4  or 5:  Life-threatening consequences ; urgent intervention indicated or death 
from infection (Specific Domain)  
Signature Page for Protocol - WA29748 - GAZYVA - v4 - Global/Core - Published
System identifier: RIM-CLIN-483560
Approval Task
Company Signatory
18-Apr-2023 14:24:31 GMT+0000
